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Abstract 
Ureaplasma parvum is one of the smallest (genome <0.8 Mb), free living, self-replicating 
organisms identified. There are seven species of Ureaplasma but only two infect humans: 
Ureaplasma parvum (serovars 1, 3, 6 and 14) and Ureaplasma urealyticum (serovars 2, 4, 5, 
7–13). While frequently thought to be a commensal, Ureaplasma spp. has been found to be 
the most frequently identified infectious organism associated with preterm delivery.  The 
mechanisms it uses to escape recognition by the host immune system and establish long term 
chronic infections in the host are unknown.  However, association of infection with pregnancy 
and preterm birth, which have lower immune response are well known and its infection of and 
induction of preterm birth leads to short and long term sequel. 
Objectives of the study 
Using a model of experimental infection, this thesis sought to investigate differences between 
systemic Ureaplasma infection in mid-second trimester equivalent and early third trimester 
equivalent, and relate these differences to the stage of development of the complement system 
in preterm lambs.  These studies required the development of a new assay to measure com-
plement function in sheep.  The ability of the infecting strain of Ureaplasma to adapt to the 
sheep immune system was also investigated, examined at varying lengths of infection.  These 
studies required the use of a new in vivo catheterisation method to establish the kinetics of 
early experimental intrauterine Ureaplasma infection and to recover Ureaplasma from the 
amniotic fluid by amniocentesis at various times during chronic infection.  Emerging re-
sistance to sheep complement was investigated in these strains and related to coincident alter-
ations in the major surface antigen (multiple banded antigen; MBA) and alterations in the 
whole genome sequence.  These studies required the characterisation of new monoclonal an-
tibodies that recognise the MBA and establishment of a synthetic MBA expressed in E.coli to 
aid in reagent characterisation. 
Materials and Methods:  
Different erythrocyte sources and sensitising antibodies were utilised to establish the guinea 
pig erythrocyte as the best target for measuring the 50% haemolytic activity in fetal and adult 
sheep sera.  Flow cytometry methods were also used to establish endogenous anti-erythrocyte 
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antibodies in adult, but not fetal sheep, revealing a failure of maternal IgG transfer across the 
placenta in contrast to humans.  A bactericidal assay for the decrease in surviving Ureaplasma 
following incubation with sheep sera was utilised and modified conditions revealed the rate 
of killing and calcium-dependence of Ureaplasma killing for both fetal and adult sera.  Ex-
perimental infection of singleton pregnant ewes by catheter or ultrasound guided needle, fol-
lowed by caesarean delivery at either 94 or 125 days gestation (term=150 days) was central 
to all of the studies.  Over 3 years, different infection duration (from 5 days to 6 weeks) and 
gestational age at infection (from 70 days to 116 days gestational age) were investigated in 
this model. Western blot analysis was also a central method for both examining the antibody 
response of foetus and ewe to Ureaplasma as well as examination of the size and number of 
MBA isoforms in evolving strains during chronic infection.  The use of genomic analysis 
software Geneious (Biomatters ltd., New Zealand) was also utilised to compare the genomic 
sequences of Ureaplasma strains recovered by amniocentesis during chronic infection relative 
to the original infecting strain to determine number and site of genetic alterations with evolv-
ing serum resistance.  Only the repeat region of the MBA gene required investigation by PCR 
and traditional Sanger sequencing, due to limitations of Illumina sequencing methods and 
repeats greater than 150 bp.  
Results:  
The 50% complement haemolytic activity of preterm sheep foetuses was very poor at 95 day 
gestation and improved by 125 day gestation, but was still much lower than adult sera.  This 
was reflected in both in vivo bacteraemia during experimental infection and in vitro examining 
Ureaplasma-cidal activity of sera.  A direct correlation (R2=0.30; p<0.05) was found between 
haemolytic activity of sera and capacity to kill Ureaplasma in vitro. The strain utilised for 
experimental infection (HPA5) has a single low mass isoform of MBA consisting of 17 
PAGKEQ repeats in the C-terminus.  Following 5-7 days infection two of six of the infected 
animals began to show emergence of a second larger MBA isoform.  The number and size of 
MBA isoforms continued to increase at 3 and 5 weeks, until recovered strains appeared to 
solely consist of strains with much larger MBA isoforms (72->120 k Da).  The underlying 
mechanisms of increased MBA mass was found to be increasing number of PAGKEQ repeats 
from 17 to >200 repeats.  Genomic analysis of recovered strains identified conserved single 
nucleotide polymorphisms in the two genes encoding the ammonium ion transport, but other-
wise very few alterations were observed and no obvious candidate to explain increased serum 
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resistance (other than increased MBA mass) were observed. For the most part, alterations 
occurred in polyA, polyT and polyAT intergenic regions.  Despite the apparent correlation 
between increasing complement resistance of recovered strains and increasing MBA number 
of repeats, transposon delivery and expression of the MBA gene from a resistant recovered 
strain and the serum-sensitive original HPA5 strain did not transfer serum resistance in one 
experiment.  
 Conclusions: Ureaplasma can change its surface epitopes continuously however, the ex-
pected phase variation loss of MBA expression with development of anti-MBA antibodies 
was not observed.  A strong selection for increased MBA mass was apparent with longer 
infections and this was coincident with evolution of serum resistance (which increased stead-
ily after 1 week infection to high serum resistance after 5 weeks infection).  The development 
of the complement system was directly related to the detection of Ureaplasma in the circula-
tion of infected lambs, but even 6 weeks of chronic persistent Ureaplasma infection was found 
to induce an inconsistent and low antibody response, and only in the later gestational age 
foetuses. While increased MBA size appears to be coincident with evolved serum resistance, 
it must require either loss of the original MBA isoform (dominant serum susceptibility deter-
minant) or other less obvious alterations in the genome of Ureaplasma.  
Key words: Ureaplasma, preterm labour, animal models, amniotic fluid, MBA gene, anti-
genic variation.                          
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1 Introduction 
1.1 Preterm labour (PTL) 
1.1.1  Definition of preterm labour (PTL):  
Preterm labour is defined according to the World Health Organisation and International Fed-
eration of Gynaecology and Obstetrics (WHO/FIGO) as delivery of a baby before completing 
37 weeks of gestation. Those born before 32 weeks of gestation are called “very preterm” 
infants and those born before 28 weeks of gestation are called “extremely preterm” infants 
(Steer, 2005; Tucker and McGuire, 2004) (WHO 1977). In developed countries the rate of 
preterm birth is 5-10% compared to 25% in developing countries. It occurs in nearly a half 
million pregnancies each year in the United States alone especially in African-American 
women (Goldenberg et al.; 2008, Peltier, 2012) and accounts for ∼70% of all neonatal mor-
bidity with long term sequelae on respiratory function and neurological consequences and the 
percentage of mortality and morbidity are inversely proportional to the gestational age (Steer, 
2005; Wen et al., 2004; Tucker and McGuire; 2009, Goldenberg et al., 2008).           
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Figure 1.1 Preterm baby; source: March of Dimes( Dezen et al., 2012)  
 
 
1.1.2 Categories of preterm labour (PTL): 
PTL can be classified into the followings, 
   1. Spontaneous (idiopathic), about 50% of cases. 
   2. Premature rupture of membranes (PROM) 25%. 
   3. Induced (Iatrogenic) 25% for maternal or foetal indications.  
(Moutquin,2003;dundleyand Papiernik, 1993; Ananth and Vintzileos, 2006; Allen, 1991; 
Goldenberg et al., 2008). 
 
 
Formatted: German (Germany)
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1.1.3 Aetiology of preterm labour (PTL) 
Preterm labour is multifactorial and in 30% of cases preceded by premature rupture of mem-
branes (PROM), other common associations are low socioeconomic status, poor nutrition, 
smoking, alcoholism, uterine distension, abruption placentae, immunological disorders, how-
ever, the greatest risk is associated with infection/inflammation at the maternal–fetal interface 
triggered by improper production of pro inflammatory cytokines (Peltier, 2003). This project 
will mainly address the most common cause of prematurity, namely, intrauterine bacterial 
infection and compare it to other studies which confirmed the relationship between infection 
and PTL (Andrews et al., 2000; Klein and Gibbs, 2005; Goldenberg et al., 2008) although the 
rate of infection is not the same throughout pregnancy; as it is inversely proportional to the 
gestational age (Agrawal and Hirsch, 2012; Di Renzo, 2006). 
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          Figure 1.2 Factors contributing to PTL, adapted from (Mendz1et al.,2013) 
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1.1.4  Infection-driven PTB 
 During pregnancy there is a complex interaction of inflammatory events controlled 
by both the innate and acquired immune systems. Likewise, parturition can be initiated 
by activation of “pro-labour” inflammatory pathways, which lead to cervical ripening 
and myometrial contraction. Premature activation of these pathways, for example, by 
infection can lead to preterm labour mostly by improper activation of inflammatory 
pathways (Lappas and Rice, 2007; Peltier, 2003). At present, infection induced chori-
oamnionitis is the only factor for which a casual association has been made with pre-
term birth. Besides elevated levels of pro-inflammatory cytokines, experiments have 
also shown that infections stimulate the production and release of both PGE2 and 
PGF2 by the amnion, chorion and myometrium. Such prostaglandin molecules are the 
direct mediators of uterine contractions through their stimulation of prostaglandin re-
ceptors (Blanco, 1995; Larsen and Hwang 2010). Many studies have highlighted a 
cause-effect relationship between infection and preterm labour (PTL) or premature 
rupture of membranes (PROM). (Gibbs, 2001; Gravett et al., 1986; Macintyre et al., 
2012; Romero and Mazor,1988; Romero et al., 1991). 
Many clinical studies have shown that a pre-existing intra-uterine immune mediated 
inflammation can act as a predisposing factor in premature labour like pre-existing 
anti-sperm IgG antibodies signifying infection from male partner (Witkin and 
MCgregor, 1991; Toth et al., 1988), as well as a pre-existing history of pelvic inflam-
matory diseases (Epstein et al., 2000; Gibbs et al., 1992; Toth et al., 1988; Abele-Horn 
et al., 1997). Women who are smokers, and have multiple sexual partners (Cram et 
al., 2002; De Francesco et al., 2009), and/or use an intrauterine contraceptive device 
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(IUCD) have increased vulnerability to premature rupture of the membranes and sub-
sequent preterm birth (Donders et al., 1991; Steven and Fraser, 1974).  However the 
frequency of pathohistological results and positive infection cultures was inversely 
proportional to gestational age (Watts, 1992; Horvath et al., 2014; Goncalves et al., 
2002; Kundsin et al., 1984). 
 
1.1.5 Bacterial vaginosis (BV) and preterm labour: 
Under normal conditions the vagina is populated by the facultative lactobacilli which 
safeguard the vagina from pathogens by maintaining an acidic pH through the secre-
tion of lactic acid, and by production of H2O2 which is toxic to other bacteria (Hillier 
et al., 1993; Hellberg et al., 2001), but sometimes alterations occur that modify the 
vaginal flora like after menstruation, hormonal therapy, prolonged antibiotic treat-
ment, vaginal medication, spermicidal creams, after sexual intercourse, or use of vag-
inal douches. These conditions lower the acidity (i.e. Increase the PH) of the vagina 
and diminish production of H2O2 and this will give other bacteria a chance to establish 
a larger occurrence leading to “bacterial vaginosis” (BV) (Hillier et al., 1993).  In 
particular increased presence of resident gram-negative and anaerobic bacteria includ-
ing Gardnerella vaginalis, Mobiluncus, Bacteroides, Prevotella, and Mycoplasma 
species have been found. Ureaplasma which belong to the class Mollicutes and the 
family of Mycoplasmatales are found to be one of the most common bacteria recov-
ered from patients with BV and frequently associated with adverse pregnancy outcome 
and neonatal mortality and morbidity (Donders et al., 2009; Goldenberg and Rouse, 
1998; Gray et al., 1992; Hillier et al., 1995; Kurki et al., 1992; Romero and Mazor, 
1988; Martius and Eschenbach, 1990; Nicola and Maxwell, 2006). 
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1.1.6 Pathophysiology of infection-induced PTL:  
Pathophysiology of premature labour is still only partly understood. Experiments on 
animal models showed that preterm labour can be induced by bacteria, bacterial cell 
wall products, and also by inflammatory cytokines such as IL-1 and tumour necrosis 
factor (TNFα) (Dudley, 1997; Casey et al., 1989; Mattsby-Baltzer et al., 1998; Adams 
et al., 2011; Farina and Winkelman, 2005). 
The keystone of infection- induced labour are believed to involve signal transduction 
cascades that begin with recognition of invading pathogens by cell-surface pathogen 
recognition receptors (PRR) like toll-like receptors (TLRs). TLR are the first line of 
defence at the amniotic fluid epithelium layer which is in direct contact with the am-
niotic fluid leading to a host response causing an `intra-uterine inflammatory response 
syndrome' and elevated transcription of genes encoding proinflammatory cytokines 
leading to increased levels of nuclear factor kappa Beta (NF-ᴋB) particularly those 
associated with labour (Shimizu et al., 2008). 
The inappropriate release of these pro inflammatory cytokines (which can be either 
clinically evident or subclinical), including TNF-α, IL-6, IL-1, and IL-8, into the am-
niotic fluid and gestational tissues, trigger leukocyte recruitment, activate prostaglan-
din synthesis and release of matrix metaloproteinases (MMPs)(Larsen and Hwang, 
2010).  These mediators in turn, lead to myometrial contractions, cervical dilatation, 
and rupture of fetal membranes, changing the state of the uterus from quiescence to 
active, ending in premature initiation of labour and expulsion of a preterm foetus. 
These cytokines have been detected in high concentration in the amniotic fluid and 
plasma of women with signs of PTL (Fig.1.3) (Bryant and Thornton, 2012; Shimizu 
et al., 2008; Kawai and Akira, 2011; Koga and Mor, 2010; Triantafilou et al., 2013). 
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Figure 1.3 Pathogenesis of infection/inflammation induced PTL 
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1.1.7 Routes of in utero infection  
  The primary mechanism of transmission of Ureaplasma is by sexual contact then by vertical 
transmission i.e. infection ascends from the colonized lower genital tract to the uterine cavity 
and the foetus or infection of the neonate during passage through birth canal (Behnam et al., 
2014; Garland et al., 2002; Sanchez and Regan, 1987; Waites, 2006; Hill, 1998). 
 
 
Figure 1.4 Routes of in utero infection ,cited from (Levy, 2007) 
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Infection can gain access to the uterine cavity and settle in the uterus even at the time of 
conception (Kasprzykowska et al., 2014). Alternatively infection can spread by haematog-
enous route through the placenta from the infected mother’s blood (Waites, 2006; Viscardi, 
2010). It could also migrate through the fallopian tubes from the abdominal cavity, and in 
cases where medical intervention has occurred, iatrogenic infection by contaminated needle 
during amniocenteses, or chorionic villous sampling (CVS) cannot be ruled out (Romero and 
Mazor, 1988; Garland et al., 2002).  In  case of ascending infection, Ureaplasma would ascend 
from the cervix, pass to the choriodecidual space, then cross the chorioamniotic membrane to 
colonise the fetal tissues, decidua and membranes (Hallman and Kaukola, 2012; Khare and 
Khare, 2007) (Fig.1.4).  It is also possible to acquire Ureaplasma infection by vertical trans-
mission during labour (due to premature rupture of membranes or passing through the colo-
nised vagina) where it establishes an infection of the neonatal airway resulting in post-birth 
respiratory disease and related neonatal morbidity (Romero et al., 2007; Romero et al., 1992; 
Sampson et al., 1997; Taylor-Robinson, 1999). The rate of vertical transmission ranges from 
18- 55% among full-term infants and from 29- 55% among preterm infants (Abele-Horn et 
al., 1997; Sánchez, 1993). In a report by Sanchez (1987) fifty-nine term infants (45%) had at 
least one culture site positive for Ureaplasma spp. (eye 4%; nasopharynx 24%; throat 16%; 
vagina, 53%; and rectum 9%). Also Sung et al (2011) found that in 65% of preterm infants 
less than 26 weeks respiratory infection by Ureaplasma spp. could be detected (Sung et al., 
2011). 
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1.1.8  Outcome following preterm labour 
PTL is a medical, social, and economic problem, especially in developed countries (Hannah 
et al., 2013; Tricia et al., 2013); it can contribute to the following: 
Mortality: Globally, PTL is considered as the commonest cause of neonatal mortality it ac-
counts for about 70% of neonatal deaths (Wen et al., 2004). Survival rate is inversely propor-
tional to the gestational age. Infant death is death of an infant before his or her first birthday; 
it can be neonatal or post-neonatal. Preterm birth has a significant influence on the U.S. infant 
mortality rate. In England and Wales data from the office for national statistics, the mortality 
rate for preterm babies (24-36wks) was reported to be 25.4/1000 live births which is 11% less 
compared to the rate reported in 2006 (28.6/1000 live births) which could be attributed to the 
new strategies in the intensive care for preterm babies (MacDorman, 2014; Moser, 2008; Wen 
et al., 2004).  Statistics separated for different preterm gestational age groups reported de-
creases in infant mortality rates of 14% for preterm infants of 24–25 weeks' gestation and 40% 
at 28–31 weeks' gestation relative to previous rates, with an approximately equal reduction in 
neonatal and post neonatal mortality (Wen et al., 2004). 
 Morbidity: Preterm birth is a predisposing factor for about 75% of neonatal morbidity (Wen 
et al., 2004). With increasing gestational age, the risk of adverse consequences of PTL de-
clines. Preterm infants are at risk of infectious and non-infectious respiratory complications 
after delivery, with up to 40% of preterm survivors having bronchopulmonary dysplasia 
(BPD; also known as chronic lung disease of prematurity or CLD), neurodevelopmental dis-
abilities, intraventricular haemorrhage, recurrent infections, retrolental fibroplasia and ne-
crotizing enterocolitis (Saigal and Doyle, 2008; Gomez et al., 1998) and even psychological, 
educational and behavioural problems (Moster et al., 2008; Ira et al., 2013). 
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1.2   Ureaplasma 
1.2.1 Characterisation of Ureaplasma  
1.2.1.1 Cell Structure and Metabolism:  
Ureaplasma is one of the smallest free living, self-replicating organisms and was first discov-
ered in primary agar cultures of urethral exudates from male non-gonococcal urethritis pa-
tients by Shepard et al. in 1954 (Shepard, 1954). Initially defined as a tiny” colony belonging 
to the pleuropneumonia-like organisms due to their minute agar colony size (15±5µm) which 
needed stereomicroscopy to be seen. It was reclassified as “Ureaplasma” in 1974 as part of 
the class Mollicutes. This class includes the Mycoplasmas and related organisms, all of which 
are characterised by a lack of a cell wall.  Instead electron microscopy showed that their cell 
membrane as a 10nm thick, triple-layered membrane with 5-8nm pilus-like projections on its 
surface. All early Ureaplasma reports therefore are listed as T-strain Mycoplasma due to its 
tiny colonies. (Tully and Taylor-Robinson, 1986; Shepard et al., 1974). Ureaplasma has a 
restricted biosynthetic activity due to the limited genetic information in the small genome, so 
they are obliged to live a parasitic life in cooperation with eukaryotic cells (Robertson et al., 
2002). For culture in vitro, they need cholesterol-rich media to supply them with fatty acids 
and cholesterol necessary for the assembly of their membrane, but they are non-glycolytic and 
lack the arginine dihydrolase pathway that is found in M. hominis (Freundt, 1983). Being wall-
less could explain the pleomorphic shape of Ureaplasma, it has been reported as spherical or 
ovoid coccus bacilli cells (Boatman, 1979; Miyata and Ogaki, 2006; Kahane and Horowitz, 
1993; Smith et al., 1994).  It also cannot be classified by Gram stain. In the Gram stain test, 
gram-positive bacteria retain the crystal violet dye, while a counterstain (commonly safranin 
or fuchsine) added after the crystal violet gives all gram-negative bacteria a red or pink col-
ouring. Therefore, Ureaplasma fail to stain with crystal violet, because they have no cell wall 
and are unlikely to be visualised by a light 
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 microscope as they are 200-500 nm in sizes. Also absence of cell wall make Ureaplasma 
extremely sensitive to dehydration so it can be physically inactivated by heating it at 100◦C 
for 10 minutes. Also lack of cell wall renders Ureaplasma resistant to antibiotics which target 
the bacterial cell wall such as ampicillin, but susceptible to antibiotics that interfere with pro-
tein synthesis like tetracyclines, macrolides, spectinomycin and quinolones (Taylor-Robinson 
and Ronald,1997; Beeton et al., 2009; Taylor-Robinson and Furr, 1986).  Ureaplasma also 
grows better at low pH and most media have a pH of 6.0-6.5 (Shepard and Lunceford, 1978; 
Romano et al., 1980). Ureaplasma differ from other Mollicutes by their ability to hydrolyse 
urea as their primary carbon source (Shepard and Lunceford, 1976; Blanchard, 1990; Takebe 
et al., 1984); they cannot ferment glucose or other carbohydrates (Robertson and Howard, 
1987) or get energy by degrading arginine (Fiacco et al., 1984). Urease activity was shown to 
be necessary for the generation of ATP by a chemosmotic mechanism (Willoughby et al., 
1991; Romano, 1980). Ureaplasma also express a human immuoglobulin A1 protease that is 
thought to facilitate its adherence to mucosal surfaces by removing adherence-blocking anti-
bodies (Felix and Nana, 1999; Robertson et al., 1984). 
 
1.2.2  Classification of Ureaplasma  
Mycoplasmas and Ureaplasma are eubacteria belonging to class Mollicutes, which is com-
prised of 4 orders, 5 families, 8 genera, and about 200 known species, but only five species 
are recognized as human pathogens (M.pneumoniae, M.hominis, Mycoplasma genitalium, 
Ureaplasma parvum and Ureaplasma urealyticum) (Razin et al.,1998;Waites et al.,2005). 
Originally it is thought to have evolved from clostridium-like ancestors through the process 
of gene deletion (Fanrong et al., 1999; Freundt, 1983; Waites, 2006). Ureaplasma was first 
discovered in 1954 samples collected from human urogenital tract and classified in 1974 as a 
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new genus and species. The name Ureaplasma was suggested for this new genus due to its 
ability to hydrolyse urea (Shepard et al., 1974). Later it was subcategorized into 14 serovars 
and into two genetically related biovars, biovar 1 and biovar 2; however, these were subse-
quently renamed parvobiovar and T960 biovar (Yoshida et al., 2005; Lin and Kass, 1980) on 
the bases of differences in a major Ureaplasma surface antigen called the multiple banded 
antigen (MBA) (Knox et al., 1998). In 1999, a systematic reclassification was undertaken 
separating two species depending on phenotypic and genotypic evidence.  The fourteen pre-
viously identified serovars of Ureaplasma from different isolates split between these two dis-
tinct species: U. parvum which contain four serovars 1, 3, 6 and 14 and U. urealyticum which 
contains serovars 2, 4, 5 and 7-13 (Robertson et al., 1993; Kong et al., 1999; Robertson et al., 
2002; Knox et al., 1998; Ren and Zhu, 2003; Harasawa and Kanamoto, 1999). The parameters 
for separation included genome size, 16S rRNA genes, 16S-23S rRNA intergenic regions, 
urease enzyme variations, different patterns arising from DNA-DNA hybridization, differen-
tial growth requirements for manganese and differences in the major surface antigen, the mul-
tiple-banded antigen gene (MBA) (Shepard and Lunceford, 1978; Teng et al., 1994; Robert-
son et al., 1994; Razin and Yogev, 1986). 
 The arrangement of the C-terminal domain of the MBA is responsible for the serovar speci-
ficity and the sequence heterogeneity of the 5' region of the MBA gene assist in dividing these 
14 serovars into subgroups. Teng, et al, (1994) and others succeeded in determining that a 
gene with high homology to the MBA gene of SV3 existed in the remaining 13 reference 
serovars as well as in all clinical isolates (Fanrong et al., 1999; Pitcher et al., 2001; Teng, 
1994). 
Later on, Kong et al, (2000) managed to further separate U. parvum into three subtypes, rep-
resented by serovars 1, 3/14, and 6 using amplicon size differences with PCR. Ureaplasma 
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urealyticum was also separated into three subtypes by subtype-specific PCR primer pairs tar-
geting the MBA genes and could distinguish subtypes within each species. Genotype A con-
sisted of serovars 2, 5, 8, and 9; genotype B contained serovars 4, 10, 12, and 13; and Genotype 
C contained serovars 7 and 11 (Kong et al., 2000).Later on, the same team subdivided U.urea-
lyticum into five genotypes depending on sequencing of the whole 5`ends and partial repetitive 
regions of the MBA genes of the ten U.urealyticum serovars (Kong et al., 2000). as in the 
following table,  
Table 1.1 Amino acid sequences of repetitive units of the MBA genes of 14 serovars of U. parvum 
and U. urealyticum. 
Serovars / subtype                                                          Repeat amino acid sequence  
UP Serovar 1                                                                   PGKEQQ 
UP Serovar 3                                                                   PAGKEQ 
UP Serovar 6                                                                   PGKE 
UP Serovar 14                                                                 PAGKEQQ 
UU  MBA genotype A                                                    TKPGSGET 
Include serovars 2, 5,8 
UU MBA genotype 
B include serovar10  
                                                 TQPGSGST 
UU MBA genotype 
C include serovars  
4, 12 ,13           
                                                 TSPEKPGNGT  
 
UU MBA genotype 
D           serovars 9 
                                                 KKPETGSTEGGS1TEG 
UU MBA genotype 
E  serovars 7 and 11           
                                                 GAQSGNGSGSASGS 
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1.2.2.1  Ureaplasma genome 
Mycoplasma are thought to have evolved from more classical bacteria of the firmicutes by 
massive genome reduction through a process called regressive evolution and hypotheticaly, 
this is attributed to its parasitic life which renders most of metabolic processes unnecessary 
(Weisburg et al., 1989; Gundersen et al., 1994; Moran, 2002; Snel et al., 2002; Silva and 
Latorre, 2008). The genome size of the various strains of Ureaplasma appears to differ exten-
sively and matches the two serovar clusters. The genome size of U. parvum is about 760 kb, 
whereas U. urealyticum ranges from 880 to 1,140 kb. It has an circular DNA which encodes 
for a predicted 614 open reading frames and 38 RNA genes, making it the second smallest 
genome ever sequenced for a free-living prokaryote (smallest being M. genitalium at 580,040 
bp)(Robertson et al., 1990; Robertson et al., 2002; Paralanov et al., 2012). The genome of the 
prototype U.parvum SV3 contains 613 predicted protein encoding genes and 39 RNA genes, 
including two identical rRNA operons (consisting of an rRNA-16s, rRNA-23s and rRNA-5s) 
(Paralanov et al. 2012). Ureaplasma thought to descend from low G+C content gram positive 
bacteria and use a non-standard genetic code (Razin et al., 1983). Moreover, all Mycoplasma 
use the codon UGA=tryptophan (trp) as a genetic code rather than being a stop codon 
(Blanchard, 1990). Serovar identification can be accomplished by serology (Pitcher et al., 
2001; Watson et al., 1990), immunofluorescence (Bowie et al., 1977; Muenster et al., 1979) 
and ELISA (Brown et al., 1983; Von Chamier et al., 2012). The latter is the least sensitive 
and has been used to predict patients at risk of PTL (Horowitz et al., 1995). Sometimes it is 
difficult to detect all serovars because of variable growth rates, and multiple serovars per spec-
imen (Yi et al., 2005). Surprisingly, U. urealyticum has a relatively unique respiration system 
with six closely related iron transporters, which apparently arose through gene duplication 
(Glass et al., 2000). Mycoplasma genomes also contain numerous repeated sequences, which 
Commented [Brad Spil1]: ? 
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has an important role in their evolution (Rocha and Blanchard, 2002). Moreover, Mycoplasma 
can gain or delete genes from its chromosome through a process called horizontal gene trans-
fer, which renders all Mycoplasmas continuously dynamic and increases their pathogenicity 
(Ochman et al., 2000; Xiao et al., 2011). 
1.2.3 Culture Characteristics 
 Ureaplasma are characterised by their rapid growth in broth media, the rapid pH increase 
caused by production of high levels of ammonium ions being detected by phenol red (clinical 
samples can range from about 10-107 colour changing units/ml) in less than 24 hrs. Colour 
change occurs only at the end of the log phase of growth as the bacteria are entering the static 
phase, but culture viability drops sharply in these wells (bright red-fushia) as the increasing 
PH by liberation of ammonium ions slow their growth and division.  For this reason 
Ureaplasma never reach a high enough culture density to cause turbidity and turbidity is a 
sure sign of culture contamination by another bacteria. In vivo, of course the toxic intermedi-
ates and fresh urea substrate would be exchanged by normal biological processes.  
Ureaplasma growth can also be shown by colony formation on A8 agar plates or Ureaplasma 
selective agar in the presence of CaCl2 indicator. Colonies of Ureaplasma can be seen after 
48 hours of incubation with a stereomicroscope. Colonies are typically 15–30 μm in diameter 
and have a brownish granular appearance caused by urease activity in the presence of CaCl2 
indicator in the agar and can be differentiated from the large Mycoplasma colonies, which 
have a “fried egg” appearance.  
More recently in clinical diagnostic laboratories, more rapid and specific methods to detect 
Ureaplasma by Real-Time PCR using primers designed against the MBA or urease genes (or 
even species and serovar specific targets) are predominant. However, it is interesting to note 
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that many reference labs (including Public Health England) still run plate culture in parallel 
for diagnostics. 
 
1.2.4 Potential virulence factors of Ureaplasma species. 
 Although Ureaplasma is considered a low virulence organism and live as commensals in the 
urogenital tract of 40-67 % of sexually active women, it is potentially pathogenic and had 
been described as an “under estimated enemy of human reproduction” as it can invade extra 
genital sites particularly in immunocompromised patients were it can cause septic arthritis. 
During pregnancy the altered immune status of the mother and the foetus will provide the 
conditions for these organisms to cause invasive and destructive disease (Waites, 2006). 
Ureaplasma spp. can be transmitted from a colonized woman to her new-born infant and it 
can colonise a wide range of human tissues resulting in multiple clinical manifestations such 
as infertility, histologic chorioamnionitis, stillbirth, preterm delivery, congenital pneumonia, 
bronchopulmonary dysplasia, meningitis and perinatal death.  In men it can cause non-gono-
coccus urethritis prostatitis and renal stones (Yu et al., 2008; Juhász et al., 2011), but still no 
direct link has been found between these pathological conditions and a specific serovar or 
species (Dando et al., 2012). Therefore, the invasive strains of Ureaplasma have some as yet 
unidentified potential pathogenic virulence factors (Paralanov et al., 2012). 
The speculated Ureaplasma virulence factors in the literature include 
1.2.4.1  Urease enzyme: 
 Ureaplasma spp. differ from Mycoplasma by uniquely expressing urease activity which hy-
drolyses urea to generate metabolic energy through creating a chemical gradient across the 
membrane (Romano et al., 1980; Willoughby et al., 1991), but at the same time liberating 
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toxic secretory products such as ammonia, which may cause a local injuries to mucosal sur-
faces and precipitate stone formation by increasing alkaline pH of urine (Takebe et al., 1984). 
Urease by-products may also induce generation of reactive oxygen radicals secreted in close 
vicinity to host cell membranes (Glass et al., 2000).  
 
1.2.4.2  Phosphatase A1, A2 and/or C: 
 It has been hypothesised that degradation of placental phospholipids by Ureaplasma phos-
pholipase A1, A2, and/or C and hydrolysing phospholipids of amniotic membranes would 
liberate arachidonic acid facilitating membrane rupture and  initiating the onset of premature 
labour (Cassell et al., 1986).  In particular, phospholipase C shows maximum activity during 
the exponential phase of Ureaplasma growth (De Silva and Quinn, 1986). Ureaplasma phos-
pholipase is also thought to be a potent inducer of fibroblast cytokine release in vitro and may 
lead to the development of neonatal BPD (Stancombe et al., 1993). However, Paralanov et 
al., 2012 disputed the presence of phospholipase activity through functional assays utilising 
the prototypic strains, raising questions as to whether this activity is real or not (Paralanov et 
al., 2012). 
 
1.2.4.3  IgA Protease: 
 This membrane-attached enzyme is necessary for pathogenicity of Ureaplasma as it facili-
tates its colonisation, gaining access to mucosal surfaces and causing diseases (Soeharso, 
2005; Glass et al., 2000). In spite of the presence of IgA1 antibodies on mucosal surfaces, the 
IgA hinge region of the heavy chain between proline and threonine can be cleaved by the 
Ureaplasma IgA1 protease (Spooner et al., 1992).  It could potentially additionally facilitate 
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colonisation of other microorganisms on the mucosal surface due to local functional defi-
ciency of IgA which act as the principle component of the mucosal immunity (Kapatais-
Zoumbos et al., 1985; Glass et al., 2000; Kilian et al., 1996).  
 
1.2.4.4   Haemolysins: 
 Shepard et al. (1974) found a soluble haemolysin that can be produced from the T-Myco-
plasma with haemolytic action against guinea erythrocytes but less against human and sheep 
erythrocytes.  These authors speculated that it was caused by a weak peroxide reaction (Shep-
ard et al., 1974). Glass et al.(2000) reported two types of haemolysin in Ureaplasma encoded 
by two genes in SV3, hylA which possibly functions as a virulence factor for Ureaplasma spp. 
The other is hlyC, and has an orthologous gene in M. pneumoniae, in which haemolysis is 
mediated by H2O2 activity (Glass et al., 2000). Supporting evidence for this concept lies in the 
fact that orthologous of the haemolysin hlyA mediate the haemolytic and cytotoxic activity in 
other microbes and some Mycoplasma that lack this gene are non-pathogenic (Robertson and 
Sherburne, 1991; Gardella and Del Giudice, 1983). 
 
1.2.4.5  The Multiple Banded Antigen (MBA):  
 This species-specific surface expressed lipoprotein first discovered in 1990 by Watson is pre-
dicted to play a major role in antigenic recognition of both Ureaplasma species by serum 
antibodies in humans during infection (Watson et al., 1990; Zheng et al., 1996). 
The MBA contains both serovar-specific and cross-reactive epitopes. Nucleotide sequence 
analysis of the MBA antigen of SV3 predict that this antigen consist of 2 regions, the C-
terminal domain which is immunogenic, contains the serovar specific repeats (the number of 
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these a. a. repeats define the size variation). The other is the N-terminal domain, which con-
sists of a conserved signal peptide and a membrane anchor (Teng et al., 1994). The MBA gene 
consists of a largely conserved 5' non-coding region; however it does contain biovar- and 
serovar-specific polymorphisms.  The 3' region, usually making up the majority of the gene 
which contains the codons for the repeats: For example, an 18-nucleotide tandem repeat en-
coding the PAGKEQ for SV3, but 12-nucleotide tandem repeat encoding PGKE for SV6. 
Phenotypic diversification of its surface antigenicity resulting from variation in the number of 
these repeating units by additions or deletions of units via a Xer-like recombinase located 
downstream of the MBA gene although there is no diversity in the repetitive sequence (Zheng 
et al., 1995).  Variation in MBA is considered an important mechanism for this wall-less path-
ogen to adapt and evade the host immune response and explain the role of antigen size varia-
tion in disease production and their ability for persistent infection in a wide range of hosts 
(Dybvig, 1990).  
 
1.2.4.6 Pathogenicity islands and horizontal gene transfer 
Horizontal gene transfer (HGT) is transfer of genetic material between bacterial cells uncou-
pled with cell division, e.g. Ureaplasma may acquire antibiotic resistance through this way. 
On the other hand, vertical gene transfer occurs during cell division where genetic material is 
transferred from the mother to the daughter cells (Karlin, 2001). Horizontal gene transfer plays 
a significant role in the adaptation and evolution of many microbial species. Although the 
average Ureaplasma genome size is unusually small for the bacterial kingdom, and such a 
feature generally does not favour DNA acquisition, nonetheless, Ureaplasma species have 
nonetheless been shown to engage in extensive horizontal gene transfer (Xiao, et al. 2011; 
Paralanov, et al. 2012). This transfer of genetic information has been documented among cells 
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of the same serovar, and between cells of different serovars. In fact, comparative genomic 
analysis has indicated the possible exchange of genetic material between U.Parvum and the 
closely related Mollicute Mycoplasma hominis (Sabine et al., 2009). In the largest 
Ureaplasma sequencing study to date, it was found that nearly 40% of all isolates were genet-
ically mosaic in nature due to horizontal gene transfer, and this included the exchange of 
serovar specific markers, including the MBA. This high frequency of genetic transfer may 
indeed explain the weak association between individual serovars and specific disease out-
comes. Moreover, it questions the very existence of distinct serovar populations in vivo since 
specific markers maybe lost, gained, or changed by horizontal gene transfer. The genomes of 
all 14 Ureaplasma serovars have now been found to contain multiple mobile genetic elements, 
including transposases, recombinases and integrative and conjugative elements. The 
presences of these elements provide a means for Ureaplasma species to engage in genetic 
transfer, although the exact underlying mechanisms have yet to be established. 
 
1.2.4.7  Adherence of Ureaplasma to cell surfaces 
Lack of cell wall enable Ureaplasma to adhere to host cell-surface and guarantee the exchange 
of compounds which facilitate its growth, on the other hand it may damage the host cell by 
delivering toxic metabolic compounds to it. Ureaplasma pathogenicity may be attributed to 
its adherence to respiratory, genitourinary, and intestinal mucosa. Certain adhesins could be 
antigenic and act as an essential characteristic for their adhesion and some of which are spe-
cies- and serotype-specific (Kahane and Horowitz, 1993; Smith et al., 1994). Depending on 
the ligand (bacterium)-receptor (host-cell) complex, the outcome of this interaction will be 
determined: if the bacterium can attach itself to the uroepithelium of human (or other species) 
it has a greater likelihood of causing non-gonococcal urethritis, encrusted cystitis, chronic 
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prostatitis, or urolithiasis (Shimada et al., 2014). It may also interfere with male fertility by 
adhering to the surface of spermatozoa, interfering with the sperm motility and sperm/egg 
recognition (Xu et al., 1997; Potts et al., 2000; Zhang et al., 2011; Diaz-Garcia et al., 2006; 
Knox et al., 2003). Also adherence of Ureaplasmas to the surface of spermatozoa and endo-
metrium even before implantation could be the mechanism whereby intrauterine infection is 
established in the amniotic fluid persistently throughout pregnancy (Volgmann et al., 2005; 
Foulon et al., 1985; Knox et al., 2003). Ureaplasma can also adhere to sulfoglycolipid recep-
tor of male germ cell membrane interfering with human fertility (Lingwood et al., 1990). In 
addition, Ureaplasma can attach itself to the sialyl residues and/or sulphated compounds on 
the surface of erythrocytes which enable scientists to use erythrocytes as a model system to 
study adherence Ureaplasma to cell surfaces (Sachse et al., 1996; Saada et al., 1991). Chronic 
lung diseases associated with Ureaplasma infection may result from direct Ureaplasma adhe-
sion and damage to the epithelial cells of human lungs or indirectly through inducing inap-
propriate pro-inflammatory response in the lungs that increases the risk of evolving bron-
chopulmonary dysplasia (BPD) (Schelonka et al.,2005; Torres-Morquecho et al., 2010). 
 
1.2.4.8 Antigenic variation in Mycoplasmas 
In spite of reduced genomic size of Mycoplasmas and their lack of protective cell wall, it still 
shows a striking ability to vary its expression of surface proteins.  This is as an effective means 
of facing challenges when infecting a wide range of hosts and evading the immune competent 
host response successfully to cause diseases that are often chronic. This can be attributed 
partly to the highly dynamic lipoproteins in the membrane which can be genetically changed 
by a number of highly sophisticated mechanisms (Zimmerman, 2014; Monecke et al., 2003). 
A lot of genetic events are responsible for the genetic modulation affecting a number of gene 
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families or “hot spots”. It can alter the expression, the size and the antigenic profile, generating 
a highly dynamic surface within a cloned population (Citti et al., 2010; Zheng et al., 1996).  
 At least four major processes have been shown to modulate Mycoplasma gene expression. 
These complex systems are based on arbitrary actions that affect the expression and the struc-
ture of a number of copious surface lipoproteins, so that modified clones arise at a rate of 10-
2 to 10-5events/cell/generation (Zimmerman, 2014). This Mycoplasma’s striking antigenic var-
iation explains why most protective control methods and vaccine trials against Mycoplasmas 
have been unsatisfactory (Zimmerman et al., 2009; Zimmerman, 2014). 
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   Figure 1.5 Schematic illustration of phase variation in Mycroplasma, and the possible 
DNA inversion events, within the MBA locus copied from (Zimmerman et al., 2009). 
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This flexibility of their surface architecture might be due to lack of some regulatory genes 
found in more classical bacteria and used as a mean to avoid the immune response and allow 
host adaptation in spite of its minute genome (Yogev et al., 2002; Silva and Latorre, 2008). 
Other mechanisms by which these unusual prokaryotes evolve to evade host immune response 
is by masking and unmasking constantly expressed molecules, some of which might be vital 
for Mycoplasma persistence and their adhesion and penetration of non–phagocytic cells (Rot-
tem, 2003). Changes in protein length at the Ureaplasma surface due to modulation of C-
terminal domains in lipoproteins is a common mechanism of antigenic size variation in My-
coplasmas. ON/OFF molecular switching (called phase variation) and size variation of sur-
face lipoproteins are of two types; either based on spontaneous mutations in regions suscep-
tible to DNA slippage by nucleotide insertion/deletion in a simple sequence repeats leading 
to stop codons, or on DNA rearrangements involving site-specific recombinase activity via a 
cut-and-paste mechanism. ON/OFF switch mechanisms modulate surface accessibility by 
masking and unmasking stably expressed components that are essential in host interaction 
and survival (Citti et al., 2010; Wisniewski-Dyé and Vial, 2008; Yogev et al., 2002). In 
Ureaplasma, the switching OFF of certain genes is matched with the switching ON of other 
genes within a gene family or locus. For example, a series of reports have shown site-specific 
DNA inversion events that change the direction of the MBA (UU375) gene promoter so that 
it drives the expression of the adjacent UU376 gene instead. Interaction of the putative tyro-
sine recombinases RipX (UU145), XerC (UU222), and CodV (UU529) of Ureaplasma par-
vum serovar 3 with specific DNA (Zimmerman et al., 2013) is another example suggesting 
the MBA N-terminal paralogue UU172 being switched off leading to the alternating expres-
sion of the neighbouring conserved hypothetical ORF UU171.  
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1.2.5  The role of Ureaplasma species in human diseases  
Ureaplasma are regarded as host-adapted and often as a commensal that mainly colonises the 
mucosal surfaces of the genitourinary and respiratory tract. However, their pathogenic poten-
tial is often underestimated.  For example, Ureaplasma and Mycoplasma have been found to 
cause septic arthritis particularly in hypogammaglobuliaemic individuals, and the role for 
contributing to a poor clinical prognosis in ventilated preterm babies is well known.  These 
patients are immunocompromised and Ureaplasma pathology in patients with AIDS also 
needs to be considered (Cordova and Cunha, 2000; Richard et al., 1993, Izraeli et al., 1991). 
Many physicians and microbiologists think of Mycoplasmas and Ureaplasmas as the last pos-
sible resort because the fastidious bacteriological media required cultivating them, left them 
undetected in clinical situations (DiGiulio et al., 2008). 
Ureaplasma spp. can be isolated from cervices or vagina of 40 -80% of sexually active asymp-
tomatic women as  a normal  mucosal parasite and during pregnancy it increases to as high as 
95% and decreases to 25% in menopausal women ( Viscardi, 2010; Volgmann et al., 2005), 
suggesting an interaction with the normal female cycle and hormone levels. 
 Healthy males harbour the infection with lower frequency (about 20-29%) in their lower 
genitourinary tract and these infections are associated with non-specific urethritis, infertility, 
prostatitis, pyelonephritis, epididymitis and renal stones (Andrade-Roch,2003; Taylor-R, 
1986). In adolescents, the incidence is about 5% (Foy et al., 1975). In women, Ureaplasma 
species can cause adverse pregnancy outcomes like spontaneous miscarriage, stillbirth, post-
partum infection, chorioamnionitis, preterm labour, preterm rupture of membranes, and neo-
natal/perinatal infections (Witt et al., 2005; Sanchez and Regan, 1987; Gibbs, 2001). Outside 
of pregnancy, Ureaplasma can cause gynaecological conditions including: pelvic inflamma-
tory disease, infertility, and vaginal discharge (Taylor-R and Ronald, 1997; Elias et al., 2005). 
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1.2.5.1 Ureaplasma spp. infection in neonates 
Ureaplasma intrauterine infection is commonly associated with neonatal diseases and mor-
bidity during the course of delivery including: congenital pneumonia, chronic lung diseases 
of prematurity (or bronchopulmonary dysplasia; BPD), otitis media, meningitis, opthalmia 
neonatorum, and even perinatal mortality (Viscardi, 2010; Waites, 2006; Prentice et al., 
1977). The rate of colonization was inversely correlated with gestational age; one study found 
that in infants younger than 28 weeks gestation, 80% were found to be colonized with 
Ureaplasma, in contrast to 17.9% of those who were 28–36 weeks of gestation (Izraeli et al., 
1991). Thirty percent of the infants colonized with Ureaplasma spp. developed chronic lung 
disease, compared to 8% of those not colonized who developed chronic lung disease (Sanchez 
and Regan, 1988). 
 
1.2.5.2 Association of Ureaplasma respiratory tract colonization with chronic lung disease of 
prematurity 
Chronic lung diseases of prematurity also recognised as bronchopulmonary dysplasia (BPD) 
is a mixed obstructive/restrictive respiratory disease of preterm infants. Multiple aspects con-
tribute to BPD, and probably act together to stimulate lung injury (Viscardi et al., 2002). The 
influence of neonatal Ureaplasma pulmonary colonisation on the development of BPD had 
been argued and its causal-association with BPD has changed since the introduction of me-
chanical ventilation, antepartum steroid, oxygen therapy and exogenous surfactant (Colaizy 
et al., 2007; Hannaford et al., 1999). On the other hand, intrauterine infection, colonisation/ 
infection with Ureaplasma have been reported to protect premature infants against the devel-
opment of respiratory distress syndrome (RDS) by inducing corticosteroid production. Ma-
ternal antibiotic treatment for intrauterine infections will not prevent BPD and not improve 
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the outcome. Diagnosis of Ureaplasma infection by culture alone may not be adequate as 
infants found negative by culture methods are sometimes found positive by PCR methods 
(Viscardi et al., 2002). 
 
1.2.5.3 Mechanisms and pathology of lung injury  
Bronchopulmonary dysplasia is multifactorial and was first described as a lung injury in pre-
term infants resulting from oxygen toxicity and mechanical ventilation by Northway and col-
leagues in 1967 (Northway et al., 1967) and has been characterised in new born animal models 
and in human stillbirth and full term human births (Johanson, et al., 1982; Broström, 2010). 
The traditional diagnosis revealed that BPD was triggered primarily by oxidant- and ventila-
tion-mediated injury, prior to the era of surfactant treatment, by inducing pro-inflammatory 
responses triggered by the injurious effect of mechanical ventilation (barotrauma) (Donn and 
Sinha,2006). Administration of high oxygen levels alone can arrest alveolar septation of lungs 
in the saccular stage of development. The higher the level of supplementary oxygen the pre-
term neonate is exposed to, the more persistent lung disease they will develop postnatally 
(Alan and Kallapur, 2010; Jobe and Bancalari, 2001). A review of studies showed that cultur-
ing of Ureaplasma from endotracheal aspirates of mechanically-ventilated infants was signif-
icantly associated with BPD development even after improvement of postnatal treatment with 
surfactant, lower oxygen levels and improvement of ventilators to remove barotrauma; how-
ever this still remains an area of contention (Abele-Horn et al., 1998). 
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Figure 1.6 Pathogenesis of bronchopulmonary dysplasia, adapted from(Luciana et al., 2005) 
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1.2.5.4  Ureaplasma infection and adverse pregnancy outcome  
It is difficult to establish the role of Ureaplasma in diseases of the genital tract for many 
reasons; its high isolation rate in healthy asymptomatic individuals its fastidious requirement 
for transport and cultivation and the risky outcome associated with sample taking from the 
upper genital tract, nevertheless, during pregnancy ascending infection of this microorganism 
to the upper genital tract by unknown mechanisms may lead to adverse pregnancy outcomes 
including: chorioamnionitis, abortion, preterm labour, still birth, intrauterine growth re-
striction (IUGR),or resulting in low birth weight infants, premature rupture of membranes 
(PROM) (Gray et al., 1992; Horowitz et al., 1995; Kwak et al., 2014), adverse assisted repro-
ductive technology (Zhang et al., 2014; Mändar et al., 2005; Knox et al., 2003) and post-
partum and post-caesarean section wound infection (Maccato et al., 1990; Newton, 2005) . 
 
1.2.5.5   Experimental Evidence for Causative Role of Ureaplasma spp. in PTL from the Study 
of Non-Human Primates (NHP) 
 Chorioamnionitis or inflammation of the fetal membranes plays an important role as a pre-
cursor in the pathogenesis of premature rupture of the fetal membranes (PROM), or preterm 
labour (Gibbs et al., 1992). The association of Ureaplasma with chorioamnionitis in preterm 
birth in humans is strongly manifested and is best outlined by the review by Viscardi (2010) 
(Viscardi, 2010). To prove this correlation, many experimental in utero Ureaplasma infec-
tions in animals have been carried out in recent years; animal models have been thoroughly 
developed and used in the study of intrauterine Ureaplasma infections, particularly in relation 
to infection associated inflammation and preterm birth. These models have been instrumental 
in the determination of the underlying relationship which exists between intrauterine infec-
Commented [insrv2]: Clin Perinatol. 2010 Jun;37(2):393-
409. doi: 10.1016/j.clp.2009.12.003. 
Ureaplasma species: role in diseases of prematurity. 
Viscardi RM. 
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tions and preterm birth, and also the cellular mechanisms which drive such pathology. Utilis-
ing animal models in these studies allows for the control of a number of experimental variables 
which would simply be impossible to regulate in human studies, including maternal age and 
time of pregnancy. As a result, animal studies can be designed to address causal relationships 
between these exposures and outcomes Novy et al. (2009 )inoculated pregnant rhesus monkey 
with ureaplasma parvum and demonstrated for the very first time that a causal relationship 
exists between chorioamnionitis and premature labour with Ureaplasma as a sole patho-
gen(Figure 1.7) (Novy et al., 2009). 
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Figure 1.7  Microscopy displaying inflammation of the amnion, chorion and parietal decidua mem-
branes of a pregnant Rhesus monkey following inoculation with Ureaplasma parvum (250x magnifi-
cation, haematoxylin and eosin straining, scale bar = 25μm). a = Amnion, c = chorion, d = decidua 
(maternal membrane).A – Shows the membranes from a control primate, and demonstrates an intact 
foetal amnion epithelium with no leukocyte invasion. B – Shows the membranes at day 143 of gesta-
tion, and 7 days post-inoculation with Ureaplasma parvum. Demonstrates oedematous thickening of 
the membranes and leukocyte infiltration throughout the chorion, decidua and the neighbouring con-
nective tissue. Arrows point to chorion trophoblast cells which display signs of necrosis and micro-
abscess formation. Source: Novy et al. 2009. 
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Other examples of the experimental animal models used for intrauterine Ureaplasma infection 
are mice (Allam et al., 2014; Uchida et al., 2013; Von Chamier et al., 2012).   In utero infec-
tion of CD-1 strain of mice at 13.5 days gestation resulted in established Ureaplasma infec-
tion, chorioamnionitis and elevated IL-1beta and MIP-2 at 17.5 days gestation. Of interest, 
age and species has an impact on Ureaplasma infection in mice: attempts to inoculate 8 week 
old CD-1 mice intratracheally failed, but succeeded in C3H/HeJ mice. Furthermore, while 
inoculation of Ureaplasma into the uterine horn of C57BL/6 and BALB/c mice resulted in 
equivalent placental infection and colonization rates, but greater numbers of BALB/c foetuses 
were infected and only BALB/c showed severe protracted chorioamnionitis with cellular ne-
crosis with greatly elevated cytokines. The significant difference in response to intrauterine 
Ureaplasma infection was subsequently determined to correlate to increased syncytiotropho-
blast expression of CD14/TLR2 (Allam et al., 2014; Von Chamier et al., 2012).  Further stud-
ies using mice found that in utero injection at 15 days gestation of enriched fractions of the 
major surface protein of Ureaplasma (the multiple-banded antigen or MBA), or a synthesized 
diacylated lipopeptide derived from the 21 amino acids of MBA, into C3H/HeN mice showed 
that MBA alone was capable of causing increased fetal mortality or induction of preterm birth 
depending on the dose or purity of the MBA (Uchida et al., 2013). Due to ethical considera-
tions and the notorious behavioural difficulties of non-human primates, sheep models have 
gathered much interest in recent years. These have been used to demonstrate the link between 
intrauterine infection and preterm labour and neonatal consequences (Dando et al., 2014; 
Knox, 2010; Moss et al., 2005). 
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Table 1.2 Differences in pregnancy and parturition in animal models from human. 
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 Because sheep have a relatively long gestational period relative to mice (150 days versus 20 
days), sheep models uniquely allow the study of chronic intrauterine infections. Furthermore, 
unlike the rodent placenta, both sheep and humans maintain pregnancy through the corpus 
luteal production of progesterone, further supporting the validity of using sheep to model hu-
man preterm birth. The much larger size of sheep also allows for longitudinal sampling of the 
amniotic fluid during pregnancy, providing a way to precisely determine the physiological 
changes which take place during infection. Beside these advantages, sheep can also be selec-
tively bred for single pregnancies, can be catheterised long term, and the physiology underly-
ing their parturition is well understood. Vitally, even after the intra amniotic injection of 
Ureaplasma species, pregnant sheep appear resistant to the induction of preterm birth through 
the production of oxytocin, allowing the maintenance of pregnancy to term despite significant 
amounts of uterine inflammation. Overall, sheep models are very well suited to the study of 
intrauterine infections and allow for the valid extrapolation of results to the human population. 
 
1.3 Host response to intrauterine Ureaplasma infection (innate and 
adaptive)  
The sterile amniotic fluid plays an important role in protecting the mother and the foetus. It 
has a wide range of anti-inflammatory innate and adaptive factors like immunoglobulins, ly-
sozyme, cytokines, and antimicrobial peptides (like defensins, lactoferrin, and LPS-binding 
protein) (Underwood et al., 2005).  The fetal immunological responses vary from patient to 
patient and are dependent on timing, intensity, duration, and virulence of infection. An intact 
immune system is necessary for limiting the infection and prevents spreading of Ureaplasma 
beyond the mucosal surfaces. Normally the immune response to any immunological stimuli 
is mediated by both innate and adaptive arms of the immune system. Innate immunity is at the 
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forefront to fight microbial infections by stimulating trans membrane pathogen-recognising 
receptors like Toll-like receptor (TLR), mainly TLR1, 2, and 6 in case of Ureaplasma (Tri-
antafilou et al., 2013). These act as immune modulators and are expressed on epithelial and 
immune cells, both in the trophoblast and decidual cells. Following receptor engagement, sig-
nalling occurs through the nuclear factor NF-kB and results in up regulation of antimicrobial 
proteins and peptides, as well as stimulates production of immune-modulating cytokines and 
chemokines.  These soluble mediators in turn recruit immune cells to the site of infection and 
alter their activation state and cellular function. Another key aspect of the innate immune 
system, the complement system plays a vital role in protecting the host against invading or-
ganisms including Ureaplasma by several mechanisms.  Complement activation results in 
attachment of opsonins to the activating pathogen surface that facilitate engulfment by phag-
ocytes, as well as enhancing the humoral response to the proteins bound to the opsonins (ad-
juvant effect) mediated through CR2 on B-cells. Complement activation also releases anaphy-
lotoxins (C3a and C5a) which recruit innate and adaptive immune cells, as well as altering the 
immune cells activation state. Complement can also directly cause lysis of pathogens through 
formation of the terminal membrane complex. In this way, complement initiates inflammation 
and acts as an important link between the innate and adaptive immune systems through its 
receptors on B and T cells (Lynch et al., 2008; Soto et al., 2009; Sung, 2010). Many studies 
have shown higher concentrations of complement products C5a and C3a in the plasma of 
mothers with spontaneous preterm labour with evidence of microbial invasion of the amniotic 
cavity (MIAC) compared to those without MIAC (Soto et al., 2009; Benstein et al., 2004; 
Swierzko et al., 2009). Complement activation can occur through three separate pathways, 
most commonly through binding of a specific IgG or IgM antibody to the pathogen (Beeton 
et al., 2012; Webster et al., 1988).  Bredt et al., in 1977 proved that some components of 
Mycoplasma pneumoniae can activate the first component (C1) of the complement system 
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directly leading to complement system activation, rounding and killing of mycoplasma cells 
by guinea pig serum (GPS) and by a purified C1 after subsequent addition of C2, C4 and C-
EDTA.  In addition, Ureaplasma can bind to mannose-binding lectin (MBL) through terminal 
mannose residues (Benstein, 2004). Furthermore, addition of complement is known to en-
hance the growth inhibitory effect of specific antibodies to Mycoplasma (Webster et al., 
1988). The resultant inflammatory response is essential to overcome the pathogen evasion, to 
decrease tissue injury and to enhance regeneration. However, sometimes the immune response 
is a double-edged sword and over-activation of the innate and adaptive immune response is 
regarded as a negative predictor of fetal well-being. A number of emerging studies have 
showed a strong causal- association between in utero inflammation and adverse pregnancy 
outcome.  The inappropriate and vigorous production of the inflammatory cytokines and 
chemokines was associated with apoptosis at maternal-fetal interface, resulting in tissue injury 
and fetal morbidity and mortality (Kemp et al., 2010; Abrahams, 2008; Witkin et al., 2011). 
Furthermore, excessive stimulation or inadequate regulation of complement can lead to leu-
kocytes recruitment and increased release of potent inflammatory and anti-angiogenic medi-
ators this in turn could lead to placental insufficiency, maternal endothelial dysfunction and 
pregnancy complications. Some reports indicate that phagocyte engulfed Mycoplasma can re-
main viable inside the neutrophil, which is inaccessible to circulating antibodies and dissem-
inate the infection to different parts of the body (e.g. septic arthritis, septic osteomyelitis), 
however, this is most commonly associated with hypogammaglobulinaemic patients, suggest-
ing that the presence of specific antibodies is capable of stopping systemic infection (Jorup-
Rönström et al., 1989). Several reports indicate that antibody alone can inhibit the growth of 
Mycoplasmas in vitro possibly by direct interference with their metabolism. This emphasizes 
the protective effect of mucosal antibodies against invasion (Webster et al., 1988), and the 
importance of the Ureaplasma IgA proteinase in immune evasion.  Activated NK cells have 
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also been reported to directly inhibit growth of Mycoplasmas by secreting IFN-γ through an 
unknown mechanism (Lai et al., 1990).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
 
1.3.1  Immunity in pregnancy 
Pregnant women are an immunologically unique population; due to the presence of a paternal 
allograft (the foetus) requiring suppression of maternal immunity to tolerate the foetus and 
maintain pregnancy (Mor et al., 2012; Zenclussen et al., 2005).  
During normal human pregnancy, the fetal/placental unit represent an additional immunolog-
ical organ. The foetus has poor immunogenicity; the decidua on the other hand has no major 
histocompatibility complex (MHC) antigens which are responsible for variability within the 
same species and this will enable the trophoblast to invade the maternal territory (Manyonda, 
2006). The placenta contains a high number of immune leukocytes, of which 70% are natural 
killer (NK) cells, 20–25% are macrophages and regulatory T cells (T reg) and 1.7% are den-
dritic cells. Regarding the adaptive immune system, B cells are absent, but T lymphocytes 
constitute about 3–10% of the decidua immune cells and its percentage rises during pregnancy 
in response to the developing fetal allograft (Moffett-King, 2002; Mor et al., 2012). Therefore, 
the immune system in pregnancy is functional and reinforced by fetal/placental unit and not 
suppressed as it was thought before (Genbacev, 2011). Furthermore, it is a common misun-
derstanding that the newborn is immunologically naïve. The foetus can evolve an active im-
mune response to invading pathogens which lead to a pathological condition known as fetal 
inflammatory response syndrome (FIRS).  FIRS is characterised as in increase in fetal plasma 
IL-6 concentration > 11 ng/L. IL-6 is an acute phase cytokine and increased in response to 
infection and often associated with tissue damage. It also stimulates production of C-reactive 
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protein (CRP) by the liver and activates T and NK cells (Galinsky et al., 2013; Romero et al., 
2007). 
Additionally, neonatal human T cells differentiate early during human embryogenesis and 
flourish in response to antigens, including allergens, autoantigens and parasites. By 14 weeks 
of gestation, single positive thymocytes can be detected in the thymus, then CD8+ and CD4+ 
T lymphocytes migrate into the fetal liver and spleen (Helen, 2002). Many reports showed 
that there is significant level of IgM antibody in the serum of foetuses whose mothers received 
tetanus toxoid vaccine during pregnancy and excess IgE in serum of those born from mothers 
with Ascaris which indicate a specific fetal immune response as only IgG antibodies are ac-
tively transported across the placenta in humans (Holt and Jones, 2000; Mutwiri et al., 1999; 
Silverstein et al., 1963; Boggess et al., 2005; Kane and Acquah, 2009). 
 
1.3.2  Host defences in the preterm neonate 
The mucosal barriers of preterm infants are known to be relatively deficient in function owing 
to the limited production of secretory IgA in response to invading pathogens, beside the im-
mature innate and adaptive immune responses (Miller et al., 2003; Brandtzaeg et al., 1991), 
deficiencies in complement components, defensins, fibronectin and cytokine response de-
creases their capacity to kill microbes. Furthermore, preterm infants have less chance to re-
ceive maternally derived immunoglobulin which is transported actively through the placenta 
reaching near maternal levels by 28 weeks gestation (Pearay, 2010; Jauniaux et al., 1995).  
This contributes further to the relative immunodeﬁciency resulting in greater vulnerability of 
preterm neonates to even low virulent organisms including viral, fungal and some bacterial 
infections (Millar et al., 2003; Eibl et al., 1988). Moreover deficiencies in cellular phagocy-
tosis decreases their capability for microbial killing rendering them more liable for systemic 
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spread of bacteria especially after colonisation of their respiratory tract mucosa (Miller, 1969; 
Maródi, 2006).  
 
1.3.3 The Complement System  
Complement acts immediately and lacks immunological memory. The complement cascade 
is regarded as the first line of defence particularly in neonates who have never been exposed 
to an antigen before. It involves a complex sequence of more than 30 soluble and membrane 
attached proteins distributed in the circulation, body fluids and on the surface of the cells. 
Once triggered, it acts sequentially to mediate an inflammatory response to protect the host 
against infection. The function of the complement system is not confined to the innate im-
munity only as it was thought before, in fact there is an interaction between the adaptive and 
innate wings of immunity .Complement acts as an adjuvant for the stimulation of adaptive T- 
and B-cell response and eventually in the generation of antibodies, by which, bridging innate 
and adaptive immunity basically through complement receptor type 2, CR2 (CD21), ex-
pressed by B cells. Deposition of complement opsonin fragments on the surface of pathogens 
assists in clearance of immune complexes and mediate phagocytosis by neutrophils and mon-
ocyte which express complement receptors (CR1,CR3, CR4) (Nielsen et al.,2000; Dunkel-
berger and Song,2010).Thus complement maintains a normal physiologic homeostasis by 
clearing apoptotic bodies, toxic cell debris, immune complexes and inflammatory products 
which can be otherwise directed against self-tissues thus preventing autoimmune and immune 
complex diseases (John et al.2002; Gasque et al., 2000). 
 Experimental studies have shown that excessive complement activation at inappropriate sites 
or inadequate regulation of complement recruits leukocytes and releases potent inflammatory 
and anti-angiogenic mediators.  These can contribute to placental insufficiency which is the 
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basis of many pathological conditions complicating pregnancy, such as pre-eclamptic toxae-
mia (PET) and intra uterine growth restriction (IUGR) (Gasque et al., 2000; Carroll, 2004; 
Sahu and Lambris, 2001; Lynch et al.,2011). 
 
1.3.3.1 Pathways of complement activation 
Three main pathways; the classical lectin and alternative pathway. They differ from each other 
by their triggering factors for activation. The three pathways converge at the generation of a 
C3 convertase which cleaves C3 (the most abundant complement component) into C3a and 
C3b. The latter covalently binds to the activating surface and acts as an opsonin by facilitating 
engulfment by phagocytic cells. A second molecule of C3b binds to the C3 convertase to 
produce the C5 convertase which cleaves C5 into C5a and C5b. C5b is the first component of 
the membrane attack complex (MAC) and associates with membranes at the site of activation.  
Sequential additional binding of components C6, C7 and C8 allow insertion of the complex 
into the membrane. Additional binding of multiple molecules of C9 then completes a lytic 
pore in the membrane called the membrane attack complex (MAC). Formation of large num-
bers of MAC on a membranous surface disrupts the osmotic balance of cells and leads to cell 
lysis or death (Cosmin et al., 2011; Janeway et al., x2001).  
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Figure 1.8 Activation of the complement system via three different pathways (the classical, lectin and 
alternative pathways), which are activated differently; the classical pathway via Ab/Ag complex; the 
MBL of the lectin pathway is activated by binding to pathogen specific carbohydrates; the alternative 
pathway activated by spontaneous hydrolysis of C3. However, they all converge at the cleavage of a 
central C3 component by C3 convertases to generate the same set of complement effector molecules, 
which play roles in opsonization, recruitment of host effector cells and direct killing of invading patho-
gens via MAC .Complement regulators are indicated by red lettering. Predicted method of Ureaplasma 
(UP) killing by the complement also shown on the diagram indicated in green. 
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1.3.3.1.1  The classical pathway 
The complement protein C1q binds to the Fc portion of IgM or IgG deposited on the surface 
of the pathogen. Interaction with a single bound IgM or multiple bound IgG in close proximity 
of the pathogen leads to conformational changes in C1 which cleave C1r and C1s into their 
active form so they can cleave C4 and C2. C4a and C2b are small fragments that are released 
while freshly activated C4b binds covalently to the activating surface and binds to C2a (likely 
as un cleaved C2 which is then further processed by C1 to generate the C4b2a complex which 
is called C3 convertase (named because it cleaves C3 into C3a and C3b).  This complex is 
inherently unstable and requires calcium to retain a short lived enzymatic complex.  The phys-
iological degradation of this complex forms part of the control for activation of complement. 
 
1.3.3.1.2  The Alternative Pathway 
This arm of the complement system is activated by the spontaneous low-level hydrophilic 
attack of C3.  C3H2O can initiate a fluid phase C3 convertase by forming a complex with factor 
B that is subsequently cleaved by factor D into Ba and Bb (Fig.1.8). Properdin (P) binds to 
C3 convertases to stabilize it and increases its half-life (Müller-Eberhard and Schreiber, 1980). 
Freshly cleaved C3b, like C4b forms covalent bonds with proteins or carbohydrates in the 
near vicinity and generate surface bound, more stable alternative C3 convertases (C3bBb). 
However, host cells rapidly degrade C3b into inactive fragments utilising surface bound factor 
H, therefore, only non-host surfaces without regulators can establish an active alternative C3 
convertase.  This pathway is also used by classical and lectin pathways to create a positive 
amplification loop as C3b generated by other pathways can bind factor B (Fig.1.8). C3bBb 
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can bind an additional C3b molecule and create a C5 convertase leading to the formation of 
the MAC (Sarma and Ward, 2011).  
 
1.3.3.1.3 The mannose-binding (lectin) pathway 
Mannan-binding lectins (MBL) or ficolins in the serum bind to non-host conformations of 
complex polysaccharide common to bacteria. Similar to C1q, the bound lectin alters confor-
mation and binds to an MBL-associated serine protease (MASP-1, MASP-2 and MASP-3 
have been described), which can then cleave C4 and C2, identically to the classical pathway.  
Therefore, the lectin C3 convertase (C4b2a) is indistinguishable from the classical C3 con-
vertase (Fujita, 2002; Teizo et al., 2004). 
 
1.3.3.1.4 The terminal complement complex (TCC) 
The C5 convertases in both the classical and alternative pathways cleave C5 to produce C5a 
and C5b. Thereafter, C5b sequentially binds to C6, C7, and C8 to form C5b-8 that catalyses 
the polymerization of up to 12 C9 molecules to form the MAC that inserts into target mem-
branes and causes Ca2+-dependent (and hypotonic) acute cell death  (Podack and Tschopp 
1982). While, erythrocytes lyse quickly by even one MAC in the cell membrane, in nucleated 
cells, deposition of limited C5b-9 complexes channels may be sub-lytic due to ability of some 
mammalian cells to repair their membrane rapidly (Telga et al., 2011).  
The biological functions of complement are mediated through the production of activation 
fragments which initiate as well as amplify inflammation (Lynch et al., 2008). Concentrations 
of the smaller complement cleavage products or anaphylatoxins (C3a, C4a, and C5a) in bio-
logical fluids reflect the magnitude of complement activation. A study by Soto et al. showed 
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supporting evidence that preterm labour is associated with complement activation in the am-
niotic fluid determined by ELIZA measurement of plasma concentrations of fragment Bb 
(fBb) (Soto et al., 2009). 
 However, humans with acquired or inherited complement proteins deficiencies are more sus-
ceptible infections and PTL (Ram et al., 2012). Many studies reported a Link between immu-
nological disorders and increased risk of in utero infections and recurrent spontaneous abor-
tion. Kilpatrick et al. (1995) reported that 16% of women with low MBL levels had preterm 
labour (Kilpatrick et al., 1995). Swierzkoa et al., in 2009 found an association between relative 
deficiency in l-ficolin with prematurity, low birth weight and infections (Swierzkoa, et al., 
2009). Mycoplasma pneumoniae is an important and sometimes overlooked pathogen causing 
infections of the respiratory tract in patient with X-linked agammaglobulinaemia and Com-
mon variable immunodeficiency (CVID) (Beeton et al., 2012; Franz et al., 1997). 
 
1.3.4  Host tissue protection against complement lysis 
As the process of C3b and C4b covalent attachment is essentially non-specific (proximity 
being the only influencing factor), the host cells need to be able to eliminate or dampen by-
stander damage at sites of inflammation. Human cells continuously express a series of com-
plement regulatory molecules which protect all cells exposed to plasma or other biological 
fluids to resist the continuous low-level complement attack and to direct complement deposi-
tion to the surface of pathogen (Gasque, 2004). There are four important cell-membrane com-
plement regulatory glycoproteins: membrane cofactor protein (MCP; CD46), decay-acceler-
ating factor (DAF: CD55), CD59 and complement receptor type 1 (CR1; CD35). DAF and 
CR1 act by accelerating the decay of the C3 convertases, MCP and CR1 bind to C3b and 
recruit serum protease factor I to cleave it to inactive fragments, CR1 can additionally induce 
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factor I cleavage of C4b.  CD59 on the other hand binds to the incomplete complex C5b678 
and blocks the binding of C9 and the formation of the lytic pore. Complement regulators vary 
in their relative importance, CD59 and DAF appear to be the most widely and highly ex-
pressed regulators on cells allowing them to survive complement-induced lysis, and their ex-
pression noticeably increases in inflammation and cancer (Varsano et al., 1995). MCP is ex-
pressed on many tissues except erythrocytes, while CR1 is mainly expressed on erythrocytes 
and thought to aid processing of circulating immune complexes. In order to achieve maximum 
protection, control is required both at the level of the C3/C5 convertase and at the level of the 
MAC. Another circulating complement regulator is C1 inhibitor which covalently binds to 
activated C1r and C1s to neutralise them. Factor I, as previously described, can cleave surface 
bound C3b into its inactive forms iC3b and C3dg but it has very low activity unless C3b is 
bound by cell surface regulators CR1 or MCP, or fluid phase factor H.  Similarly, it can cleave 
C4b into its inactive fragment C4d in the presence of cell surface bound CR1 or fluid phase 
C4b-binding protein (C4bp). These regulatory proteins are lacking on the surface of patho-
gens, but have been reported to be recruited by some (Funabashi et al., 1994; Jones et al., 
1994). 
 
1.3.4.1 The therapeutic role of complement regulators 
Complement regulatory proteins or complement inhibitors are normally expressed on cells to 
protect them from bystander attack by activated complement.  Any imbalance in the mecha-
nism that regulates cell-surface complement or damage to these protective membrane proteins, 
such as after ischemia reperfusion injuries I/R, may allow direct complement–induced host 
tissue damage or precipitate inappropriate immune cell recruitment by liberating biologically 
active anaphylatoxins (Arumugam et al., 2004; Mollnes et al., 2002). Hypoxic/reoxygenated 
human endothelial cells in particular can be injured by a marked recruitment of neutrophils to 
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the site of inflammation with superoxide production (Monsinjon et al., 2001; Collard et al., 
2000). Abnormal expression of these complement-regulatory proteins like CD55, CD46 and 
CD59 may result in complement-mediated and autoimmune diseases. Exogenous administra-
tion of recombinant soluble therapeutic forms of complement regulators have been examined 
in vitro as well as in animal models.  In particular addition of these synthesized soluble forms 
have been found to prevent complement –induced damage to host cells following reperfusion 
injury and increase tolerance of transplanted organs (Makrides et al., 1998; Kalli et al., 1994). 
Many experiments in molecular biology, physiology and biochemistry have been tried to find 
powerful synthetic complement inhibitors or modulators to use as therapeutic tool for com-
plement-associated diseases. Some of these therapies are available in for treatment, some are 
in clinical trials, and others are still in pre-clinical development. In contrast to the novel role 
of these proteins in protecting normal tissues from accidental injury by activated complement 
components, it can provide cancer cells with some resistance. For example, CD59 appears to 
be the most effective mCRP protecting tumour cells from complement-mediated lysis (Fishel-
son et .al., 2003), trials to use neutralising antibodies targeted specifically the membrane com-
plement regulators (mCRP) on cancer cells in combination with anticancer complement-fixing 
antibodies treatment hopefully will improve the therapeutic efficacy by increasing tumour cell 
susceptibility to in situ complement deposition . DAF, MCP, and CD59 expressed on the glo-
meruli protect them against immune-mediated renal injury, hence, any change in their expres-
sion levels can result various glomerular disorders. Promising results have been published for 
several animal experiments administering soluble recombinant complement regulatory pro-
teins and trials for overexpressing complement regulatory proteins locally on the glomeruli 
are hoped to be future therapeutic approaches (Nangaku, 1998). Similarly, in ovarian cancer, 
experiments showed that the use of antibody neutralization of CD59 expressed by the ovarian 
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tumour significantly increased the susceptibility of the cells to complement-mediated lysis 
(BJØRGE, et al., 1997). 
In 1974, Kavanagh et al., submitted evidence for the pathogenic role of the alternative path-
way of complement following mutations in the complement regulatory proteins factor H, 
MCP protein (CD46), and factor I which predispose to development of Haemolytic Uremic 
Syndrome (HUS) (Kavanagh et al., 1974). Some clinical inhibitors are well known like Ecu-
lizumab (trade name Soliris) which is a humanized monoclonal antibody that blocks the cleav-
age of C5 and blocks the terminal pathway, approved to be effective in treating atypical HUS 
and paroxysmal nocturnal haemoglobinuria (PNH) (Hellman et al.,2006; Rother et.al.,2007) 
and in other diseases such as after kidney transplantation to decrease the chance of rejection 
(as reviewed on Alexion Pharmaceuticals website: http://alxn.com/research-develop-
ment/alexion-research/soliri). Another pharmaceutical monoclonal antibody is Pexelizumab, 
which also blocks C5 cleavage and has been found to reduces the risk of death in patients 
undergoing coronary artery bypass grafting (Testa et al., 2008). 
Also a small, natural, broad-acting complement inhibitory protein (termed OmCI) was ex-
tracted from the soft tick Ornithodoros moubata. This native 17-kDa non glycosylated protein 
inhibits classical and alternative complement pathways activation of both human and guinea 
pig targeting C5 itself and complement terminal pathway (Nunn et al., 2005).  
However, in my model I used a recombinant form of a native blocker of complement compo-
nents, that is the soluble Complement Receptor type 1(sCR1) which has the ability to block 
both the classical and the alternative pathway by binding to C3b, enhancing cleavage of C3b 
dimers by factor I, it also inactivates C3 and C5 convertases assembled on pathogen mem-
brane. In 1997, a study by Klickstein showed that in humans, C1q can bind specifically to 
CR1,  therefore all three complement opsonins C3a,C5a and C1q could be recognised by sCR1 
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(Klickstein et.al., 1997). Nevertheless, sCR1 has a disadvantage as it inhibits important anti-
bacterial complement products like C3b and C3 opsonic product which limits its therapeutic 
application (Ross and Densen, 1984). Some mutant versions have been created to be used as 
an alternative to sCR1 with fewer side effects (Scesney et al., 1996). Wild type CR1 is com-
posed of 35 extracellular repeat domains and a trans-membrane domain.  Soluble versions 
containing the entire 35 extracellular repeat domains (TP10 or CDX-1135), or versions only 
containing the 3 N-terminal repeats (APT070) have been examined. It was used by Weisman 
et al. in 1990 in rats to decrease the ischemic /reperfusion injury by 44%.  They noted a sig-
nificant decrease in both C5a levels and MAC deposition, indicating that it reduced both direct 
and indirect routes of tissue damage. Most of the early work has focused on a cardio protective 
effect in animal models of ischemia/reperfusion injuries (Homeister and Lucchesi, 1994; 
Weisman et al., 1990); however, in theory it should be able to diminish any complement- 
mediated injury.     
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Aims  
1- To characterise complement activity in preterm lambs sera compared to matched maternal 
sera by creation of a novel haemolytic assay. 
2- To characterise complement killing by preterm fetal sera compared to the matched maternal 
sera using an established Ureaplasma bactericidal assay. 
3- To manipulate the Ureaplasma bactericidal assay to determine the activation pathway and 
rate of killing, comparing different gestational age lamb and adult sera. 
4- To examine systemic Ureaplasma infection in lambs of different gestational ages. 
5- To evaluate the physiological and physical alterations in Ureaplasma with increasing length 
of in vivo infection. 
6- To investigate genomic changes in Ureaplasma after chronic intrauterine infection. 
 
 Hypothesis 
The ability of the infecting strain of Ureaplasma to adapt to the ovine immune system for 
extended durations in spite of its extreme sensitivity to fetal and adult serum is related to co-
incident alterations in the major surface antigen (multiple banded antigen; MBA) and altera-
tions in the whole genome sequence in order to enable Ureaplasma to escape the evolving 
fetal immune system. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
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2 Materials and Methods 
2.1 Ureaplasma 
2.1.1  Source of Ureaplasma isolation 
Labouratory samples of Ureaplasma parvum (Achilias, Roupakias et al.) serovar 3 (HPA5), 
SV1 (DFK1), SV6 (HPA2), SV14 (HPA32) were kindly provided by Dr. Victoria Chalker 
from the Health Protection Agency (HPA; Colindale, London, UK) currently known as Public 
Health England (PHE). Measurement of Ureaplasma isolated from experimentally HPA5-
strain infected animals were from sheep samples (serum, amniotic fluid and tissue) collected 
from date-mated singleton pregnant ewes housed and acclimatised in a purpose built facility 
at the University of Western Australia. Samples were given ID numbering and sent in dry ice 
boxes to Cardiff. All prototype serovar reference strains available from the American Type 
Culture Collection (ATCC) were received in my institution from original sources: the Institute 
of Medical Microbiology, University of Arthus, Denmark or from Prof. Janet Robertson (Uni-
versity of Calgary, Canada). The complete genome sequence of U. parvum serovar 3 (ATCC 
strain 700790) was published in 2000, which is available in GenBank under accession no. 
NC_002162, (Glass, 2000). Likewise, the full genome sequence of U.urealyticum serovar 10 
(ATCC 33699 strain) is also accessible in the GenBank (accession no.  NC_011374). All 
strains were aliquoted and stored as stocks at -80 ˚C freezers until used for analysis. 
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2.1.2 Culture media of Ureaplasma 
Trials to find the best media for growth of Ureaplasma was found to be the commercial 
Ureaplasma selective medium (USM; Mycoplasma experience ltd., Surrey, UK), using stand-
ard techniques as previously published (Beeton, Daha et al. 2012). This medium is made up 
of a simple broth base medium complemented with yeast extract 2.5 g/L, urea 1 g/L, and 10% 
heat-inactivated porcine serum, with a pH indicator (phenol red), medium pH= 6.65, Ampho-
tericin B 2.5 µg/ml and Ampicillin 0.25 mg/ml. One hundred and eighty microlitres of USM 
was loaded into each well of the first column of 96 well flat- bottom plates then 20 µl of stock 
growth or fresh clinical samples were inoculated into the first well in the column to give an 
initial dilution of 1:10 from which 20 µl was titrated down to a dilution of 10-7 leaving the last 
well as a negative control.  Plates were covered with clear air tight adhesive sealing tape 
(Elkay, Basingstoke).  For Western blot analysis the last positive well was scaled up in 7 ml 
bijoux tubes (Elkay, Basingstoke).  All incubations were performed in a humidified tissue 
culture incubator set at 37oC, with ambient CO2 concentration overnight. Non-turbid colour 
changes of the broth from orange-yellow (negative) to reddish-pink (positive) indicated 
Ureaplasma growth (Shepard and Lunceford, 1976; Shepard and Lunceford, 1978; Stemke 
and Robertson, 1982).  Sub culturing was performed at 24 hours; whereas titrations were al-
lowed to proceed for 48 hrs to reach completion as colour changing unit /ml are the quantifi-
cation measurement of Ureaplasmas. Change in colour of the medium from yellow to red is 
due to liberation of ammonium ions and production of NH4+ causes a pH rise from 6.5 to > 9, 
detected by the pH indicator in the medium Ureaplasma cultures never reach turbidity, unless 
the culture get contaminated, due to self-toxicity caused by ammonium ion accumulation. 
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2.1.3  Quantification of Ureaplasma growth 
To determine the number of colour changing units (CCU) of Ureaplasma per millilitre of 
sample fluid which is directly correlated to colony-forming units (CFUs) on agar plates, 
Ureaplasma titres were quantified by serial 10-fold dilution (or 2-fold dilution for killing as-
say) in USM, in triplicate using the methods outlined in the previous section. Colony-forming 
units were quantified for comparison by inoculating Ureaplasma selective agar plates (Myco-
plasma experience) with 5-μl drops of the 1:10, 1:100, and 1:1000 dilutions the plates were 
then incubated in atmospheric CO2 at 37°C for 48–72 hrs; subsequently, colonies were 
counted under x4 and x10 objective lenses using a stereo microscope (Leica Microsystems, 
North Ryde, NSW, Australia) to count colony forming units per ml of broth.  Purification of 
single colonies was also performed on these plates by scraping a single colony by microscope 
guided sterile 10 µl tip and inoculating in 100 µl USM overnight. Strains for sequencing were 
colony purified three consecutive times (triple-cloned). 
 
 
 
 
 
 
 
 
 57 
 
 
 
 
 
Figure 2.1   96 well plate displaying the colour change which occurs during Ureaplasma culturing.  
Following serial dilution and incubation for 24 hours, this plate shows the differential growth patterns 
exhibited by 6 different U.Parvum SV3 strains. A pink colour indicates shift toward alkaline PH. By 
48 hour, all positive wells will be dark pink. 
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2.1.4 Scaling up of Ureaplasma growth 
Following culturing of Ureaplasma isolates from frozen stock, the final well was added to 5 
ml USM in a 7 ml bijou.  If this were to be used for Western blot analysis, then it was allowed 
to incubate at 37oC for 48 hours. If it was to be scaled up for genome sequencing, it was 
incubated for 8 hours prior to addition to 250 ml of USM prior to 48 hour incubation at 37oC.  
Five ml cultures were spun in 4 sterile 1.5 ml Eppendorf tubes for 20 min at maximum speed 
(13,500 xg) in a bench top centrifuge, while 250 ml cultures were spun at 13,000 xg for 3 hour 
in sterile polycarbonate bottles. Pellets were washed with 1x sterile phosphate-buffered saline 
(PBS), and then pooled into a single 1.5ml centrifuge tube, centrifuged at 13,500 xg for 30 
mins. For Western blot, pellets were washed 3 times prior to preparation for separation on 
polyacrylamide gel.  Pellets for genomic sequencing were extracted using DNeasy Blood & 
Tissue Kit (Qiagen, UK) following manufacturer’s instructions, which resulted in an elute of 
400 µl in elution buffer.  This was concentrated by speed vac in Central Biotechnology Ser-
vices to 50 µl or less prior to submission to PHE for sequencing. 
 
2.1.5 Quantification of proteins  
Pellets for Western blot were solubilised in 50 µl of 1% SDS in PBS prior to using the Quanti-
ProTM BCA Assay kit (Sigma- Aldrich Company).  A standard curve was obtained from a 
dilution series of standard bovine serum albumin (BSA; Sigma Aldrich).  The assay was set 
up in a 96-well plate following manufacturer’s instructions and colorimetric analysis per-
formed using a Dynex plate-reader and protein concentration calculated using the quadratic 
curve fitting program and the Dynex MRX Revelation internal software.  Sample and control 
dilutions were incubated for 2 hours at 37oC. Purple-blue colour is caused by the reduction of 
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CU+2 into Cu+1 mediated by the protein and buffers, measured by absorbance at 562 nm 
(Walker, 2009). 
 
2.2 Sheep Experiments 
2.2.1 Animal ethics 
All experimental sheep procedures were performed in Perth, Australia following approval by 
the University of Western Australia Animal Ethics Committee (RA/3/100/1289) to use the 
animals for scientific purposes. 
2.2.2  Animals and Sample Collection 
In these experiments date-mated merino-cross ewes (Ovis aries) carrying singleton pregnan-
cies were used as a model to replicate intrauterine infection and follow the pathological 
changes of our lab reference strain of U.parvum serovar 3 (HPA5).  
Phase one experiments were started in July 2012.  These experiments utilised 6 pregnant sheep 
with catheter implantation into the foetuses and 6 pregnant sheep where ultrasound guided 
needle injection were utilised to deliver the experimental infection.  Strain HPA5 (SV3) was 
thawed on ice and titrated in USM media then (107) of fresh infectious units/ml were injected 
in all cases.  
Catheterised lambs: 6 date-mated ewes with singleton foetuses at 120d gestational age (GA) 
had aseptic recovery surgery to install catheters into the fetal jugular vein, trachea and two 
catheters into the amniotic fluid as described previously (Kemp et al., 2013). After a 24h 
recovery, animals were experimentally infected through amniotic fluid catheter “A”.  Using 
catheter “B”, amniotic fluid was serially sampled immediately before and 2, 6, 12, 24 and 48h 
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after infection. Animals were euthanized with an intravenous bolus (100mg/kg) of pentobar-
bitone at 120 h. Fetal cord blood, maternal venous blood and amniotic fluid were collected at 
delivery and fetal tissues were snap frozen in liquid nitrogen for subsequent analysis.  
Non-catheterised lambs: 6 date-mated ewes with singleton foetuses at 119d GA were injected 
by ultrasound guided needle and infection allowed proceeding for 1 week, when animals were 
euthanized as above.  Fetal cord blood, maternal venous blood and amniotic fluid were col-
lected at delivery and fetal tissues were snap frozen in liquid nitrogen for subsequent analysis.   
Phase two experiments were started in July 2013.  For these experiments, ultrasound guided 
needle injection into the amniotic fluid was used to experimentally infect the animals with the 
same strain (HPA5) at a much earlier GA.  Eight date-mated merino-cross ewes carrying sin-
gleton pregnancies received a single intra amniotic (IA) injection of 107 CCU Ureaplasma at 
83 d GA.  Ultrasound guided amniocentesis samples were taken from these animals at 3 and 
5 weeks post-infection. Animals were euthanized with an intravenous bolus (100mg/kg) of 
pentobarbitone at 6 weeks post-infection (125 d GA). Fetal cord blood, maternal venous blood 
and amniotic fluid were collected at delivery and fetal tissues were                                                                                                                                                                                                                                                                                                                                                        
snap frozen in liquid nitrogen for subsequent analysis.  
Phase three experiments were started in July 2014.  For these experiments, ultrasound guided 
needle injection into the amniotic fluid was used to experimentally infect the animals with 
HPA5 for 10 days at 116 d GA or for 24 days at 70 d GA (N=8 per group), so that delivery 
was performed at 125 d GA (as for all experiments above) and 94 d GA (earlier than all pre-
vious experiments). Again animals were euthanized with an intravenous bolus (100mg/kg) of 
pentobarbitone at the appropriate GA for the foetus and delivered by Caesarean section. Fetal 
cord blood, maternal venous blood and amniotic fluid were collected at delivery and fetal 
tissues were snap frozen in liquid nitrogen for subsequent analysis.    
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Control animals: For each of the experiments above there were 4 to 6 singleton pregnancies 
run in parallel and instead of Ureaplasma, these animals received an injection of sterile saline.  
Samples were collected as for the infected animals and these are used as comparative controls.  
Sera were also obtained from 3 non-pregnant, non-infected sheep from TCS Bioscience by 
peripheral venepuncture of Merino cross to be used as non-immune sheep sera. 
 
 
Figure 2.2 Diagram showing the Study design 
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2.3 Complement Assay 
2.3.1 Preparing serum for complement studies 
Sera to be tested had been collected into Becton Dickinson serum separator tubes and allowed 
to clot for 10 min at room temperature, then kept on ice until they could be centrifuged at 3000 
xg for 10 min and the sera aliquoted into 400 microliter aliquots in sterile Eppendorf tubes, 
which were stored at -80oC prior to use.  Sera was only thawed once and used immediately 
prior to each assay. The heat–inactivated serum (HI) was prepared by heating the serum ali-
quots at 56◦C for 30 min; this will inactivate C2 component of the complement system on 
which both the classical and the lectin pathway depend on for their activation. Heating also 
inactivate factor B which is necessary for alternative pathway activation. 
2.3.2 Serum bactericidal assay 
Serum bactericidal assay, or serum killing, was performed as described previously by Beeton 
et al. (Beeton et al., 2012). For killing assays, log-phase growth Ureaplasma was diluted to 
1:10 in USM and set up in v-shaped bottom 96 well plates in triplicate for each serum dilution 
or control and centrifuged at 3,600 xg for 10 min to pellet bacteria.  All supernatant was re-
moved and pellets re suspended in serum diluted in complement fixation buffer (CFB; Oxoid 
ltd., Basingstoke, UK) and incubated at 37oC.  Following incubation, serum was removed by 
centrifugation and the bacterial pellet re suspended in USM prior to titration of each replicate 
individually to quantify the surviving Ureaplasma, as previously published (Beeton et al., 
2012). For some experiments, serum concentration was varied, while for other experiments 
the length of incubation with serum was varied.  For those experiments examining fixed incu-
bation times, 10 mM EDTA (final concentration) was added to block further complement 
activation and the serum removed by centrifugation and re suspension in USM prior to titra-
tion of surviving bacteria.  Serum killing was calculated as the fold decrease relative to the 
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titration of surviving bacteria following identical exposure to the same sera, except that all 
complement activity had been removed by heat-inactivation at 56◦C prior to the experiment. 
All killing assays were repeated three times to avoid bias.    
To disable the calcium-dependent classical and lectin pathways (LP) but allow the alternative 
pathway (AP) to stay intact, the serum was diluted in EGTA buffer (CFB supplemented with 
10mM EGTA and 10mM Mg+2).  Using this buffer the calcium ions were differentially che-
lated from serum, while the added Mg+2 enhanced the assembly of C3bBb keeping the activity 
of the alternative pathway intact.    
Additionally, Ureaplasma populations were subjected to continuous immunological pressure 
by transferring the surviving bacterial growth from the last well serially through broth con-
taining 1:100 dilution of rabbit polyclonal antibodies against serovar 3 (Gift from Janet Rob-
ertson, University of Calgary), to test if there is any possibility of phase variation of MBA in 
vitro. After each attack 20 µl of the surviving bacteria were collected and stored at -80 o C to 
be analysed by Western blot and/or PCR. 
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Figure 2.3 Schematic diagram of the 96-well plate set up for complement killing assay for four rep-
resentative sheep sera (A - D) under two conditions: 50% heat inactivated sheep serum (HI-ShS) and 
50% normal sheep serum (NShS). 20µl of Ureaplasma following incubation with sera was added to 
the first well of each column to a dilution of 1:10.  This was repeated for the next 2 wells to give a 
final dilution of 1:1000, surviving Ureaplasma were then diluted by 2-fold dilution (equal volume for 
the rest of the plate.  This was then allowed to incubate for 48 hr at 37oC, resulting in the plate at the 
bottom.  Red wells represent growth and the comparative growth between N and HI allows calculation 
of killing as shown. 
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2.3.3  Pathways responsible for non-immune sheep serum killing 
2.3.3.1  Classical pathway (CP), depletion of sheep serum Igs  
One ml of ice cold sheep serum was pushed by a syringe through a HiTrap™ Protein A-
sepharose column (GE Healthcare, Slough) and then flushed through with ice cold CFB into 
a collecting tube to elute all Igs from sheep serum.  The depleted samples were collected in 
1.5 ml Eppendorf tubes and an aliquot tested by Western blot to check for complete depletion 
from Igs and the rest was stored in -80◦ C for future use in serum killing assays. 
 
2.3.3.2  MBL depletion  
In order to deplete lectins from the sheep serum, one ml of ice cold sheep serum was circulated 
several times through a mannan-agarose column on ice (Sigma-Aldrich) and then collected in 
sterile Eppendorf tubes. There are no reagents available to test the depletion of MBL or other 
lectins from sheep sera, however, the samples were compared for their capacity to kill 
Ureaplasma relative to un-depleted sera.  
 
2.3.3.3  Alternative pathway 
Killing assays were performed following dilution of the sera in 10mM ethylene glycol tetra 
acetic acid (EGTA) and 10mM Mg+2, so that calcium ions which is necessary for activation 
of the classical and lectin pathway were chelated allowing only the alternative pathway to 
function.  This makes presumptions about the cation requirement of complement pathways 
based on other species; however, is standard practice for isolating the alternative pathway.   
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2.3.4  Measurement of complement activity  
2.3.4.1 Antibodies and erythrocytes 
Guinea pig, chicken, sheep and rabbit erythrocytes were purchased from TCS Biosciences 
(Oxford, UK). Human erythrocytes were obtained from consented healthy volunteers by phle-
botomy (approved by the Cardiff University School of Medicine Research Ethics committee) 
and coagulation was inhibited by the addition of 100 U of heparin sulphate. Sheep serum from 
non-pregnant sheep was obtained from TCS Biosciences, whereas maternal serum from preg-
nant sheep was obtained by peripheral venepuncture of Merino cross ewes and fetal cord blood 
was obtained from  their lambs during Caesarean delivery at 85, 95 and 125 days of gestational 
age. 
 
Table 2.1   Type and source of reagents used in modified complement haemolysis test 
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2.3.4.2  Modified measurement of the CH50 assay 
The CH50 is a screening assay for the total functional activity of the complement system by 
determining the dilution of serum required to lyse 50% of a one percent suspension of rabbit 
antibody-coated sheep erythrocytes (Whaley, 1985; Nilsson and Nilsson, 1984). However, 
erythrocytes are generally protected from complement-mediated lysis in a species-restricted 
manner (i.e. serum has poor ability to lyse erythrocytes from the same species) due to the 
expression of complement regulators on the erythrocyte surface (Ish et al. 1993; Kim et al., 
1995; Rushmere et al., 1997; Yu et al., 1997). Hence, the standard CH50 test using sheep 
erythrocyte targets is suboptimal for measuring sheep complement activity so a range of dif-
ferent species erythrocytes (guinea pig, sheep, chicken, rabbit and human erythrocytes) were 
tested to find that guinea pig erythrocytes were the optimal target for this test. Herein, I de-
scribe an optimized, modified CH50 test that is more sensitive for sheep complement. 
Two hundred microliters of pelleted erythrocytes of each species (guinea pig, rabbit, chicken 
and human erythrocytes) were washed three times in 1x phosphate buffered saline (PBS), by 
centrifugation at 1000 xg for 5 min and resuspension in PBS (1%). When pre-sensitised eryth-
rocytes were investigated, following 2 washes, they were resuspended in 10 ml PBS contain-
ing 1mg purified rabbit anti-erythrocyte antibody (antibody matched for chicken or guinea pig 
erythrocytes) or 100 μl of anti-human CD55 and 100 μl of anti-human CD59 rabbit polyclonal 
antisera (human erythrocytes) or 50μl of rabbit anti-sheep erythrocyte antiserum (Table 2.1) 
and incubated at 225 rpm and 37oC in a shaking incubator for 30 min. Pre-sensitised erythro-
cytes were washed two further times with 1x PBS before being washed twice in complement 
fixation buffer (CFB; Oxoid Ltd. Basingstoke, UK).  
A working stock of erythrocytes was diluted to approximately 1% in CFB (or in CFB contain-
ing 20 mM (EGTA) and 40 mM Magnesium chloride for alternative pathway studies) and the 
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dilution adjusted to yield a reading of 1.00 absorbance units at 595 nm in a 96 well flat bot-
tomed plate. Unlike some other methods, % lysis for this method is calculated by measuring 
the increased transmission of light (at 595 nm), which is blocked by whole erythrocytes but 
not absorbed by haemoglobin released after lysis. This also allows repeated lysis measure-
ments with increasing incubation at 37oC (as outlined in the supplementary material for Ah-
med et al., 2014).  
Percent remaining unlysed target cells was calculated = 100 x (A/B).  
Where A= absorbance sera-absorbance background and  
B = absorbance non-lysis control-absorbance background  
Then %lysis = 100 - % remaining unlysed targets. (See supplementary methods appendix for 
detailed explanation and calculation using a representative data set). Serum for measurement 
by haemolysis assay (non-pregnant adult, maternal adult, or preterm fetal sera) were set up as 
doubling dilutions from 50% in CFB in triplicate to 0.78% in a 96 well plate (50 μL in rows 
B to G). No serum lysis controls (50 μL CFB only) were set up in row H, and 100% lysis 
controls (50 μL 0.1% sodium dodecylsulphate) were set up in row A. Fifty microliters of 
erythrocyte suspension were then added to all wells for each triplicate (rows A to H) and 
incubated at 37oC. Absorption readings at 595 nm were taken at 5, 10, 20, 30, 60, 90 and 120 
min using a Dynex MRX II micro plate reader (Worthing, UK). The integral Revelation TM 
software subtracted the background absorption of the 100% lysis control (row A) from the 
rest of the plate. The corrected absorbance for all serum dilutions was then transformed as a 
ratio of the 0% lysis control (row H) to reflect the % lysis of target cells and all data transferred 
to Graphpad Prism for analysis (La Jolla, CA).  
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2.3.4.3  Inhibition by complement inhibitor CDX-1135 
 CDX-1135 is a recombinant form of sCR1, representing the N-terminal 30 short-consensus 
repeats (Weisman et al., 1990) and was provided by Celldex Therapeutics, Inc (Needham, 
MA). Inhibition of haemolysis by CDX-1135 was determined by comparing haemolysis of 
antibody sensitised guinea pig erythrocytes as detailed above, except that the dilution series 
for each serum (in triplicate) was performed in CFB, compared to CFB containing 1 mg/mL 
or 0.25mg/mL CDX-1135. 
 
2.3.5 Flow cytometry 
 The presence of endogenous cross-reacting antibodies binding to erythrocytes was  deter-
mined by incubating unsensitised 1% rabbit or guinea pig erythrocyte suspension (diluted in 
flow cytometry buffer (FCB): PBS containing 15 mM EDTA, 1% fetal bovine serum albu-
min(BSA), and 30 mM sodium azide) with sheep serum (non-pregnant adult, maternal adult, 
or preterm fetal) pre diluted in FCB. Erythrocytes were incubated for 30 min at 4oC and then 
washed by centrifugation at 1000 xg for 2 min followed by resuspension in 200 μl CFB, re-
peated three times. Bound sheep antibody was detected by incubation with 10 μg/ml FITC-
conjugated rabbit anti-sheep serum (Abcam plc, Cambridge UK) for 30 min at 4oC and un-
bound secondary removed by three washes in FCB. Cellular fluorescence was measured using 
a Becton Dickinson FACscalibur flow cytometer, collecting 10,000 events per sample and 
analysed using CellQuest software (Becton Dickinson; Oxford UK). Titration of individual 
sheep serum was performed in triplicate and the experiment repeated twice. 
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2.4 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-
PAGE) and Western Blot 
 Ureaplasma growth from samples or from stock was cultured overnight in 96 wells flat-bot-
tom plate as detailed before in 2.2. The presence of anti-Ureaplasma antibodies in the fetal 
sera or amniotic fluid were determined by Western blot analysis. Gels made to a final concen-
tration of 7.5%, 10%, 12.5% or 15% were utilised according to the expected size of the test 
protein (table 2.2 & 2.3).  Using the first well to load 5 µl of the molecular mass marker 
(Sigma-Aldrich Ltd.) 3 µg of HPA5 (or other test strain as indicated) per lane was separated 
by non-reducing polyacrylamide electrophoresis prior to electrophoretic transfer to nitrocel-
lulose membranes.  In some blots a non-related Ureaplasma serovar 6 strain (HPA61) was 
also included to examine the presence of pan- Ureaplasma reacting antibodies. Proteins were 
separated for 60 minutes at 120 volt and approximately 120mA. Then by using a BioRad 
Mini-Protein 3 system, the proteins were transferred from the gel into 0.22 mm nitrocellulose 
membrane (Appleton Woods).  Transfer apparatus were assembled as per manufacturer’s in-
structions and immersed in 1x transfer buffer (14.4 g/L glycine, 3.03g/L Tris and 20 % meth-
anol), and an ice block and a magnetic stir bar to circulate the transfer buffer and keep it cool. 
After one hour at 100 volts, the membranes were transferred into falcon tubes (EIkay, Basing-
stoke) and blocked with 25 ml blocking buffer (5% w/v non-fat milk in 1x PBS +0.05% Tween 
(PBST)) for 1 hour on a roller at room temperature.  Membranes were then probed with pri-
mary antibodies or sheep serum diluted 1:1000 and 1:500 respectively in blocking buffer as 
shown in( table 2.4 and 2.5), incubated on a roller at 4◦C overnight.  After repeated buffer 
exchange wash (PBST then PBS alone) bound sheep antibodies were detected with peroxi-
dase-conjugated donkey anti-goat antibodies (minimum species cross-reaction, Jackson Im-
munoResearch UK) or with species matched peroxidase-conjugated secondary antibodies for 
alternative primary antibodies (Sigma-Aldrich Ltd.) at a dilution of 1:10,000 in blocking 
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buffer (1% dry skimmed milk powder in PBST) for 1 hour prior to repeat buffer exchange 
washes.  The membrane was then transferred to chemiluminescence reagent (Pierce® ECL 
Western Blotting Substrate; Thermo scientific, Loughborough) and the signal captured by ex-
posing the blot to FUJI Super RX X-ray films (FUJIFILM, Tokyo, Japan) in a dark room. X-
ray films were then scanned and images 
 were stored as TIFF files.
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Table 2.2  Recipes for preparing 4% stacking gel 
 
 
 
    
Table 2.3 Recipes for preparing different percentage resolving gel 
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                    Table 2.4 Primary and secondary antibodies used in my experiments 
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Table 2.5 Anti-MBA monoclonal antibodies (mAbs) used in this study 
MAb             Serotype to which mAb was designed                     Source 
6522               both U.parvum &urealyticum Virostat Inc, Portland ME 
6523               all U. parvum  Virostat Inc, Portland ME 
6525              only SV3 & SV14 Virostat Inc, Portland ME 
2G9                SV1&6 Virostat Inc, Portland ME 
4H2                SV1&6 Virostat Inc, Portland ME 
2B11               all U.parvum Virostat Inc, Portland ME 
8B5.2              SV3&14 &all other SVs but weakly Watson et al., 1990 
8A1.2              SV10 Watson et al., 1990 
10 C6.6           SV3 Watson et al., 1990 
5B1.1             SV3 and 14 Watson et al., 1990 
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2.5 Molecular Biology Studies 
2.5.1  Polymerase Chain Reaction (PCR) assay for Ureaplasma cultured isolates  
PCR for differentiating the two groups of Ureaplasma spp. into U. parvum and U. urealyticum 
was utilised as described by Teng (1994) (Teng, 1994). Primers ( UMS-125 and UMA226 
(PCR UM-1) (Table 2.7) to amplify a DNA fragment within the MBA gene were used to  
verify the two strains of Ureaplasma where they give different sizes of PCR products, 403 bp 
for U. parvum and 448 bp U. urealyticum.  U. parvum  isolates were further differentiated into 
the four serovars (1, 3, 6, 14) by sequencing with the UM-1 primer set and aligning sequence 
results with the known sequences of MBA of the serovars (Kong, 2000). Differentiation of 
the four serovars of U.Parvum  mainly based on variations within two regions (between -54 
to -56 and -81 to -83) of the MBA gene (Table 2.6).                     
 
Table  Table 2.6 Location of the nucleotide variations within MBA gene of U. parvum 
 
Serovar Location of variation in nucleotides within MBA gene 
Region 1 Region 2 
-54 -55 -56 -81 -82 -83 
SV1 A C A T C G 
SV3 A T A C C A 
SV6 G A T T A A 
SV14 A T A T A A 
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PCR for multiple-banded antigen gene (MBA) assay for Ureaplasma in sheep serum or amni-
otic fluid was prepared by centrifuging 300µl of overnight Ureaplasma growth for 10 min at 
13,000xg, the pellet was dissolved in 50 µl deionized water, boiled for 10 minutes to lyse the 
cell proteins and release its DNA. The DNA was used immediately or stored at -20◦C to be 
used for future analysis. Ureaplasma PCR was performed using 2 X KAPA2G Hotstart PCR 
master mix (KAPA Biosystems, London, UK) and run on a Techne PCR thermal cycler. Re-
actions were run in 200 µl PCR tubes (Star lab, Milton Keynes), in accordance with the man-
ufacturer’s instructions to make a final PCR mixture of 50μL (including 2.5μL DNA template 
and 2 μL of each 10pmol primer pair working stock dilutions).Table 2.7 shows the primers 
used in this thesis are as follows (Primers are shown in Figure 6.9 for placement relative to 
the genome; sequences are provided from 5’ to 3’):   
 
Table 2.7 Primers used in this thesis (Teng et al., 1994) 
No Primer Name Sequence (5` to 3`) 
 
 
1 
2 
Multiple Banded Antigen 
UM-1  
UMS-125 
UMA-226 
 
 
 GTATTTGCAATCTTTATATTTTCG  
 CAGCTGATGTAAGTGCAGCATTAAATTC 
3 SV3 end     TCTAGATTATTTTCCAGTAGTTTCTTTAC-
CTG 
4 SV3 start      AAAAGCTTAACCAGCAGGTAAA    
GAACAACC 
5 PreMBA(containingall intergenic 
sequence between UU375 and 
UU376) 
 GTGTCTAGAGAGATGGTTGTTGGCTTGG 
6 UU374  rev(gene 3’ to UU375)  CATCTTCTCTTAATTGTCTTCCCA 
 
Formatted: German (Germany)
Formatted: English (United Kingdom)
Formatted: Spanish (Spain)
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All PCR reactions were subject to the cycling conditions of: initial denaturation at 95°C for 5 
min, followed by 40 cycles (denaturation at 95°C for 30s, annealing at 54°C for 40s, extension 
at 72°C for 1min/1000 bp) with a final extension at 72°C for 5 min after which the products 
were cooled to 10 ºC until required. Following PCR completion, the presence and size of the 
amplified DNA fragment(s) were confirmed by running 5μL of the PCR product on a 1% 
agarose gel electrophoresis relative to the KAPA Universal DNA ladder to determine the DNA 
fragment size.  Control reactions with U. parvum obtained from the American Type Culture 
collection (ATCC 700970, serotype 3) were used as positive controls while the negative con-
trol consisted of reactions run without the addition of boiled Ureaplasma as source of DNA 
to rule out any false positive results. 
 
2.5.1.1  Agarose gel electrophoresis 
Depending upon the desired agarose concentration, agarose gel was prepared by dissolving a 
specific amount (i.e. 1g per 100 mL for 1%) of molecular grade agarose powder into a 1x Tris-
borate EDTA (TBE) buffer (composed of Tris base 8.9 mM, boric acid 8.9 mM, EDTA 0.2 
mM, pH 8.3). Agarose was melted in a microwave oven for 2 min on high then ethidium 
bromide was added at a concentration of 4μg/ 100 mL. After the gel was set in the casting 
apparatus, it was submersed in 1x TBE in the electrophoresis chamber and the comb and dams 
were removed. As reactions already had loading dye present, 5μL of each PCR product was 
introduced into a single well. 5μL of KAPA Universal DNA ladder (KAPA Biosystems) was 
also loaded into the first well to allow fragment size determination. The gel electrophoresis 
was then carried out for 45 mins at constant 150V (safety maximum of 400mA set). Upon 
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completion, the ethidium bromide stained DNA fragments were visualised using a UV-trans 
illuminator (Bio Rad Labouratories; Bio-Docit). 
 
2.5.1.2  Sequencing the PCR amplicon products 
PCR products were purified using Qiagen PCR purification kits as per the manufacturer’s 
instructions (below).  The purified DNA fragments from the PCR amplicons shown in the 
previous step were submitted either to MWG Eurofins (Germany) by post (15μL of purified 
PCR DNA plus 3 μL of single primer at 10pM), or submitted to the local Central Biotechnol-
ogy Sequencing service at the School of Medicine facility. After receiving the results of se-
quencing we used BLAST software program to align the PCR sequences with a reference 
sequences was performed (NCBI http://www.ncbi.nlm.nih.gov/ ). 
 
2.5.1.3 Purification of DNA from PCR products for Sequencing  
After testing the PCR products by agarose gel to confirm the amplification of DNA fragment, 
amplicons were purified. Five volumes relative to the PCR reaction were added to the “PB” 
binding buffer. This was then transferred into QIAquick spin column attached to a 2ml col-
lecting tube. These were centrifuged at ≥10,000 rpm for one min and the flow through dis-
carded. 750 µl of buffer PE was added to wash bound DNA and the tube re-centrifuged as 
above and the flow-through discarded.  An additional spin for 1 min was performed to air dry 
the column.  The column was transferred to a clean pre labelled 1.5ml microcentrifuge tube 
and 30 µl molecular-grade water added and incubated for 1 min at room temperature prior to 
centrifugation for 1 min at 13,000 rpm.   
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2.5.1.4 Extracting DNA using QIA quick Gel Extraction Kit 
When more than one band was amplified, or for sub cloning inserts after restriction enzyme 
digest, reactions were separated on 1% agar gels containing 0.1% crystal violet instead of 
ethidium bromide. DNA bands were excised with a sterile sharp scalpel, the piece of gel con-
taining the band then weighed and dropped in a 1.5ml sterile Eppendorf tube, 3 volume of 
buffer QG was then added (100mg of gel= 100 µl) using the QIA quick gel extraction kit. Gel 
was dissolved completely at 50◦C and then 1 volume of isopropanol added and the tube in-
verted. The solution then transferred to QIA quick column and centrifuged at 13,000rpm for 
1min. The sample then washed by 0.75 ml of PE buffer, spun for 1min at 13,000rpm. Then 
the column placed on a sterile pre-labelled Eppendorf tube and overlaid with 50 µl of Sigma 
biological water to the centre of the column, incubated at RT for 1 min, then spun at 13000 
rpm for 1 min.  The eluted material contained the band for further analysis or ligation.     
 
2.5.1.5 Extraction and purification of genomic DNA from Ureaplasma species 
Two hundred ml from each strain of Ureaplasma were grown in 250 ml sterile tubes for 48 
hours in USM, centrifuged for 3 h at 13,000 xg in a cold centrifuge, supernatant was discarded 
and the pellet was resuspended in 1ml PBS and transferred to a 1.5ml Eppendorf tu-be, spun 
for an additional 30min at 13,000 rpm, then supernatant were discarded and the pellet was 
used for DNA extraction using the DNeasy Blood & Tissue Kit (Qiagen, UK). The pre-treat-
ment protocol for gram negative bacteria was followed, including incubation with proteinase 
K from QIAGEN tissue lyser Kit, at 56°C for 2 hours. Because RNA-free genomic DNA was 
desired, the optional step of adding 4 μL RNase A (100 µg/mL) was performed. DNA was 
then extracted and purified in accordance with the manufacturer’s spin-column protocol.  
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2.5.1.6 Precipitation of DNA 
The volume of the DNA sample from the previous step was measured. Then 1/10 volume of 
sodium acetate, pH 5.2, added (final concentration of 0.3 M), mixed well, then added 2.5 
volumes of cold 100 % ethanol and mixed well. Tubes were placed on ice or at -20°C for >20 
minutes. Tubes were centrifuged at maximum speed in a centrifuge for 15 minutes. Carefully 
decant supernatant. Add 1 ml 70% ethanol. Mix. Spin briefly (~5 minutes). Carefully decant 
supernatant. Air dry pellet, re-suspend in the appropriate volume of TE buffer. DNA concen-
tration was then measured in a spectrophotometer. Final DNA yield was determined using a 
spectrophotometer at a wavelength of A260 nm.  The spectrophotometer was blanked against 
TE prior to measuring absorbance of DNA. Purified aliquots of DNA were stored at -80 °C 
until required. 
 
2.5.1.7  Creation of the pMT85 expression vector for MBA expression 
PCR was performed as above using the preMBA and SV3end primers, which have Xba1 sites 
incorporated into the primers.  The appropriate band was isolated by gel extraction and the 
purified band incubated with Xba1 restriction enzyme (Promega) for 4 h using manufacturer’s 
instructions.  The expression vector pMT85 (Aboklaish et al., 2014) was cut in parallel and 
the insert containing the MBA gene and natural promoter were ligated into the expression 
vector, following removal of the restriction enzyme by QiaQuick PCR purification kit (Qi-
agen), using T4 ligase (Promega) as per manufacturer’s instructions.  Following overnight 
ligation at 15oC the pMT85 was transformed into One Shot competent E.coli (Life Technolo-
gies) and selected on 100 mg/L gentamicin agar plates.  Single colonies were grown up and 
sequenced to ensure no errors were introduced and then scaled up and transformed into HPA5 
by Dr. Ali Aboklaish. 
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2.5.2  Designing a synthetic gene 
The synthetic gene “histag-SV3-MBA” was designed using the web site  
http://www.lifetechnologies.com/uk/en/home/life-science/cloning/gene-synthesis/geneart-
gene-synthesis.html 
https://www.lifetechnologies.com/order/geneartgenes/launchConfigurator.action?docu-
ment_Id=140948 
The sequence of serovar 3 MBA (amino acid sequence) was utilised to generate a codon-
optimised DNA for expression in E.coli.  In particular tryptophan is encoded by UGA in 
Ureaplasma, but this is a stop codon in other prokaryotes.  Additionally, Ureaplasma genomes 
have a 25% GC content. The synthesised gene was also constructed to have the EF-tu pro-
moter added prior to the ATG start codon: 
TGAAGAAGTAATGGTAGCACGTGCAAAAAAATAATTATTTTAACAATTAACAA-
TAAAGTATTTAATTAATAATCTAAAAAGTTAAAATGTTATAATTATAAGGTATAATAC-
CTTTTATTATGTATTCAAAAATTATTTAGAAAATAAATTAATTTTTAAGGAGATTTAAA 
Codons for 6 histidine residues were also inserted prior to the TAA stop codon. The sequence 
was sent to MWG Eurofins for gene synthesis and it was delivered in the plasmid pEX-A2.  
This was transformed into E.coli and selected in ampicillin resistant plasmid (100 mg/L) and 
this transformed bacteria used in my experiments. Only 2 repeats could be engineered in the 
synthetic version of serovar 3 MBA as gene synthesis is confounded by recurring repeats 
(according to the provider).  Following transfection of the plasmid into One Shot competent 
E.coli (as per manufacturer’s instructions) the MBA protein was separated into membrane and 
cytoplasmic fraction by Triton-X114 fractionation methods (detailed below) and tested by 
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Western blot analysis to localise the site of expression of the MBA protein by using monoclo-
nal antibodies that recognise incorporated histidine repeats (Biolegend) or by using anti-MBA 
monoclonal antibodies 6522, 6523 and 6525 (Virostat Inc.). 
 
2.6 Culturing E.coli 
2.6.1 Preparing LB broth E.coli 
Twenty five grams of LB broth powder purchased from(Q Bio gene) was added to 1 L water 
in an autoclave bottle and mixed with a magnetic stir bar and plate.  The bottle was autoclaved 
for 15 min at 121oC and allowed to cool to 50 º C then 100 mg of ampicillin (Sigma) was added 
and allowed to cool and stored at 4ºC until needed. 
 
2.6.2 Preparing agar plates for E.coli 
The equivalent procedure to broth was followed except that the LB agar powder (Q Bio gene) 
also contains agar.  Following addition of ampicillin at 50oC as above, the agar was poured into 
10 cm diameter sterile plates and allowed to set prior to store at 4ºC until needed.  
 
2.6.3  Triton X 114 extraction of E.coli membrane proteins 
Triton X-114 is used to separate membrane fractions from solubilised whole cells, as this de-
tergent comes out of solution when heated to 37oC (cloud point). Membrane-associated pro-
teins can thus be separated from cytoplasmic and insoluble proteins and identified as such in 
membrane or cytoplasmic fractions following separation by warm centrifugation. 
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Colonies of MBA-expressing E.Coli (and controls transformed with empty plasmid) were 
grown overnight in 25ml LB broth at 37oC and 225 rpm in a bacterial shaking incubator. Bac-
teria were pelleted at 3600 xg for 10 min and the pellets re suspended in 5 ml Triton x114-TBS 
(10mM Tris, pH 7.4, 150mM NaCl, 1% Triton X114) on ice for 30 min and vortexed every 5 
minutes.  Insoluble material was removed by centrifugation for 10 min (3600 xg ,4ºC).  One 
ml of the supernatant was layered on top of 500 µl sucrose cushion (TBS, 1% Triton x114, 
0.6% sucrose) in 1.5 ml Eppendorf tubes, which were then warmed to 37 ºC for 10 min and 
then spun for 5 min in bench top centrifuge at 25oC at 17,000 xg.  The top layer was separated 
(cytoplasmic fraction), while the oily pellet was washed in warm TBS twice and then dispersed 
by suspension in an equal volume of 10 % SDS (in TBS).  Cytoplasmic and membrane fractions 
were added to an equal volume of LDS loading buffer (Life Technologies) and heated for 5 
min at 95oC prior to separation by SDS-PAGE.  If not used immediately, the samples were 
frozen at -80ºC for future use. 
 
2.7   Immunohistochemistry  
E.coli colonies from LB agar plates (both SV3-MBA expressing and control strains) were 
removed and embedded in paraffin wax by Central Biotechnology Services.  These paraffin 
blocks were then sectioned, deparafﬁnised, then paraffin section rehydrated with xylene 2 x 5 
minutes, isopropyl alcohol (IPA) 2 x 5 minutes, and washed in tap water 5 minutes. Antigen 
retrieval was performed for 1 hour in 10mM citrate acid buffer (pH 6) containing 0.005% 
Tween 80 at 95◦C prior to being probed for with monoclonal anti MBA antibodies (6522, 
6523 and 6525) diluted in 10mM PBS + 0.6% BSA (PBS/BSA) to confirm the localisation of 
the synthetic MBA protein on the surface of individual E.coli bacilli in comparison to staining 
of E.coli that are transformed with an empty plasmid.  Unbound monoclonal antibodies were 
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removed by three washes for 1 min each in PBS/BSA. Bound antibody was detected with 
1/100 dilution of peroxidase conjugated donkey anti-mouse IgG (Jackson Immunoresearch) 
in PBS/BSA then wash and develop 3 minutes in 0.025% DAB + 15-30% H2O2.  In some 
cases the bacilli were additionally stained for 10 sec in 0.02% picromethyl blue prior to being 
dehydrated, cleared in IPA, xylene and mounted with a coverslip.
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Statistical Analysis 
 Statistical analysis was carried out using GraphPad Prism (La Jolla, CA). For screening of 
lysis targets or flow cytometry binding, significant lysis or binding was determined by com-
paring data for all concentrations of serum relative to a serum-negative control using ANOVA 
with Bonferroni correction for multiple comparisons in post-hoc analysis. Comparisons of 
lysis or binding curves with different variables (adult versus fetal sera, sera from pregnant 
versus non-pregnant ewes, lysis of sensitised versus non-sensitised targets, aged versus fresh 
erythrocyte targets, no-complement inhibitor versus differing concentrations of CDX-1135, 
etc.) were analysed by repeated measures ANOVA with Bonferroni correction for multiple 
tests in post-hoc analysis of individual concentrations of sera being compared. All serum kill-
ing assay data were expressed as mean and standard error of the mean (SEM). Comparisons 
were only considered significant for P values < 0.05.                                                          
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3  Comparison of Complement Activity in Adult and Preterm 
Sheep Serum 
3.1  Introduction 
The complement system is a key part of innate immunity. It does not require previous expo-
sure to be effective,  but  it does  make  the  humoral immune system more   effective   in  
clearing   pathogens,  and   complement activation recruits  innate and  adaptive immune cells 
to the site of inflammation, where it aids in modulating and  refining the  adaptive immune  
response [reviewed in(McGreal, 2012)]. The complement system  is composed of a series of 
serum  proteins that  circulate in proactive forms  that  are  sequentially cleaved  and  activated 
in an  amplifying cascade,  forming  a  series  of bioactive intermediates following  activation. 
Complement is activated by specific triggers   that   are   designed   to detect ‘foreign’ surfaces.  
Specific IgG and IgM anti- bodies adopt a complement-activating conformation following 
binding to recognized antigen epitopes (the classical activation pathway), which leads to the 
activation of complement component C1.  Similarly, many   of the innate immune lectins (e.g. 
mannan- binding lectin (MBL),  ficolins, and collectin  11) activate complement via com-
plexes with  associated  serine proteases  following   lectin   binding   to  carbohydrates that  
are  composed of sugar  moieties or carbohydrate combinations/linkages that  are  not  found  
in the  host (the  lectin  activation pathway)(Hansen et al., 2010). Both of these triggers for 
complement activation require calcium to form the active enzymatic convertase complexes 
[reviewed in (Degn and Thiel, 2013)]. The final method of complement activation does not 
utilize active recognition molecules, but is a failure to regulate the low-level fluid-phase con-
version of the central component C3 to a fluid-phase activating convertase (the alternative 
activation pathway). This last activation pathway can be assessed independently as it functions 
in the absence of calcium and has been best characterized through studies of complement 
activation by yeast cells (Meri et al., 2002). 
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Complement activation leads to ‘tagging’ of the activating surface by covalent attachment of 
opsonins (component C3b and   processed   fragments), which enhance complement receptor-
mediated phagocytic engulfment. Further processing of the C3b covalently bound to foreign 
antigens leads to enhanced antibody production and refinement against those antigens by B-
lymphocytes (Caroll,2004) while  release  of small  soluble  fragments called  chemotaxins 
and  anaphylatoxins  (C3a and C5a) act to recruit and prime  innate and  adaptive immune 
cells to the  site of complement activation. 
Complement  activation  can   also  result   in  direct lysis of the  activating cells by formation 
of the  membrane attack  complex, a non-covalent  complex of complement components C5b,  
C6,  C7,  C8,  and  C9 which  insert  pores  into  the  membrane of activating surfaces.   It  is  
this  last  consequence of  complement activation  that   is  measured  by  the   standard  CH50 
(50% complement haemolysis assay)  functional test, determining the  dilution of  serum   re-
quired to  lyse 50%  of a one-per cent  suspension of rabbit  antibody- coated  sheep  erythro-
cytes (Whaley, 1985; Nilsson and Nilsson, 1984). However, erythrocytes are generally pro-
tected from complement-mediated lysis in a species-restricted manner (i.e.  serum   has poor  
ability  to  lyse  erythrocytes from  the  same  species) due  to the  expression of complement 
regulators on   the    erythrocyte  surface (Ish et al., 1993; Kim et al., 1995; Rushmere et al., 
1997; White et al., 1994; Yu et al., 1997). These   regulators include CD59, CD55 (also known 
as decay-accelerating  factor), and  CD35  (also  known as  complement receptor  (1)  as  well  
as  cell  surface   recruitment   of serum    complement   regulators  factors H and I [reviewed 
in(Lindahl et al., 2000)]. Some of these regulators have been characterized for sheep (Kišová-
Vargová, 2012; Vanden Berg, 1993; Stohl et al., 2012; Beth et al., 2013); however, it is likely 
that homologues for all of these regulators exist.  For this reason, the standard CH50 test using 
sheep erythrocyte targets is suboptimal for measuring sheep complement activity.  Data  from  
previous studies  suggest that   the   close  homology between  sheep   and   goat immune  
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proteins also  renders sheep  erythrocytes a poor target  for goat complement,  requiring crea-
tion of a modified  CH50 assay for goat serum. Herein, I describe an optimized, modified   
CH50 test that is more sensitive for sheep complement. 
Although complement does  not  require  previous exposure to be fully effective,  it is not 
fully functional at birth  in humans, and  the  lysis measured by CH50 requires 2–3  times  
more  neonatal serum  than adult serum  due  to reduced concentrations of complement com-
ponents[reviewed in (McGreal et al., 2012]. The insufficiency of neo- natal   complement is  
further  increased in  neonates born prematurely, with a correlation of lower complement com-
ponent concentration, and  greater amounts of serum  for the  CH50 values,  with  increasing 
degree of pre-maturity (McGreal et al., 2012). However, complement activity during gesta-
tional development animal models of human pregnancy is under-investigated. The sheep 
model has gained popularity in examining gestational inflammation and preterm birth pathol-
ogy including gestational reperfusion injury, (Castillo-Melendez et al., 2013; De Matteo et 
al., 2010; Wolfson et al. ,2012), in utero Ureaplasma  parvum infection (Kemp et al., 2011)  
and   Escherichia  coli  lipopolysaccharide-mediated inflammation (Dean et al., 2011; Zhang 
et al., 2012). Moreover, complement has been shown to be activated or play a role in the 
underlying pathogenesis in non-sheep models and humans for these conditions (Beeton et al., 
2012; Sun et al., 2011; Li et al., 1999). Soluble  human CR1 (sCR1) has successfully  been  
used  to experimentally  identify  the  contribution of complement activation  to pathogenesis 
by inhibition of complement in rats,  guinea pigs,  pigs,  and  mice (Lillegard et al., 2013; 
Weiser et al., 1997; Souza et al., 2005; Wagner et al., 1999)   using  soluble recombinant 
forms  from  various  commercial sources (TP10, later  renamed CDX-1135, and  APT070), 
but to the best of our knowledge, not in sheep. 
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3.2  Aims  
1-To develop an assay to measure the complement activity in sheep sera as traditional methods 
use sheep erythrocytes as a model, which are protected by sheep complement regulators. 
2-To compare the complement function in preterm lambs sera at three different gestational 
ages: 85, 95 and 125 days gestation relative to adult sheep sera. 
3- To investigate the ability of full-length soluble CR1 (CDX-1135) to suppress sheep com-
plement activation in an ex vivo model. 
 
3.3 Results 
3.3.1  Screening Target Erythrocytes for Lysis by Sheep Serum 
Lysis of guinea pig, rabbit, and human erythrocytes by diluted maternal adult   sheep   sera is 
shown in Fig.3.1.  No  significant   lysis was  observed for  human erythrocytes without pre-
incubation with  both  rabbit anti-CD55 and  anti-CD59 antibodies, and  no  lysis of chicken 
erythrocytes, including following  pre-sensitization  with  rabbit  anti-chicken erythrocyte an-
tibody, was   observed  (data   not   shown).  Erythrocyte  lysis relative   to  concentration  of  
sheep   serum   changed with   longer   incubation at  37°C,  and  higher serum concentrations 
achieved complete lysis early  on,  but lower    concentrations   required   longer    incubation 
times to achieve  maximum  lysis (Fig.3.1). Little increase in lysis was observed after 30 min.  
Guinea pig erythrocyte lysis was only marginally greater if the cells were pre-sensitized with 
rabbit anti guinea pig erythrocyte antibody (Fig.3.1b and d), whereas human erythrocytes pre-
incubated with both rabbit anti-CD55 and anti-CD59 antiserum required longer incubation to 
achieve similar cell lysis to guinea pig erythrocyte targets (Fig.3.1a). Rabbit erythrocytes were 
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also lysed by sheep serum, even in the absence of pre-incubation with an anti- rabbit erythro-
cyte antibody, but required higher concentrations of sheep serum to achieve significant lysis 
(Fig.3.1c). Ageing the human erythrocytes for 2–4 weeks at 4°C prior to use in the assay 
greatly increased their susceptibility to lysis (aged human erythrocyte lysis is shown in 
Fig.3.1a, but a comparison between fresh and aged human erythrocytes is available in  the 
Appendix Figure Supp.1). Lysis of target erythrocytes was the same when comparing serum 
obtained from non-pregnant ewes to serum from pregnant ewes.  
 
Figure 3.1 Lysis of rabbit antibody pre-sensitised human (A) or guinea pig (B) erythrocytes 
compared to lysis of rabbit (C) or guinea pig (D) erythrocytes that were not pre-coated with anti-
erythrocyte antibody. Target erythrocytes were incubated with increasing concentrations of ma-
ternal sheep sera and lysis measured following incubation at 37°C for 5, 10, 30 or 120 min.  
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3.3.2  Complement-mediated Lysis by Neonatal Sheep 
The ability of cord serum obtained from 125-day gestational age caesarean-delivered lambs 
to lyse our target erythrocytes was also examined (Fig.3.2). The lysis of rabbit anti-erythrocyte 
pre-sensitized human and guinea pig cells was similar to the maternal sheep sera (Fig.3.2a and 
3.2b); however, target cell lysis was much lower at earlier time points, and maximum lysis 
was about twofold lower relative to maternal sera (Fig.3.1a and b). Foetal serum was unable 
to lyse more than 20% of target rabbit erythrocytes (Fig.3.2c), even after incubation for 120 
min. Furthermore, a reasonable response curve required to evaluate serum concentrations 
yielding 50% haemolysis for unsensitized guinea pig erythrocytes (Fig.3.2d).It took 90 min 
longer than if the guinea pig cells were pre-coated with antibody (Fig.3.2b). The ability of 
sera taken from foetal sheep at earlier 95- and 85-day gestational ages was also examined. 
Lysis of pre-sensitized guinea pig erythrocytes was lower for sera at 25 and 12.5% concentra-
tion for sera from 85-day and 95-day gestational age sera compared with 125-day gestational 
age sera following short incubation times (Fig.3.3a), whereas these differences between lysis 
were shifted to lower concentrations of 6.25 and 3.15% when allowed to incubate for an hour 
(Fig 3.3b). 
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Figure 3.2 Lysis of rabbit antibody pre-sensitised human (a) or guinea pig (b) erythrocytes compared 
to lysis of rabbit (c) or guinea pig (d) erythrocytes that were not pre-coated withanti-erythrocyte anti-
body. Target erythrocytes were incubated with increasing concentrations of 125-day gestational age 
foetal sheep sera and lysis measured following incubation at 37°C for 5, 10, 30 or 120 min. 
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Figure 3.3 Lysis of rabbit antibody pre-sensitised guinea pig erythrocytes by sera from fetal sheep 
at 125, 95 or 85 days of gestational development. Target erythrocytes were incubated with increas-
ing concentrations of sera and lysis measured following incubation at 37°C for 10 min (a) or 60 min 
(b). 
 
 
3.3.3 Lysis by the Alternative Pathway in Sheep Sera 
As lysis of the rabbit and guinea pig erythrocytes occurred in the absence of pre-sensitizing 
antibody, the contribution of the alternative pathway was examined by investigating erythro-
cyte lysis in the absence of calcium. Unlike the classical and lectin pathways, the alternative 
pathway can function in the presence of calcium chelator EGTA (Fig.3.4). Twice as much 
serum was required to achieve the same degree of rabbit erythrocyte lysis in the absence of 
calcium (alternative pathway), compared with lysis in the presence of calcium. Moreover, the 
maximum alternative pathway lysis (achieved after 60 min incubation) was equivalent to the 
cell lysis observed after only 10 min in the presence of calcium (Fig.3.4a). Similar results 
were observed for un sensitized guinea pig erythrocytes in the absence of calcium, with four-
fold more serum required to achieve the same degree of guinea pig erythrocyte lysis by the 
alternative pathway alone (Fig.3.4b). Foetal sheep sera (125 day gestation) failed to achieve 
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50% lysis of guinea pig erythrocytes via the alternative complement pathway, even after 120 
min incubation (data not shown).  
 
 
 
 
 
 
 
 
Figure 3.4 Lysis of rabbit (a) or guinea pig (b) erythrocytes that were not pre-coated with anti-eryth-
rocyte antibody. Target erythrocytes were incubated with increasing concentrations of maternal sheep 
sera and lysis measured following incubation at 37°C for 10 or 60 min. Lysis was performed in the 
presence of EGTA (alternative complement pathway only) and compared with serum diluted in normal 
complement fixation buffer (all complement pathways active). 
 
 
3.3.4 Endogenous Antibodies in Maternal Sheep Sera Binding to Erythrocyte Targets 
Flow cytometry was utilized to measure sheep serum antibody binding to unsensitized rabbit 
and guinea pig erythrocytes from five maternal and foetal pairs (Fig.3.5). Incubation of eryth-
rocytes with maternal sheep sera at a concentration >10% resulted in the aggregation of both 
guinea pig or rabbit erythrocytes and, consequently, an inability to analyse them by flow cy-
tometry. In contrast, incubation of rabbit or guinea pig erythrocytes with 50% foetal sera (125 
day gestation) did not result in a significant binding of sheep antibody to the surface of the 
target erythrocytes (Fig.3.5). This identifies the mechanism underlying the differential ability 
 96 
 
between foetal and maternal sera to lyse un sensitized target erythrocytes. No significant dif-
ference was observed for erythrocyte antibody binding between pregnant and non-pregnant 
sheep, and no significant antibody binding was observed for any of the foetal serum from 
gestational ages 85, 95 or 125 days.  
 
 
Figure 3.5 Binding of sheep antibodies from 125 day gestational age and maternal sheep sera to un 
sensitised rabbit (A) or guinea pig (B) erythrocytes as determined by flow cytometry Mean and standard 
error for five matched maternal foetal pairs are shown. 
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3.3.5 Failure to Inhibit Sheep Sera-mediated Lysis by Human Complement Inhibitor  
By comparing the lysis of antibody pre-sensitized guinea pig erythrocytes by sheep sera in the 
presence or absence 1 or 4 µM (final concentration) of complement inhibitor CDX-1135, I 
observed no inhibition of maternal sheep sera above a serum concentration of 6.25% 
(Fig3.6b); however, under the same conditions, human serum showed strong inhibition even 
at concentrations as high as 50% (Fig.3.6b). Inhibition of human serum by CDX-1135 re-
mained unchanged when measured again after 120-min incubation (data not shown). The abil-
ity to inhibit human serum was reduced if fourfold less CDX-1135 was used (Fig.3.6a). The 
ability of CDX-1135 to inhibit rat sera lysis of sensitized guinea pig erythrocytes was compa-
rable with that observed for human sera (data not shown), indicating that this form of soluble 
human CR1 is fully capable of regulating complement from other species. However, these 
findings demonstrate that an alternative method of complement inhibition will be required to 
examine the contribution of complement to pathology in sheep models.  
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Figure 3.6 Lysis of rabbit antibody pre-sensitised guinea pig erythrocytes by human serum (A) or adult 
sheep serum (B)Inhibition of target cell lysis by 4.0 or 1.0 µM (final concentration) of complement 
inhibitor CDX-1135 as compared to serum lysis in the absence of inhibitor. As sheep serum lyses eryth-
rocytes faster, an earlier incubation is shown; however, the trend is the same for all incubation time 
points. 
 
 
3.4  Discussion 
The complement system is composed of a series of over 30 proteins in the serum component 
of the blood, produced by the liver and some blood cells. This system has evolved to detect 
invading pathogens and eliminate them directly or indirectly through recruitment and refine-
ment of the cellular innate and adaptive immune systems. As a result, host cells; in particular 
erythrocytes need to protect them against bystander lysis following complement activation. 
The dominant surface complement regulator is CD59, and it has been shown to protect cells 
in a largely species-restricted manner (Ish et al., 1993; Kim et al., 1995; Rushmere et al., 
1997; White et al., 1994; Yu et al., 1997). Due to the close genetic homology between goats 
and sheep, the inability of goat serum to lyse sheep erythrocytes have recently been high-
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lighted (Moreno-Indias et al., 2012). Sheep CD59 has been characterized, and blocking mon-
oclonal and polyclonal antibody has been raised (van den Berg et al., 1993) however, I was 
unable to achieve significant lysis of sheep erythrocytes even when pre-sensitized with rabbit 
antisheep erythrocyte antibody, and blocking anti-CD59 antibodies were used (data not 
shown).Similar to the studies by Moreno-Indias et al.,(Moreno-Indias et al., 2012). I found 
that human erythrocytes were a good substitute and their sensitivity was increased by ageing 
the cells for 2–4 weeks at 4°C prior to use; however, guinea pig erythrocytes were found to 
be the best haemolysis assay target, and both the cells and the rabbit anti-erythrocyte antibody 
are available commercially. The contribution of complement to pathogenesis extends beyond 
infection. Damage arising from reperfusion injury, either caused by hypoxia, vascular occlu-
sion or transplantation, is largely due to the activation of complement immediately following 
reperfusion (Gorsuch et al., 2012).  
Complement has also been found to be a significant component underlying autoimmune dis-
ease as well as renal disease and age-related macular degeneration (McCaughan et al., 2013; 
AMBAti et al., 2013). As a result, a wide variety of complement regulators are currently under 
development for use in renal disease patients, age-related macular degeneration, transplanta-
tion, stroke, and myocardial infarction patients (Barilla-Labarca and Furie, 013).These range 
from blocking monoclonal antibodies against complement component C5 (such as Eculi-
zumab) to recombinant forms of naturally occurring complement regulators such as factor H 
or complement receptor 1 (CR1;CD35). Given the differences in homology of complement 
components, the latter group has been more extensively examined in animal models. Soluble 
forms of CR1 have been favoured in animal models as CR1 is known to regulate all the path-
ways, and it has multiple C3b and C4b binding sites in the full-length molecule that mediates 
both accelerated decay of multiple convertases and factor I-cofactor activity, leading to the 
inactivation of C4b and C3b (Crehan et al., 2012). I found a recombinant form of sCR1 that 
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is composed of the 30 N-terminal domains was a poor inhibitor of sheep complement even at 
concentrations effective at regulating human serum (Fig.3.6b) and despite previous studies 
showing effective reduction of complement-mediated pathology by CDX- 1135 in other ani-
mal models, including rats (Lillegard et al., 2013, Weisman et al., 1990).The use of sheep as 
a non-primate model of human disease is increasing, especially for studies of disease in preg-
nancy and pregnancy complications. For example, neonatal asphyxia induced by transient oc-
clusion of the umbilical cord before birth has been shown to lead to reperfusion injury and to 
mimic the intrauterine hypoxia that complicates a proportion of human births (Castillo-Melen-
dez et al., 2013). Further, hypoxic injury following preterm birth and associated new born 
respiratory disease is also studied in sheep models (Wolfson et al., 2012). More recently, 
sheep models have been developed to investigate intrauterine inflammation induced by injec-
tion or infusion of lipopolysaccharides or bacterial infection (De Matteo et al., 2010; Dean et 
al., 2011; Kemp et al., 2011; Zhang et al., 2012). None of these studies has investigated the 
contribution of the complement system to the disease pathogenesis, largely due to the current 
lack of knowledge on the sheep complement system. I have optimized an assay that allows 
the comparison of sheep sera from different conditions. I found no difference in haemolytic 
capacity between pregnant and non-pregnant adult sheep sera, but found that complement 
activity in preterm foetal sheep was decreased relative to matched maternal sera, but still had 
considerable activity even in sera from preterm lambs at 85 days gestation (150 days is normal 
gestation), which makes them considerably more immune competent than the equivalent ges-
tational age humans [reviewed in(McGreal 2012)]. The inability of foetal sheep sera to lyse 
rabbit and unsensitized guinea pig erythrocytes was the biggest difference observed. However, 
this was related to the complete absence of cross-reacting antibodies in foetal serum that 
bound to rabbit and guinea pig erythrocytes (Fig.3.5). This identifies an additional difference 
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between humans and sheep: in humans, maternal IgG actively transfers to the foetal circula-
tion from about 13 weeks gestation and reaches 50% maternal concentration by 28– 32 weeks 
[reviewed in(Palmeira et al., 2012)], equivalent to gestational age 95–125 days in sheep, 
whereas, in sheep, it has been suggested that IgG may cross the placental barrier to the allan-
toic sac(Morris, 1980; Omwandho, 1997) , but not to the amniotic cavity or foetal circula-
tion(Morris , 1980); this difference between the species probably results from the haemo-
chorial structure of the human placenta in contrast to the syndesmochorial placentation of the 
sheep. In fact, other than primates, it appears that only rabbits and guinea pigs have the ca-
pacity to transfer maternal IgG to foetuses across the placenta (Pentsuk and van der Laan, 
2009) this means that any immune response observed in foetal sheep and other ruminants has 
to reflect the foetal response. This may also suggest that the immune system of ruminants may 
be more competent at birth. Herein, I describe a new assay to evaluate the functional comple-
ment activity in sheep. I found that serum from normal Caesarean-delivered preterm lambs 
had lower, but still substantially active, complement systems. I also found that maternal sheep 
serum contains significant cross-reacting antibodies that bind guinea pig and rabbit erythro-
cytes, which are absent from matched preterm sheep serum, resulting in a requirement to pre-
sensitize guinea pig erythrocytes to measure foetal serum haemolysis activity. As the potent 
complement inhibitor, CDX-1135 was not effective in inhibiting sheep complement; further 
studies are required to identify an inhibitor that has application to pathogenesis studies in 
sheep models of in utero infection and hypoxia. 
In conclusion, I found that serum from normal Caesarean-delivered preterm lambs had lower, 
but still substantially active complement systems. I also found that maternal sheep serum con-
tains significant cross-reacting antibodies that bind guinea pig and rabbit erythrocytes, that 
are absent from matched preterm sheep serum, resulting in a requirement to pre-sensitise 
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guinea pig erythrocytes to measure fetal serum haemolysis activity. As the potent complement 
inhibitor, CDX-1135 was not effective in inhibiting sheep complement; 
 further studies are required to identify an inhibitor that has application to pathogenesis stud-
ies in sheep models of in utero infection and hypoxia.
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4 Increased Ureaplasma bacteraemia in lambs of lower gesta-
tional age is proportional to increased insufficiency of the 
complement system with greater prematurity. 
4.1 Introduction 
Like most parts of the innate immune system, the complement system does not require previ-
ous exposure to be effective.  The complement system encompasses a series of >30 serum 
proteins that interact through an amplification cascade following activation by antibodies, im-
mune complexes, pattern recognition molecules or foreign microbial surfaces.  Complement 
also acts to integrate the innate and humoral immune responses through recruiting innate and 
adaptive immune cells to the site of activation (via chemotaxin and anaphylotoxin release), 
improving the humoral response through a natural adjuvant activity, and increasing engulf-
ment of microbes through decorating the surface with opsonins (Henri et al.,1979; John et al., 
1984; Dunkelberger and Song, 2010). Complement also has direct anti-microbial activity me-
diated by the formation of lytic pores on activating surfaces, which makes it a pivotal barrier 
to initial invasion by pathogens.  However, as we have previously reviewed, the complement 
system does not have full potency at birth in humans due to lower circulating levels of some 
of the components and this insufficiency is greater with increasing prematurity (McGreal, 
2012).The reduced capacity of the complement system at term birth, which is exacerbated 
with increasing prematurity, has been proposed to be responsible for the increased suscepti-
bility of neonates to bacterial infection and sepsis (Levy, 2007; Strunk et al. 2011). I have 
recently found decreasing complement function in sheep with increasing prematurity (Ahmed 
et al., 2014) which is often used as an experimental model for in utero infection. Sheep are 
commonly used to investigate the effects of Ureaplasma parvum infection, which is the most 
common infectious organism associated with preterm birth (Epstein, et al. 2000; Moss, et al., 
2005; Knox, et al. 2010).   Ureaplasma parvum is one of the smallest self-replicating micro-
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organisms identified to date and is unusual in that its minimal genome confers a failure to 
make a cell wall like gram-positive and gram-negative bacteria (Waites et al., 2012). The cell 
wall has been shown to confer a protective effect against complement mediated killing partic-
ularly in gram-positive bacteria, and U.Parvum has been shown to be relatively susceptible to 
lysis by human complement (Beeton et al., 2012). 
4.2 Aims of this chapter are 
 To check the capacity of Ureaplasma following experimental intrauterine infection to es-
tablish an in vivo infection and replicate inside the amniotic fluid and cause bacteraemia 
in vulnerable foeti.  
 To follow the evolution of the Ureaplasma-cidal activity between 95 and 125 days in pre-
term foetuses compared to adult sheep. 
 To define the kinetics of in vitro Ureaplasma killing by non-immune adult and preterm 
sheep sera. 
 To investigate the susceptibility of the plasma and amniotic fluid –recovered strains to 
adult and preterm sheep sera. 
 To investigate the decreasing ability of preterm sheep sera to lyse inert complement targets 
(sensitised guinea pig erythrocytes) correlated with bactericidal activity between two ges-
tational ages, as well as amongst sera samples of the same gestational age. 
 To correlate the bactericidal efficiency of serum from bacteraemic and non-bacteraemic 
lambs to complement function (measured by 50% haemolytic assay).
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4.3 Results 
4.3.1 Determining kinetics for infection in experimentally infected sheep  
The kinetics of acute Ureaplasma infection were determined by time course sampling via 
surgically implanted catheters (Figure 4.1) following injection of 107CCU of Ureaplasma into 
the amniotic fluid via a separate isolated catheter to avoid contamination. At 2 h post-inocu-
lation a mean of 176.5 +/- 47.0 CCU/ml was measured.  The titre of Ureaplasma in the amni-
otic fluid then doubled at 6 h and increased by 7.7-fold at 12 h, but didn’t show a significant 
increase until 24 h when it increased to 133-fold relative to the 2 h levels (23,455 +/- 8,710 
CCU/ml; p<0.05). Ureaplasma titres continued to increase to a peak at 48 hr and then ap-
peared to slightly decrease at 5 days, but no statistical significance was found comparing the 
Ureaplasma titre between 24, 48 and 72 hours (Figure 4.1).  
 
Figure 4.1 Growth kinetics for U. parvum parent strain (HPA5) in vivo. Mean and standard 
deviation of Ureaplasma titres in samples taken via surgically implanted intrauterine catheter at 
2, 6, 12, 24, and 120 h after experimental intrauterine infection.  Each point represents 6 separate 
pregnant ewes and average titre for each time point/ewe was determined in triplicate. 
 
 107 
 
Comparing the AF HPA5 titres from three groups of sheep following different length of in-
fection showed relatively stable level of Ureaplasma in the AF from 2 days up to 6 weeks 
post –infection (Figure 4.2). 
 
 
Figure 4.2 Amniotic fluid (AF) titres for HPA5 following various lengths of infection.  Red 
bars indicate samples taken from the catheterised animals in Figure 4.1. The blue bar indicates 
delivery samples following a 1 week infection in 125D GA animals administered by ultrasound-
guided needle injection into the amniotic fluid.  The beige bars indicate ultrasound guided nee-
dle samples at 3 and 5 weeks following infection at 80D GA as well as samples taken at delivery 
(6 weeks).  Each bar is the average and standard error of 6 animals per group. 
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4.3.2 Plasma titres of Ureaplasma in the circulation of lambs of different GA 
To examine the rate of fetal bacteraemia following experimental intrauterine Ureaplasma    in-
fection, three different groups of pregnant sheep were inoculated with Ureaplasma.  Amniotic 
fluid sampling catheters do not remain clear for longer periods of study; therefore, inoculation 
of these groups was performed by ultrasound-guided needle, and samples were then collected 
at Caesarean-section delivery.  Lambs were surgically delivered at either 94 d or 125 d GA.  
For all groups the Ureaplasma titre in the amniotic fluid was similar (range = 1-6x105 
CCU/ml; data not shown), but variation was seen in the number of animals with culturable 
Ureaplasma in their plasma (Table 4.1).  Group 1 was experimentally infected at 116d GA 
and the lambs were delivered at 125d GA (10 d post-inoculation) while group 2 were infected 
at 83d GA and delivered at 125d GA (42 d post-inoculation).In the third group Ureaplasma 
was injected  at early age (70D GA)  and delivered at day 94 (24 d post-infection). Only one 
lamb at 125 d GA was found to have Ureaplasma recoverable from the plasma and this was 
from the shorter infection group.  However, 50% of the lambs in group 3, infected for 24 days, 
had Ureaplasma that could be cultured from their plasma samples. No bacteremia was de-
tected in 125 gestational day animals after 42 day chronic infection.   The single positive 125 
d GA lamb had 100 CCU/ml viable Ureaplasma recovered from their plasma and the range 
of viable Ureaplasma in cord plasma from 94 d GA lambs ranged from 10-10,000 CCU/ml 
(Figure 4.3).   
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Table 4.1 Rate of Ureaplasma recovery from amniotic fluid and plasma of preterm lambs infected in 
utero with HPA5 for variable durations, Ureaplasma infection at early age (70D GA) caused bacterae-
mia in 50% of infected lambs. While at 125 days only 1 out of 10 animals infected for 10 days had 
detectable Ureaplasma. No bacteraemia was detected in 125 gestational day animals after 42 day 
chronic infection. 
GA infected GA at delivery Length of 
infection 
Amniotic 
fluid 
Cord 
Blood 
116 days 125 days 10 days 10/10 1/10 
83 days 125 days 42 days 7/8 0/8 
70 days 94 days     24 days    8/8     4/8 
 
 
Figure 4.3 Ureaplasma titres in cord plasma as determined by culture in lambs delivered at 94 d or 
125 d GA.  Each point determined in triplicate. 
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4.3.3  Immunoblot analysis of antibody response in preterm lambs 
 Anti-Ureaplasma antibody response in the sera of all lambs were determined by reactivity of 
sera by immunoblot to Ureaplasma proteins (both the inoculating strain HPA5 and unrelated 
Ureaplasma serovar 6 strain HPA61) separated by non-reducing polyacrylamide electropho-
resis. No evidence of anti-Ureaplasma antibody response was found for sera following 10 or 
24 d infections (groups 1 and 3).While 3/8 of the 125 d GA lambs were found to have anti- 
Ureaplasma antibodies that specifically reacted with the inoculating strain (Figure 4.4).  The 
50 kDa bands were identified as the major surface antigen (multiple banded antigen) through 
co-identification with specific monoclonal antibodies (data not shown). 
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Figure 4.4 Screening sera from preterm lambs (F=foetus) infected with Ureaplasma for 42 days and 
delivered at day 125 GA against the inoculating (HPA5) and antigenically distinct serovar 6 
(HPA61).Representative results of 3 repeat experiments shown. 
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4.3.4  Ureaplasma-cidal activity of serum from adult sheep and preterm lambs 
The capacity of sera from non-immune adult sheep and preterm sheep of gestational ages 
125D and 95D were examined for their ability to kill the Ureaplasma strain used to inoculate 
the pregnant sheep for experimental in utero infection. Adult sera, despite the fact that the 
animals had not been exposed to Ureaplasma previously and have no anti-Ureaplasma react-
ing antibodies when tested by Western blot against purified strains, showed strong bactericidal 
activity against HPA5. Adult sera, at dilutions as low as 6.25%, was capable of completely 
killing the total input of Ureaplasma (Figure 4.5). Whereas, dilutions below 50% of 125D 
sera showed some survival of challenged Ureaplasma and sera from 95D animals only de-
creased the input Ureaplasma by a maximum of 450 +/- 190 fold relative to Ureaplasma titres 
incubated with heat-inactivated sera. Therefore the most immature sera were significantly de-
ficient in bactericidal activity, consistent with bacteraemia being observed in lambs delivered 
at 94D GA following in utero experimental Ureaplasma infection above.  
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Figure 4.5 Ureaplasma killing by diluted non-immune sera from adult sheep (black circle), 125 d GA 
preterm lambs (open square) and 95 d GA preterm lambs (grey triangles) following 1 h incubation at 
37oC.  Killing determined by relative decrease in Ureaplasma titre compared to incubation with 
matched heat-inactivated sera.  Each point represents average and standard deviation of sera from 4 
separate animals. 
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4.3.5  Kinetics and calcium dependence for sera killing of Ureaplasma 
The rate of bactericidal activity of 50% non-immune sera from adult sheep, and 95 d GA 
preterm lambs were examined by stopping complement activation with the addition of the 
calcium and magnesium chelator EDTA following varying lengths of incubation with sera.  
The residual survival of Ureaplasma was then assessed by removing the sera and resuspend-
ing in culture medium.  The kinetics of Ureaplasma killing by both adult and preterm sera 
were comparable: the majority of bactericidal activity occurred in the first 10 minutes follow-
ing serum addition (Figure 4.6), with a negligible increase in Ureaplasma killing for preterm 
sera even if incubated for an additional 4 hours (data not shown).  Isolated function of the 
alternative complement pathway can be assessed if serum killing is performed in the presence 
of calcium-chelator EGTA. Under these conditions, no alternative pathway killing was ob-
served for Ureaplasma indicating killing is mediated by the classical or lectin pathways. 
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Figure 4.6 Ureaplasma killing kinetics of non-immune adult sheep and 95 d GA sera.  Fifty percent 
dilutions of sera in the presence of calcium and magnesium (all complement pathways active, black 
circle = adult, black square = 95 d GA lamb) were incubated with ureaplasma for various times before 
blocking further complement activation with addition of EDTA prior to titration of surviving 
Ureaplasma.  No killing of Ureaplasma was observed if sera was (adult = grey circle, 95 d GA = grey 
square) diluted in the presence of EGTA and magnesium (only alternative complement pathway active).  
Each point represents average and standard error of sera from 4 separate uninfected animals, killing 
calculated by decreased titre relative to Ureaplasma titre following incubation with matched heat-inac-
tivated sera. 
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4.3.6  Investigation of serum susceptibility of recovered plasma and amniotic fluid 
Ureaplasma strains  
Ureaplasma strains recovered from plasma were examined to determine if they were less sus-
ceptible to serum killing than strains recovered from amniotic fluid from bacteraemic and non-
bacteraemic lambs. Recovered isolates were separated into 3 group: (1) Plasma-recovered 
isolates; (2) amniotic fluid recovered isolates from the same animals that had Ureaplasma 
recovered from their plasma; and (3) amniotic fluid-recovered isolates from animals that did 
not have bacteraemia.  Susceptibility to 50% adult sheep sera and 50% 95 d GA sera from 
control uninfected animals are shown in Figure 4.7.  Isolates cultured directly from plasma 
were as susceptible to sera as amniotic fluid-recovered isolates from matched bacteraemic or 
non-bacteraemic animals.  All recovered isolates were equally resistant to non-immune sera 
from uninfected control 95 d GA, except (paradoxically) for one of the plasma-derived isolates 
from lamb (115).  
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Figure 4.7 Serum susceptibility of plasma-recovered and amniotic fluid-recovered strains (infected for 
24 days) to non-immune sera from 50% adult sheep or 50% 95 d GA preterm lamb sera. Pooled sera 
from uninfected animals 95 days and adult were used and each point was determined in duplicate.  Rep-
resentative data shown from 3 repeated experiments. Killing calculated as decreased titre relative to 
Ureaplasma titre following incubation with matched heat-inactivated sera. 
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4.3.7  Ureaplasma-cidal activity of sera from bacteraemic versus non-bacteraemic 
lambs. 
As no advantage of serum resistance in plasma isolates was observed, the capacity of the sera 
from these two groups of 94 d GA preterm lambs was compared for their capacity to kill 
HPA5 parental strain inoculated into the pregnant sheep.  Endogenous Ureaplasma in bacte-
raemic sera was reduced by filtration through a 0.22 micron filter and the remaining endoge-
nous Ureaplasma was measured by titration and subtracted from the matched results at the 
conclusion of the assay. The serum killing from the 94 d GA Ureaplasma-infected animals 
was higher for non-bacteraemic than bacteraemic with one exception (lamb 116) (Figure4.8).  
However, the overall range for both non-bacteraemic and bacteraemic lambs reflected the 
range found for serum taken from uninfected 95 d GA control animals.  However, it was noted 
for the serum with the lowest killing was from the animal with the highest plasma titre of 
Ureaplasma (lamb 115) and that the serum from the animal with the highest serum killing 
was from the animal with the lowest plasma titre (lamb 116). As no anti-Ureaplasma antibod-
ies were present in the immunoblot analysis (data not shown), this suggested that killing ca-
pacity of the sera was directly linked to Ureaplasma titres in the serum. 
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Figure 4.8 Serum killing of Ureaplasma original strain by 50% sera from bacteraemic (plasma 
Ureaplasma), non-bacteraemic (no plasma Ureaplasma) and uninfected 95 d GA preterm 
lambs. Each point represents the average of 3 separate killing assays. Killing calculated as de-
creased titre relative to Ureaplasma titre following incubation with matched heat-inactivated 
sera. Individual points for lambs 115 and 116 are identified 
 
 
 
 
 
Formatted: English (United Kingdom)
 120 
 
4.3.8 Complement activity of sera from bacteraemic versus non-bacteraemic lambs. 
The complement activity (measured by lysis of guinea pig erythrocytes) was examined for the 
sera from infected and uninfected 95 d GA lambs.  The complement activities in the serum 
from bacteraemic lambs were much lower than those found to have no Ureaplasma in their 
plasma (non-bacteraemic).  Furthermore the lowest complement function was observed in the 
lamb with the highest Ureaplasma titre (lamb 115; 104 culture units/ml in plasma) while high-
est complement activity for the bacteraemic group was found in the lamb with the lowest 
Ureaplasma plasma titre (lamb 116; 10 culture units/ml in plasma; (Figure 4.9A).  The com-
plement activity for the non-bacteraemic Ureaplasma infected lambs was all relatively uni-
form and higher than the average for the bacteraemic lambs (Figure 4.9B).  Complement func-
tion for both groups were representative of the range observed from age matched (95 d GA) 
uninfected lambs (Figure 4.9C), indicating Ureaplasma infection (or bacteraemia) did not in-
fluence the overall development of the complement system.  A correlation between 
Ureaplasma-cidal activity and complement activity in 95 d GA sera, irrespective of experi-
mental Ureaplasma infection, was found (R2=0.30, p<0.05; Figure 4.10).  Furthermore, com-
plement function of 125D GA serum, which was shown to have significantly greater 
Ureaplasma-cidal activity was found to be higher than all 95 d GA serum tested, but not as 
high as adult sera (Figure 4.9D). 
 121 
 
 
 
                                                                     
 
Figure 4.9 Complement activity in bacteraemic (A), non-bacteraemic (B) and uninfected (C) 95 d 
GA preterm lambs serum. Complement activity for 125 d GA preterm lambs and adult sheep (D) are 
also shown.  Complement activity measured as haemolysis of rabbit antibody-sensitised guinea pig 
erythrocytes by diluted sera after 30 min incubation at 37oC.  Each point determined in triplicate. 
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Figure 4.10   Correlation between complement activity (haemolysis) and 50% serum killing of 95 d 
GA sera (50% dilution, 30 min incubation at 37oC for both conditions) from bacteraemic (plasma 
Ureaplasma), non-bacteraemic (no plasma Ureaplasma) and uninfected preterm lambs. Each point de-
termined in triplicate.  Spearman’s coefficient (R2=0.30, p<0.05) shown for untransformed data.   
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4.4  Discussion 
Neonates, particularly those born prematurely, are known to be more susceptible to morbidity 
and mortality due to infections.  The innate immune system represents the primary defence 
against infection in neonates and the complement system is a significant component of this 
defence.  Term human neonates are known to have an under-developed complement system 
relative to adults, and complement insufficiency increases with increasing prematurity 
(McGreal, 2012).  Previously I developed a haemolysis assay to show that sheep could be 
used to model the developmental complement insufficiency of prematurity (Ahmed et al., 
2015) and here I extended this model to examine the role of complement insufficiency in an 
experimental intrauterine bacterial infection.  Consistent with the in vitro complement func-
tion assays, the in vitro bactericidal capacity of sera diminished with increasing prematurity.  
This was also reflected by the increased incidence of bacteraemia detected in experimentally 
infected lambs at 94 d GA (50%) relative to 125 d GA (10%) lambs.  Within the 94 d GA 
cohort, the bactericidal serum activity was found directly correlated to the complement func-
tion in the serum (R2=0.30, p<0.05) with one exception, lambs with bacteraemia were found 
to have lower complement function compared to non-bacteraemic lambs.  Further, this one 
exception was also found to have the lowest plasma titre of Ureaplasma.  The correlation 
between Ureaplasma bactericidal activity and complement function was not influenced by 
experimental infection, suggesting that the natural variation in complement activity at 94 d 
GA determined whether Ureaplasma infection in the amniotic fluid became systemic or not.  
The only group found to develop specific anti-Ureaplasma antibodies was infected at 83 d 
GA and delivered at 125 d GA, and only 3 of 8 animals were found to respond.  Inability to 
sample fetal blood except at delivery makes it impossible to determine if the seropositive 
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group represent those that were bacteraemic at 94 d GA, but it is a tempting speculation as it 
is just short of 50% of the infected animals.  The anti-Ureaplasma antibodies are of fetal 
immune origin, as we have previously shown no maternal transfer of IgG occurs in uninfected 
sheep (Ahmed et al., 2015) and experimental Ureaplasma infection did not alter this as we 
found no characteristic maternal anti-guinea pig erythrocyte reactivity in the sera from any of 
the preterm lambs (data not shown). 
The HPA5 strain has previously been shown to be susceptible to human serum killing in the 
absence of specific anti-Ureaplasma antibodies (Beeton et al., 2012).  As with human serum 
studies with this strain, sheep serum bactericidal activity appears to be mediated by the clas-
sical pathway; however, no reagents to examine the lectin pathway (also calcium-dependent) 
in sheep are available and the contribution of the ovine lectin pathway to Ureaplasma killing 
cannot be ruled out. It was unexpected that the kinetics for both adult and preterm sheep serum 
killing was identical, rather than a prolonged killing curve for the preterm serum.  However, 
no significant increase in Ureaplasma killing was observed if incubation with sera was in-
creased from 10 min and 4 h for either adult or preterm sheep sera.  
The use of sheep as a non-primate model of human disease is increasing, especially for studies 
of disease in pregnancy and pregnancy complications. For example, neonatal asphyxia in-
duced by transient occlusion of the umbilical cord before birth has been shown to lead to 
complement-mediated reperfusion injury and to mimic the intrauterine hypoxia that compli-
cates a proportion of human births (Castillo-Melendez et al., 2013). Further, hypoxic injury 
following preterm birth and associated newborn respiratory disease is also studied in sheep 
models (Wolfson et al., 2012). More recently, sheep models have been developed to investi-
gate intrauterine inflammation induced by injection or infusion of lipopolysaccharides or mi-
crobial infection (Dean et al., 2011; Hillman et al., 2014; Kemp , 2011; Maneenil et al.,  2015; 
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Zhang et al.,  , 2012) .  None of these studies has investigated the contribution of the comple-
ment system to the disease pathogenesis or to the role of complement in controlling systemic 
spread, largely due to the current lack of knowledge on the sheep complement system. 
In conclusion, I provided the first detailed kinetic analysis of establishment of Ureaplasma 
infection in sheep amniotic cavity following experimental infection. Amniotic fluid titres of 
Ureaplasma rapidly increased to maximal levels by 48 hours post inoculation that was stable 
for weeks following the infection.  Ureaplasma could be cultured from 50% of cord blood 
(indicative of systemic spread of amniotic fluid infection) for Caesarean-delivered lambs that 
were infected at 70 d GA and delivered at 94 d GA, but only from 10% of lambs infected at 
116 d GA and delivered at 125 d GA.  No anti-Ureaplasma immune response was observed 
in either of these groups and serum complement function was directly related to the 
Ureaplasma titres in the plasma in vivo and the capacity of preterm lamb sera to kill 
Ureaplasma in vitro.  Lambs that were experimentally infected at 83d GA and delivered at 
125 d GA did not have any Ureaplasma detected in their plasma and only 3 of 8 of those 
infected for 42 days had evidence for an antibody response to Ureaplasma; however, presence 
of anti-Ureaplasma in sera had no effect on the amniotic fluid titres measured at delivery. 
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5  Characterisation of monoclonal antibodies used for typing 
different strains of Ureaplasma species. 
5.1 Introduction 
Ureaplasma species are the smallest, free living mucosal parasites that inhabitant the human 
urogenital tract. It can be isolated from 40-70% of sexually active women and has been re-
ported to increase to as high as 90% during pregnancy but drop to 25% after menopause ac-
cording to reports, while in men it is found to a lesser extent (19.2 %) and in can be isolated 
in 5 % of children where girls are about eight times more infected than boys (Foy et al., 1975; 
Iwasaka et al., 1986; Viscardi, 2010; Volgmann et al., 2005,). Ureaplasma play a role in 
diseases of the genital tract and adverse pregnancy outcomes and fetal and neonatal patholog-
ical sequel (Cassell et al., 1993; Kramer, 2011). Following Shepard’s initial differentiation of 
Ureaplasma from Mycoplasma based on agar plate colony morphology (T for “tiny” colony, 
rather than Mycoplasma “fried egg” morphology) (Shepard, 1954), a maximum separation 
into 14 “serovars” was subsequently published by Robertson and Stemke in (1982) using a 
panel of polyclonal rabbit anti-sera and a combination of modified metabolic inhibition test 
and a colony indirect epifluorescence methods.  In the years that followed, it became clear 
that these 14 serovars could be grouped into two separate sub-types that were initially called 
“biovar” 1 and 2(Robertson and Stemke, 1982).  However, in 2002 Robertson et al., utilised 
conserved differences in DNA-DNA hybridisation, distinctive restriction fragment length pol-
ymorphism(RFLP) patterns, and other genomic differentiators to divide the 14 serovars into 
two distinct species: U. parvum (serovars 1, 3, 6 and 14) and U. urealyticum (serovars 2, 4, 5, 
and 7-13)(Robertson et al., 2002). A conserved 45 bp size difference in a PCR amplicon using 
primers recognising the promoter and coding region of the major surface protein (multiple 
banded antigen; MBA) was found capable of separating clinical U. parvum from U. urealyti-
cum strains (Teng, 1994).  These authors also found that different sized amplicons for related 
 128 
 
primer sets in this region could also separate U. urealyticum serovars 2, 5, 7, 8, 9 and 11 from 
U. urealyticum strains 4, 10, 12 and 13, as well as uniquely identifying U. parvum serovar 6 
from all other isolates(Teng, 1994) .The MBA is a lipid-anchored protein that is expressed on 
the surface of Ureaplasma and is composed of a signal peptide, a lipid addition signal se-
quence and a relatively well conserved non-repeating region of approximately 100 residues at 
the N-terminus. However, the C-terminus region is composed of repeats that vary in sequence 
between serovars and in repeat number amongst strains of the same serovar (Zheng et al., 
1996). Kong et al., (2000) found that the predicted amino acid sequence for the repeat region 
of each U. parvum serovar was slightly different and that U. urealyticum serovars could be 
separated into a unique serovar 10 repeat (genotype B) and two groups (with identical MBA 
N-terminal repeats) encompassing serovars 2, 5 and 8 (genotype A) and serovars 4, 12 and 13 
(genotype C), but that serovars 7, 11 (genotype E) and 9 (genotype D) could not be differen-
tiated by MBA repeat sequence in their study.  Development of monoclonal antibodies against 
the MBA have also been reported (Cheng et al., 1993; Cheng et al., 1994; Naessens et al., 
1998; Watson et al., 1990; Zheng et al., 1996),some of these recognise single serovars, while 
others recognise groups of U. parvum or U. urealyticum sub-groups.  However, all of these 
antibodies belong to independent research groups and are not readily available.  In this chapter 
I provide the first characterisation of commercially available monoclonal antibodies and I 
show results for the first single monoclonal antibody capable of specifically detecting the 
MBA of all U. parvum and U. urealyticum strains simultaneously. 
 
 129 
 
5.2  Aims  
1-To find the regions and similarities between the MBA gene within the best characterised 
Ureaplasma species serovar 3 and serovar 10 relative to the other prototype strains to localise 
and define the C-terminal repeats characteristic for the remaining serovars.  
2-Characterisation of a panel of commercially available monoclonal antibodies raised against 
the MBA for binding and differentiation of prototype strains of Ureaplasma parvum and 
Ureaplasma urealyticum. 
3-To develop a recombinant serovar 3 MBA expressed in E.coli to confirm specificity and to 
determine the capacity of monoclonal antibodies to be used for immunohistochemistry. 
 
5.3 Results  
5.3.1 Defining the regions and similarities among the MBA gene within the best 
characterised Ureaplasma type: serovar 3  
 First it is important to define the regions and similarities among the MBA gene within the best 
characterised Ureaplasma type: serovar 3.  There are 3 fully annotated genomes available for 
serovar 3 in GenBank (strains 700970, 27815 and SV3F4)(Figure5.1) .  The first 2 strains 
have a single MBA gene copy in their genomes, while the clinical strain SV3F4  has 2 identi-
fied copies (Figure5.2).  However, only one of these MBA genes in the latter sequence aligns 
perfectly to the first two strains (Wu et al., 2014). Kong et al. (2000) had identified serovar 
specific repeats for U. parvum that allows the identification of the MBA genes in the whole 
shotgun sequence database (Table 5.1) as well as many of the MBA genes for U. urealyticum 
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(Kong et al., 2000).  Table 5.1 shows lists of the prototype serovar strains with available se-
quences in GenBank and the identification of patterns consistent with the genotype classifica-
tion of Kong et al. (2000), including some of my proposed modifications. The analysis of the 
MBA genes is difficult as most of the available genes are from shotgun sequences that have 
not been completed to seal the genome; therefore some sequences may reflect sequencing 
fragments.  It is well known that repeats regions, like the C-terminus of the MBA gene, cause 
a break in the contig assembly. Many of the putative MBA genes also do not start with a 
consensus sequence which would include the lipid anchor sequence.  Comparing the consen-
sus U. parvum serovar 3 N-terminus to the only completely sequenced and annotated U. urea-
lyticum genome (serovar 10) identifies a single MBA protein with the C-terminal repeat 
TQPGSGST.  The alignment of the N-terminal region of this protein compared to the consen-
sus N-terminus from serovar 3 is shown in Figure 5.3.  Cross-examining the U. urealyticum 
MBA protein database with this consensus N-terminus sequence from serovar 10 MBA iden-
tified the best candidates for MBA from the remaining U. urealyticum serovars listed in (Table 
5.2). 
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CLUSTAL O(1.2.1) multiple sequence alignment 
 
27815        MKLLKNKKFWAMTLGVTLVGAGIVAIAASCSNSTVKSKLSNQFAKSTDGKSFYAVYEIEN 
700970       MKLLKNKKFWAMTLGVTLVGAGIVAIAASCSNSTVKSKLSNQFAKSTDGKSFYAVYEIEN 
SV3F4_1      MKLLKNKKFWAMTLGVTLVGAGIVAIAASCSNSTVKSKLSNQFAKSTDGKSFYAVYEIEN 
             ************************************************************ 
 
27815        FKDLSNDDKKSLSNIEFNAALTSAENKTESTLEKGHLVGEKIYVKLPREPKPNEQLTIIS 
700970       FKDLSNDDKKSLSNIEFNAALTSAENKTESTLEKGHLVGEKIYVKLPREPKPNEQLTIIS 
SV3F4_1      FKDLSNDDKKSLSNIEFNAALTSAENKTESTLEKGHLVGEKIYVKLPREPKPNEQLTIIS 
             ************************************************************ 
                                                              ↓Start of repeats 
27815        KSGLIKTSGLLISDNLNYQTEKVNFETTQPGKEQPAGKEQPAGKEQPAGKEQPAGKEQPA 
700970       KSGLIKTSGLLISDNLNYQTEKVNFETTQPGKEQPAGKEQPAGKEQPAGKEQPAGKEQPA 
SV3F4_1      KSGLIKTSGLLISDNLNYQTEKVNFETTQPGKEQPAGKEQPAGKEQPAGKEQPAGKEQPA 
             ************************************************************ 
 
27815        GKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPA 
700970       GKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPA 
SV3F4_1      GKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPA 
             ************************************************************ 
 
27815        GKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQ------PA 
700970       GKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPA 
SV3F4_1      GKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKETTGK----------- 
 
             *********************************************  . 
 
 
Figure 5.1 Alignment of amino acid sequences for serovar 3 strains 700970, 27815 and SV3F4.  The 
non-repeating region is present in the N-terminal 129 residues that are then followed by multiple re-
peats of PAGKEQ repeats in the C-terminus. 
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Figure 5.2 Alignment of the two MBA proteins in strain SV3F4 Only 33% identity was found with 
8% gaps for the N-terminus region only.  The second MBA protein also lacked a C-terminal repeat re-
gion. 
 
 
Figure 5.3 Alignment of N-terminus of confirmed serovar 10 MBA protein against the conserved 
serovar 3 MBA protein N-terminus However only 109/151(72%) of the residues were identical, con-
sistent with species divergence. 
 
.   
 
NCBI Blast 2 sequences alignment 
 
MBA#1  1    MKLLKNKKFWAMTLGVTLVGAGIVAIAASCSNSTVKSKLSNQFAKSTDGKSFYAVYEIEN  
60 
            MKLLKNKK W +T+   L+G  ++   ASCS+S ++SKLS++  +  D  ++Y  Y+I N 
MBA#2  1    MKLLKNKKIWVLTISSVLIGVSVITSIASCSSSNIESKLSDKLVEDEDN-NYYVAYQISN  
59 
 
MBA#1  61   FKDLSNDDKKSLSNIEFNAALTSAENKTEST------LEKGHLVGEK---IYVKLPREPK  
111 
            ++ L + +KK L  + F+ ++T  + KT+++      + +G L  ++    Y+KL R+P+ 
MBA#2  60   YEKLKDFEKKQLEKVTFSTSITPTD-KTKNSQVFNAKVNEGILFNQQAKTFYIKLVRKPE  
118 
 
MBA#1  112  PNEQLTIISKSGLIKTSGLLISD-NLNY  138 
              E + I+  + ++KT G ++++ NLN+ 
MBA#2  119  VGESIIILPNNSILKTHGFVVTNENLNF  146 
CLUSTAL O(1.2.1) multiple sequence alignment 
 
SV10      MKLLKNKKFWAITLGVTLVGAGVVAVAASCSSSNVKSKLSSQLVKSKDEKSFYAVYDIEN 
SV3       MKLLKNKKFWAMTLGVTLVGAGIVAIAASCSNSTVKSKLSNQFAKSTDGKSFYAVYEIEN 
          ***********:**********:**:*****.*.******.*:.**.* *******:*** 
 
SV10      FDDLNENDKKALNEAEFNVAITSAENKTENATTKGHLLNKKIYVKLPREPKAKEQLTIIN 
SV3       FKDLSNDDKKSLSNIEFNAALTSAENKTESTLEKGHLVGEKIYVKLPREPKPNEQLTIIS 
          *.**.::***:*.: ***.*:********.:  ****: :*********** :******. 
 
SV10      KGGLLKTASLVLPDNLNYQTENIGFETQPGSGSTTQP 
SV3       KSGLIKTSGLLISDNLNYQTEKVNFETTQPGKEQ--- 
          *.**:**:.*:: ********:: ***   . .     
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Table 5.1 Analysis of multiple banded antigen sequences available in GenBank. 
 
Species Serovar GenBank number Accession number Repeat amino acid se-
quence 
U. parvum 1 27813 (1 gene) AAD09744.2 PGKEQQ 
U. parvum 3 700970 (1 gene), 
28715 (1 gene) 
SV3F4 (2 genes-
only 1 with repeat) 
AAF30784.1; 
ACA32903.1; 
BA073668.1 
PAGKEQ 
U. parvum 6 27818 (1 gene) AAD09745.2 PGKE 
U. parvum 14 33967 (3 genes) AAD09743.2; 
EDT87551.1; 
EDT87494.1;  
PAGKEQQ 
U. urealyticum 10 33699 (6 genes-
only 2 with repeat) 
AAD02692.2; 
ACI60338.1 
TQPGSGST 
U. urealyticum 2 27814 (10 genes- 
only 1 with repeat) 
AAD02696.2 TKPGSGET 
U. urealyticum 5 27817 (6 genes- 
only 2 with repeat) 
AAD02698.2; 
EDU06213.1 
TKPGSGET 
U. urealyticum 8 27618 (10 genes – 
only 1 with repeat2)  
AAD02700.2 TKPGSGET 
U. urealyticum 9 33175 (3 genes- 
only 2 with repeat) 
AAD02701.2; 
EDX53694.1 
KKPETG-
STEGGS1TEG 
U. urealyticum 4 27816 (2 genes) AAD02697.2; 
EDY74356.1 
TSPEKPGNGT 
U. urealyticum 12 33696 (4 genes – 
only 2 with repeat3) 
AAD02694.2; 
EDX53195.13 
TSPEKPGNGT 
U. urealyticum 13 33698 (1 gene) AAD02695.2 TSPEKPGNGT 
U. urealyticum 7 27819 (5 genes- 
only 1 with repeat4) 
EDU56636.14 GAQSGNGSGSASGS? 
U. urealyticum 11 33695 (3 genes- 
only 1 with repeat) 
EDU67198.1 GAQSGNGSGSASGS4 
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1. My analysis has found that the repeat is not completely conserved and that this residue 
is either an S or a T to detect all copies of the repeat in the C-terminus for gene 
UUR9_0631. 
2. There are 3 other serovar 8 MBA genes that appear to have the conserved N-terminus, 
but without identifiable repeat. 
3. One of the genes with the expected C-terminus repeat unit does not start with the ho-
mologous N-terminus sequence but instead begins with MNYQTEKVEFETQPGNGT 
4. Only one of the serovar 11 MBA genes has the conserved N-terminus and it has a C-
terminus repeat of GAQSGNGSGSASGS, and the serovar 7 MBA gene with this con-
served C-terminus repeat does not start with the homologous N-terminus sequence but 
instead begins with MNYQTEKVDFKSTHTPEPTPTPTPAPKEDKAVVSN-
VEFSDVDAKAKTAKVKLTFALVVQLKDESQKLLKL 
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Serovar Accession 
number 
Identity Repeat  
SV5 (27817) EDU06213.1 148/151 TKPGSGET  
SV5 (27817) AAD02698.2 148/151 TKPGSGET  
SV2 (27618) AAD02696.2 148/151 TKPGSGET  
SV8 (27618) AAD02700.2 148/151 TKPGSGET   
SV4 (27816) EDY74356.1 147/150 TSPEKPGNGT  
SV4 (27816) AAD02697.2 147/150 TSPEKPGNGT  
SV13 (33698) AAD02695.2 147/150 TSPEKPGNGT  
SV12 (33698) AAD0694.2 147/150 TSPEKPGNGT  
SV12 (33698) EDX53543.1 144/149 AEVDKLTKLIKEKEAKVAEVQKAIEE-
GEKVVKTKQATKTTAENELTAAQKVVDDK-
KAEKTTLDKELADAKAQLDKANKKDPKDQ 
 
SV2 (27814) EEH02498.1 139/143 None  
SV9 (33175) AAD02701.2 141/146 KKPETGSTEGGSTEG  
SV9 (33175) EDX53694.1 141/146 KKPETGSTEGGSTEG  
SV8 (27618) EEH01641.1 141/146 KEEKVKAVKAKLDAAEKELTTAKS-
DVETKQKAVDAAKTKLDQATKESTDANQS-
LETAKENQKTKQQAVDSAKEELKVAEGSTEN 
 
SV8 (27618) EEH01837.1 141/146 KEEKVKAVKAKLDAAEKELTTAKS-
DVETKQKAVDAAKTKLDQATKESTDANQS-
LETAKENQKTKQQAVDSAKEELKVAEGSTEN 
 
SV2 (27814) EEH01994.1 140/145 NKDEKIQKAEEKLAKAKEELNKVNELVTT-
KDTAVKEATKALETAKADAKTKEAAVTTA-
TRELEEAKKSNEA 
 
SV13 (33698) EDT49352.1 143/149 None  
SV11 (33695) AAD02693.2 137/147 None  
SV7 (27819) AAD02699.2 137/147 None  
SV7 (27819) EDU56613.1 137/145 None  
SV11 (33695) EDU67198.1 137/147 GAQSGNGSGSASGS  
 
Table 5.2 MBA protein sequences similar to the conserved N-terminus of serovar 10 MBA 
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As shown from (Table 5.2) serovars 2, 5 and 8 had the closest homology to the serovar 10 N-
terminus with only 3 polymorphisms.  Moreover, all these homologues had the expected 
TKPGSGET repeat, and it is interesting that serovar 5 had two copies in the genome.  The 
next closest group of homologues included serovars 4, 12 and 13 with the expected TSPEK-
PGNGT repeat.  However, one variant of SV12 with a long 84 residue repeat was also found 
in the database.  Two unusual MBA homologues with a 84 residue repeat different from SV12 
above were found for serovar 8 and a variant of serovar 2 with a 71 residue repeat.  MBA 
homologues with no identifiable repeat in the C-terminus were found for two serovar 7 MBA 
genes, as well as putative genes for serovar 2, 11 and 13.  The potential repeat of 
GAQSGNGSGSASGS was identified for serovar 11 in an MBA homologue, but the potential 
MBA protein with this repeat for serovar 7 does not retain high homology for the N-terminal 
sequence.  Furthermore, two different MBA putative proteins were identified for serovar 10 
(ACI60338.1 and AAD02692.2) were found in the database with 100% identity, both with the 
expected TQPGSGST repeat.  However, variants (other than the validated annotated serovar 
10 genome) of the U. urealyticum may be due to errors in the shotgun genome sequencing 
data. 
 
5.3.2  Visualisation of MBA proteins from U. parvum by Western blot 
Using the above prototype strains, I next utilised Western blot to visualise MBA proteins from 
U. parvum (Figure 5.4) using some of the monoclonal antibodies (mAbs) previously published 
by Watson et al., (1990) (Table 5.3) to validate the panel of monoclonal antibodies to be tested 
from Virostat plc.  For those monoclonal antibodies that detected all U. parvum species, the 
reactivity against all Ureaplasma spp. was then examined (Figure 5.5)  The previously pub-
lished (Watson et al., 1990) mAbs, behaved mostly as expected: 5B1.1 detected only serovars 
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3 and 14, 10C6.6 detected only serovar 3, and 8A1.2 did not react with any of the U. parvum 
MBAs (Figure 5.4). 8B5.2 did not react as well as expected and did not seem to detect serovar 
3. However, equivalent patterns to the previously published monoclonal antibodies were 
found in the commercially available antibodies: 6525 behaved exactly as 5B1.1 (although in 
one experiment it did seem to weakly cross-react with serovars 1 and 6; Figure 5.5), while 2 
other mAbs (4H2 and 2G9) reacted in a mirror fashion by detecting the MBAs of serovar 1 
and 6, but not serovars 3 and 14.  However, three of the commercial mAbs detected all the U. 
parvum MBA species equivalently (6522, 6523 and 2B11), performing better than the previ-
ously published mAb 8B5.2 (Figure 5.4).  These antibodies differed when extended to detect-
ing the MBAs from U. urealyticum prototype strains (Figure 5.5).  The reactivity of 2B11 
appears to be restricted only to U. parvum MBA, while 6523 reacted strongly with U. parvum 
MBA and weakly with U. urealyticum serovars 7 and 11.  However, 6522 appeared to detect 
the MBA from both U. parvum and U. urealyticum equivalently, although the intensity of the 
MBA from serovar 4 was negligible (Figure 5.5) or weak (Figure 5.6).  Moreover, 6522 de-
tected a range of MBA from clinical isolates (Figure 5.6).  Identical MBA species were de-
tected by both serovar 10 specific antibody 8A1.2 (Figure 5.7) and 6522 (Figure 5.6) confirm-
ing that the reactivity of the commercial antibody is restricted to the MBA.  The summary for 
the reactivity of the commercial antibodies is shown in (Table5.4). 
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Table 5.3 Reactivity of monoclonal antibodies provided by Prof. Gail Cassell. 
Clone Recognised species Published reactivity 
8B5.2 U. parvum 
U. urealyticum 
SV1, 3, 6, and 14 strongly 
Weakly all except SV2 
and 5 
10C6.6 U. parvum SV3 only 
5B1.1 U. parvum SV3 and 14 
8A1.2 U. urealyticum SV10 only 
 
 
 
 
Table 5.4 Reactivity of commercial Virostat monoclonal antibodies. 
Clone Recognised species Published reactivity 
6522 U. parvum 
U. urealyticum 
SV1, 3, 6, and 14 strongly 
All strongly, except SV4 
weakly 
6523 U. parvum 
U. urealyticum 
SV1, 3, 6, and 14 strongly 
SV7 and 11 weakly 
6525 U. parvum SV3 and 14 
2B11 U.parvum  
U. urealyticum 
SV1, 3, 6, and 14 strongly 
No reactivity 
2G9 U. parvum SV1 and 6 
4H2 U. parvum SV1 and 6 
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Figure 5.4 Western blot analysis of whole bacterial proteins from prototype U. parvum  serovars A. MBA 
proteins detected by previously characterised antibodies from Watson et al. (2000) separated on a 7.5% 
polyacrylamide gel. B. MBA proteins detected by Virostat plc. monoclonal antibodies on a 7.5% poly-
acrylamide gel.  Representative blots shown for multiple repeats.  Molecular mass for each serovar was 
maintained for each detected MBA, validating the reactivity of the monoclonal antibodies. 
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Figure 5.5 Western blot analysis of whole bacterial proteins from prototype U. parvum and U. urealyt-
icum strain separated on a 7.5% polyacrylamide gel and transferred to nitrocellulose prior to probing with 
commercial antibodies 6522, 6523, 6525 and 2B11. Relative molecular mass of MBA bands for specific 
serovar 1, 3, 6, 7, 11 and 14 strains where identical when detected by more than one antibody.  Repre-
sentative blot from multiple repeats of the experiment are shown. 
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Figure 5.6   Western blot analysis of whole bacterial proteins from prototype  U. parvum and U. 
urealyticum strains (A) and 11 clinical isolates  (B) by 6522 following separation on a 7.5% polyacryla-
mide gel and transfer to nitrocellulose. Figure reprinted from thesis of Ali Aboklaish with permission. 
 
Figure 5.7 Identical Western blot analysis of whole bacterial proteins from prototype U. parvum and 
U. urealyticum strains as in Figure 5.6except that it was probed with the serovar 10 specific mAb 8A1.2 
Comparison of the detected MBA species shows exactly the same pattern as 6522 for those strains.  
Sequencing of C-terminus of clinical isolates HPA24 and 31 confirmed they were the only strains with 
the unique TQPGSGST repeat.Figure reprinted from thesis of Ali Aboklaish with permission. 
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5.3.3  Use of monoclonal antibodies to detect serovar 3 by immunohistochemistry  
The capacity of these antibodies to detect serovar 3 by immunohistochemistry was also inves-
tigated.  However, this is technically very difficult as the size of individual U. parvum bacteria 
is between 200-400 nm and below the resolution of a light microscope.  Therefore, a scaled 
up culture of characterised serovar 3 strain HPA5 was pelleted at 17,000 xg and the pellet was 
embedded in paraffin wax, sectioned and processed for peroxidase-conjugated secondary 
staining using the monoclonal antibodies.  As the pellet was colourless, blue agar beads were 
added to the pellet prior to embedding to locate the pellet.  Antigen recovery steps utilising 
boiling citrate solution were required to facilitate mAb signal.  All of 6522, 6523 and 6525 
gave strong signals relative to the isotype matched negative control (Figure 5.8).  However, 
the U. parvum pellet appears amorphous and is not a very appealing example of immunohisto-
chemistry success.  Therefore, a recombinant form that could be expressed on E. coli was 
created so that more convincing immunohistochemistry could be performed. Figure 5.9 shows 
the sequence of serovar 3 MBA that was optimised for expression in E.coli (this is required 
as the endogenous tryptophan codon in the serovar 3 sequence is UGA – a stop codon in E. 
coli) and Figure 5.10 shows the process by which the synthetic MBA was created.  Only 2 
repeats could be engineered in the synthetic version of serovar 3 MBA as gene synthesis is 
confounded by recurring repeats (according to the provider).  Following transfection of the 
plasmid into E.coli the MBA protein was expressed and was found to segregate into the mem-
brane, rather than the cytoplasmic fraction, by Triton-X114 fractionation methods and West-
ern blot analysis (Figure 5.11).  The protein was detected both by monoclonal antibodies that 
recognise histidine repeats as well as by 6525.  Immunohistochemistry of E.coli colonies re-
moved from ampicillin containing Luria agar plates and embedded in paraffin wax and sec-
tioned show that 6522, 6523 and 6525 all detect the synthetic MBA protein and the distribu-
tion clearly show the outline of individual E.coli bacilli (Figure 5.12). 
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Figure 5.8 Immunohistochemistry of a serovar 3 (strain HPA5) pellet of U. parvum embedded in 
paraffin wax. No signal was seen when an isotype matched negative control monoclonal antibody was 
utilised, while brown peroxidase staining was distinct when the pellet was incubated with antibodies 
6522, 6523 and 6525.  The blue beads were added for section orientation and the scale bar is shown. 
 
 
 
 
 
 144 
 
 
 
 
Expasy translate tool prediction: 
M  K  L  L  K  N  K  K  F  W  A  M  T  L  G  V  T  L  V  G 
E.coli: atgaaactgctgaaaaacaaaaaattctgggcaatgaccctgggtgttaccctggttggt 
SV3:    atgaaattattaaaaaataaaaaattctgagctatgacattaggtgttaccttagttgga 
 
A  G  I  V  A  I  A  A  S  C  S  N  S  T  V  K  S  K  L  S 
E.coli: gcaggtattgttgcaattgccgcaagctgtagcaatagcaccgttaaaagcaaactgagc 
SV3:    gctggaatagttgctatagcagcttcatgttctaattcaactgttaaatctaagttaagt 
 
N  Q  F  A  K  S  T  D  G  K  S  F  Y  A  V  Y  E  I  E  N 
E.coli: aatcagtttgcaaaaagcaccgatggtaaatccttttatgccgtgtatgaaatcgaaaac 
SV3:    aaccaatttgctaaatcaacagacggtaaaagtttttatgcggtttacgaaattgaaaac 
 
F  K  D  L  S  N  D  D  K  K  S  L  S  N  I  E  F  N  A  A 
E.coli: ttcaaagatctgagcaacgatgacaaaaaaagcctgagcaacatcgaatttaatgcagca 
SV3:    tttaaagatctaagtaatgatgataaaaaatcattaagtaacattgaatttaatgctgct 
 
L  T  S  A  E  N  K  T  E  S  T  L  E  K  G  H  L  V  G  E 
E.coli: ctgaccagcgcagaaaacaaaaccgaaagcaccctggaaaaaggtcatctggtgggtgaa 
SV3:    cttacatcagctgaaaacaaaacagaaagtacacttgaaaaaggtcatttagttggtgaa 
 
K  I  Y  V  K  L  P  R  E  P  K  P  N  E  Q  L  T  I  I  S 
E.coli: aaaatctatgttaaactgcctcgtgaaccgaaaccgaatgaacagctgaccattattagc 
SV3:    aaaatttacgttaaattacctcgtgaaccaaaacctaatgaacaattaactattattagt 
 
K  S  G  L  I  K  T  S  G  L  L  I  S  D  N  L  N  Y  Q  T 
E.coli: aaaagcggtctgattaaaaccagcggtctgctgattagcgataatctgaattatcagacc 
SV3:    aaaagtggattaatcaagacttcaggtttgttaatatctgataatttgaattatcaaaca 
 
E  K  V  N  F  E  T  T  Q  P  G  K  L  Q  P  A  G  K  E  Q 
E.coli: gaaaaagtgaactttgaaaccacccagcctggtaagcttcagcctgctggcaaagaacaa 
SV3:    gaaaaagtgaactttgaaactacacaaccaggtaaagaacaaccagcaggtaaagaacaa 
 
P  A  G  K  E  Q  H  H  H  H  H  H 
E.coli: ccggcaggtaaagagcagcaccatcaccatcaccattaaaagctttaa 
 
Figure 5.9 MBA amino acid sequence utilised to generate codon-optimised sequence for 
expression in E.coli.  Original U. parvum sequence is provided for comparison.  The use of 
TGA as a tryptophan in Mollicute sequences is highlighted in green.  Two added BamH1 
restriction sites (highlighted in grey) engineered into the sequence are also shown that will 
remove the repeat sequence; however, this resulted in one sequence alteration of E to L (high-
lighted in red) in the recombinant version. 
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Figure 5.11 Western blot analysis following TritonX-114 partitioning  to separate membrane bound and 
cytoplasmic fractions .Monoclonal anti-MBA 6525 was used to detect recombinant MBA expression from 3 
separate colonies of E.coli transfected with a plasmid expressing the gene outlined in figure 5.9 (MBA1-3) 
compared to a colony that was transfected with an irrelevant gene.  The predicted mass of the protein (by 
http://www.bioinformatics.org/sms/prot_mw.html) was 18.97 kDa however this does not take into account 
the removal of the signal peptide and addition of the lipid anchor.  Figure shown is representative of repeated 
experiments. 
Submit MBA amino 
acid sequence to 
Life Technologies 
codon optimising 
service for E.coli 
 
Add strong house-
keeping promoter 
(EF-tu) to the 5’ 
DNA sequence 
 
Submit sequence 
to MWG Eurofins 
for gene synthesis 
and delivery in 
AmpR plasmid 
Figure 5.10 Process by which the sequence in above figure was generated and configured prior to 
 submisssion for gene synthesis. The promoter utilised consistent of -170 bp to ATG start codon for the tuf  
 Gene for serovar 3  (UU522 in ATCC strain 700970 full genome annotation). 
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Figure 5.12 Immunohistochemistry visualisation of synthetic serovar 3 MBA expressed by trans-
formed E.coli by monoclonal anti-MBA 6522 (B) 6523 (C) and 6525 (D) as compared to 6522 stain-
ing of E.coli that are transformed with an empty plasmid (A). Counterstaining E.coli bacilli with 
Gram-stain obscures the peroxidase staining (inset C), therefore, no counter stain was used in the 
larger images, although outline of individual bacilli at the edge of colonies are distinguishable in B-
D.  Images are taken with oil-emersion 100x objective lens, scale bar included to indicate magnifica-
tion. 
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5.4 Discussion 
Ureaplasma is one of the smallest self-replicating organisms with a minimal genome, ranging 
in size from 0.75 to 0.95 Mbp (Paralanov et al., 2012) .  These genomes are predicted to 
encode on average 604 (U. parvum) or 664 (U. urealyticum) protein encoding genes, with 515 
genes universally conserved across all serovars.  Separating the serovars by phylogenetic anal-
ysis has been performed in the past showing a clear separation of U. parvum from U. urealyt-
icum (Harasawa et al., 1996; Maniloff, 2002), but it is the conserved domain of the MBA gene 
that has been used to separate the phylogeny of the different serovars(Knox et al., 1998; Kong 
et al., 1999).  The MBA protein is an excellent target for separation of the Ureaplasmas into 
distinct sub-groups as it is highly expressed, often being the obvious variation between strains 
when separated by SDS-PAGE and stained with Coomassie blue.  It is therefore likely to 
represent a significant immunological target.  However, all serovars cannot be completely 
resolved from one another based on MBA sequence (e.g. serovars 2, 5 and 8).  Molecular 
methods of separating the serovars based on targets external to the MBA gene have been suc-
cessful for the prototype strains(Xiao et al., 2010); unfortunately application of these typing 
schemes to clinical isolates did not maintain clear serovar differentiation(Sung et al., 2011) , 
likely due to a propensity for Ureaplasma species to undergo extensive horizontal gene trans-
fer(Paralanov et al., 2012) . 
There have been several reports for the development of mAbs that recognise serovars in the 
past.  The first report was by Watson et al. (1990) where a panel of monoclonal antibodies 
were characterised and antibodies that recognised individual serovars 3, 8 and 10 were char-
acterised (Watson et al., 1990).  Further characterisation of these antibodies by peptide map-
ping identified the key aspects of the amino acid sequence of the repeat region motifs that 
differentiated serovar 3 specific mAbs 10C6.6 (KEQPA) and 3B1.5 (EQP) from an antibody 
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(5B1.1) that recognised both serovars 3 and 14 (GK) equally (Zheng et al., 1996) .  However, 
this last motif exists in the repeat of all U. parvum strains, so should not be specific only to 
serovars 3 and 14. Other mAbs that have been characterised bind specifically to serovar 4 
(Cheng et al., 1993), serovar 9(Naessens et al., 1998), and serovar 1, 3, or 6 (Cheng et al., 
1994).  However, the one commonality to these reagents is that they are sequestered in indi-
vidual research labouratories.  Here I have characterised a panel of commercially available 
monoclonal antibodies and found the first monoclonal antibody (6522) that appears to recog-
nise all strains of U. parvum and U. urealyticum (with the possible exception of serovar 4).  I 
also found an antibody that only recognises epitopes common to U. parvum (2B11) as well as 
one that recognises all U. parvum and weakly binds to serovars 7 and 11 (which belong to the 
same genotype)(Kong et al., 2000) .  Comparison of the entire MBA sequence between all 
Ureaplasma strains shows 4 potential regions of complete homology with hydrophilic and 
charged residues and some regions that could be the targets of differential recognition (Figure 
5.13).  Equally, the antibody 2B11 could recognise the areas that are conserved between 
U.parvum serovars, but altered for U. urealyticum serovars.  The weak recognition of serovars 
7 and 11 in addition to U. parvum by 6523 is difficult to explain as there is no obvious region 
of the conserved N-terminal region that separates these two serovars from the remaining U. 
urealyticum strains.  With regards to previously published monoclonal antibodies, visual in-
spection of the amino acid sequence of the repeat regions shows differences that justify how 
antibodies could specifically recognise serovars 1, 3, 6, 9, and 10, but the shared repeat regions 
for serovar 4, 10, 12 and 13 and 2, 5 and 8 make it difficult to understand antibodies that only 
detect serovar 4(Cheng et al., 1993) and serovar 8(Watson et al.,1990).  I have validated the 
bands recognised by the commercial antibodies against previously characterised antibodies, 
to confirm it is the MBA protein that the commercial antibodies are binding. 
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Using the MBA as a method to classify strains is not without potential disadvantages.  The 
MBA is phase variable.  When grown in the presence of rabbit polyclonal anti-MBA antibod-
ies, expression has been found to be shut off(Zimmerman et al., 2009) , as have selection of 
non-adherent sub-populations(Monecke et al., 2003) .The mechanism of phase variation is 
speculated to involve tyrosine recombinases (particularly XerC) and inversion of promoter 
regions driving expression of the open-reading frames(Zimmerman, 2013: Zimmerman et al., 
2015).  The tendency for recombination can also result in multiple copies of the MBA gene 
being present in the genome and comparative genomic analysis has suggested that repeats 
characteristic of different serovars can be found in a single genome of the same strain (Para-
lanov et al., 2012); however, no evidence of co-expression of separate serovar repeat expres-
sion was provided in that report.  
It is interesting that phase variation of MBA could be induced by co-culturing with polyclonal 
anti-MBA antibodies (Zimmerman et al., 2009), and may well relate to the original serotyping 
methods where polyclonal anti-serovar sera were found capable of inhibiting the metabolism 
of matching strains through an unknown mechanism.  Watson et al. (1990) confirmed that 4 
of 6 monoclonal antibodies also had differing capacities to inhibit metabolism of matching 
serovars.  Whether different epitopes on the MBA relate to metabolic inhibition, or whether 
only those monoclonal antibodies that recognise epitopes available in the native protein in-
hibited metabolism remains unknown(Watson et al., 1990).  While it is difficult to speculate 
a mechanism for how antibody binding to a lipid anchored bacterial protein would result in 
bactericidal or bacteriostatic activity, the future of anti-MBA monoclonal antibodies as ther-
apeutics in exploiting this phenomenon remains open. 
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Conclusion, here I provide a detailed analysis that differentiates between the reactivity of a 
panel of monoclonal antibodies raised against the MBA.  The results will enable other re-
searchers to speciate clinical isolates, or assign specific serovars in some cases, based on dif-
ferential detection by Western blot or immunohistochemistry.  More importantly, these rea-
gents will enable researchers to begin to examine correlations between MBA size or numbers 
of MBA isoforms present in each sample, rather than just nucleic acid determinations.  This 
may be of particular importance for future investigations as experimental investigations in 
pregnant sheep have found increased pathology when less than 5 MBA isoforms were ob-
served compared to pregnant sheep infected with 9 or more MBA isoforms for the same 
strain(Knox et al., 2010) . 
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Figure 5.13 Alignment of MBA from all Ureaplasma species for potential epitopes recognised by 
6522.  Green highlighted regions indicate regions of conserved homology with hydrophilic and 
charged residues that could serve as immunogenic epitopes.  Amino acids prior to the first cysteine are 
expected to be removed as a signal sequence. 
CLUSTAL O(1.2.1) multiple sequence alignment 
 
Signal sequence–expected to be removed ↓ 
sv6       MKLLKNKKFWAMTLGVTLVGAGIVAIAASCSNSTVKSKLSSQFVKSTDDKSFYAVYEIEN 
sv1       MKLLKNKKFWAMTLGVTLVGAGIVAIAASCSNSTVKSKLSNQFAKSTDDKSFYAVYEIEN 
sv14      MKLLKNKKFLAMTLGVTLVGAGIVAIAASCSNSTVKSKLSNQFAKSTDGKSFYAVYEIEN 
sv3       MKLLKNKKFWAMTLGVTLVGAGIVAIAASCSNSTVKSKLSNQFAKSTDGKSFYAVYEIEN 
sv4       MKLLKNKKFWAITLGVTLVGAGVVAVAASCSSSNVKSKLSSQLVKSKDEKSFYAVYDIEN 
sv13      MKLLKNKKFWAITLGVTLVGAGVVAVAASCSSSNVKSKLSSQLVKSKDEKSFYAVYDIEN 
sv12      MKLLKNKKFWAITLGVTLVGAGVVAVAASCSSSNVKSKLSSQLVKSKDEKSFYAVYDIEN 
sv8       MKLLKNKKFWAITLGVTLVGAGVVAVAASCSSSNVKSKLSSQLVKSKDEKSFYAVYDIEN 
sv5       MKLLKNKKFWAITLGVTLVGAGVVAVAASCSSSNVKSKLSSQLVKSKDEKSFYAVYDIEN 
sv2       MKLLKNKKFWAITLGVTLVGAGVVAVAASCSSSNVKSKLSSQLVKSKDEKSFYAVYDIEN 
Sv10      MKLLKNKKFWAITLGVTLVGAGVVAVAASCSSSNVKSKLSSQLVKSKDEKSFYAVYDIEN 
sv9       MKLLKNKKFWAITLGVTLVGAGVVAVAASCSSSNVKSKLSSQLVKSKDEKSFYAVYDIEN 
sv11      MKLLKNKKFWAITLGVTLVGAGVVAVAASCSSSNVKSKLSSQLVKSKDEKSFYAVYDIEN 
          ********* *:**********:**:*****.*.******.*:.**.* *******:*** 
 
sv6       FKDLSDNDKKSLNDIEFNAALTSVENKTENLVTKGHLVGEKIYVKLPREPKPNEQLTIIN 
sv1       FKDLSDNDKKSLNDIEFNAALTSVENKTENLVTKGHLVGEKIYVKLPREPKPNEQLTIIN 
sv14      FKDLSNDDKKSLSNIEFNAALTSAENKTESTLEKGHLVGEKIYVKLPREPKPNEQLTIIS 
sv3       FKDLSNDDKKSLSNIEFNAALTSAENKTESTLEKGHLVGEKIYVKLPREPKPNEQLTIIS 
sv4       FDDLNENDKKALNEAEFNVAITSAENKTENATTKGHLLNKKIYVKLPREPKAKEQLTIIN 
sv13      FDDLNENDKKALNEAEFNVAITSAENKTENATTKGHLLNKKIYVKLPREPKAKEQLTIIN 
sv12      FDDLNENDKKALNEAEFNVAITSAENKTENATTKGHLLNKKIYVKLPREPKAKEQLTIIN 
sv8       FDDLTENDKKALNEAEFNVAITSAENKTENATTKGHLLNKKIYVKLPREPKAKEQLTIIN 
sv5       FDDLTENDKKALNEAEFNVAITSAENKTENATTKGHLLNKKIYVKLPREPKAKEQLTIIN 
sv2       FDDLTENDKKALNEAEFNVAITSAENKTENATTKGHLLNKKIYVKLPREPKAKEQLTIIN 
Sv10      FDDLNENDKKALNEAEFNVAITSAENKTENATTKGHLLNKKIYVKLPREPKAKEQLTIIN 
sv9       FDDLTENDKKALNEAEFNVAITSAENKTENATTKGHLLNKKIYVKLPREPKAKEQLTIIN 
sv11      FDDLTENDKKALNETEFNVAITSVENKTENATIKGHLLNKKIYVKLPREPKAKEQLTIIN 
          *.**.::***:*.: ***.*:**.*****.   ****: :*********** :******. 
 
sv6       KSGLIKTSGLLIPNNLNYQTEKVNFETAPKTQEPGKEPGKEPGK-E--PGKEPG---KEP 
sv1       KSGLIKTSGLLIPDNLNYQTEKVNFETASKTEEPKENVGEQP-GKEQQPGKEQQ---P-- 
sv14      KSGLIKTSGLLISDNLNYQTEKVNFETTQPGKEQQPAGKEQ-----QPAGKEQQ---P-A 
sv3       KSGLIKTSGLLISDNLNYQTEKVNFETTQPGKEQPA-GKEQPAGKEQPAGKE-Q---P-A 
sv4       KGGLLKTASLVLPDNLNYQTEKVEFETQPGNGTTSPE---KPGNGTTSPEKPG------- 
sv13      KGGLLKTASLVLPDNLNYQTEKVEFETQPGNGTTSPE---KPGNGTTSPEKPG------- 
sv12      KGGLLKTASLVLPDNLNYQTEKVEFETQPGNGTTSPE---KPGNGTTSPEKPG------- 
sv8       KGGLLKTASLVLPDNFNYQTENIGFETKPGSGETTKP---GSGETTKPGSGETT------ 
sv5       KGGLLKTASLVLPDNFNYQTENIGFETKPGSGETTKP---GSGETTKPGSGETT------ 
sv2       KGGLLKTASLVLPDNFNYQTENIGFETKPGSGETTKP---GSGETTKPGSGETT------ 
Sv10      KGGLLKTASLVLPDNLNYQTENIGFETQPGSGSTTQP---GSGSTTQPGSGSTT------ 
sv9       KGGLLKTASLVLPDNFNYQTEKVDFENAPTPTPEPTP---TPTPKEDKAIVSNVEFSEVN 
sv11      KGGLLKTASLALPDNLNYQTEKVDFKSTHTPEPTPTP---TPAPKEDKAVVSNVEFSDVD 
          *.**:**:.* : :*:*****:: *:.                                  
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6 Evolution of Ureaplasma parvum during in utero infection 
6.1 Introduction  
The most commonly isolated bacteria from uterus of women in spontaneous preterm labour 
with intact membranes are mixture of low virulence bacteria like Ureaplasma species, Myco-
plasma hominis, peptostriptococci, Gardenella vaginalis, and bacteroids (Holst et al., 1994; 
Rodney et al., 2006). One of the most common but underestimated pathogens of female re-
production, as mentioned in 2005 by Volgmann and colleagues (Volgmann et al. 2005) is 
Ureaplasma, a member of the class Mollicutes, found to be the most common organism iso-
lated from the amniotic fluid and tissues of those born prematurely between (23-32wk) and 
those with low birth weight in an inversely proportional rate with their gestational age  (Kal-
lapur et al. 2013; Novy et al. 2009; Watts  et al. 1992). Additionally, many reported studies 
showed that Ureaplasma long thought to be a harmless commensal is potentially pathogenic 
for humans particularly during pregnancy where it can establish chronic intrauterine infection 
in spite of its extreme susceptibility to fetal serum and may end in devastating reproductive 
sequel (Alfa et al., 1995; Cassell et al., 1986; Viscardi et al., 2010; Waites et al., 2006;). 
Experimental in utero infection in sheep with U. parvum has been used to investigate the 
pathogenicity of these bacteria which is associated with induction of preterm birth (Jennifer 
et al., 2010; Knox et al., 2010; Moss et al., 2005). 
Ureaplasma are fastidious and require a highly supplemented culture environment to grow 
and reproduce. It hydrolyses urea as the sole source of energy and requires cholesterol for 
synthesis of its lipid cell membrane and it is a facultative anaerobe (Masover et al., 1977). 
This explains the preference of Ureaplasma to adhere and colonise the urogenital track mu-
cosa and live as normal commensals in a large proportion (62%) of sexually active women.  
Colonisation is increased during pregnancy (80-90%) and drops to less than (25%) during 
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puerperium and menopause which may reflect a hormonal effect on mycoplasma infection 
(Iwasaka et al., 1986).  On the other hand, Ureaplasma can cross the chorioamniotic mem-
branes and get access to the amniotic cavity during pregnancy either by ascending from the 
lower genital tract across the cervix (which is the most plausible route) or by haematogenous 
distribution through the placenta, or by descending into the uterus from the peritoneal cavity.  
Iatrogenic infection can also occur during invasive procedures like amniocentesis or chorionic 
villous sampling, as these methods mechanically bypass anti-infective mechanisms which de-
fend normal pregnancy. Most Ureaplasma infections are sub-clinical and difficult to detect 
except by amniotic fluid aspiration and analysis by molecular techniques or by cultivation 
(Waites et al., 2009; Gerber et al., 2003). 
Once inside the host, it will be confronted by the immediate innate immune response and later 
by the adaptive immune response. In spite of that, Ureaplasma can survive, colonise and rep-
licate inside the host tissues. The ability of Ureaplasma to escape the host immune response 
during its colonisation in the uterus has been examined by the scientists for many years(Citti 
et al., 2010; Dando, et al. 2012). Ureaplasma has many virulence factors to overcome the host 
immune response including an IgA protease, phospholipase A and C, urease and the ability to 
generate hydrogen peroxide, which help the organism to overcome host defence and enable it 
to hydrolyse and invade host tissue (Viscardi, 2012; Kallapur et al. 2013). Yet, the most im-
portant immunodominant antigen in Ureaplasma is a surface-exposed lipoprotein referred to 
as the multiple banded antigen (MBA), which has two domains; the variable part (consisting 
of a number of uniform repeating units) and a conserved part (consisting of a signal peptide 
and a lipid–anchor signal and a conserved non-repeating stalk).  The variable repeating units 
define its serovar specificity but for U. parvum these have cross reactive epitopes (Teng et al., 
1994; Viscardi, 2012). The MBA gene can undergo continual antigenic variation either by 
changing the number repeats (by expansion of the multiple C-terminal short amino acid 
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(QPAGKE) repeats; i.e. size variation) or by synchronised inversion of the promoter region 
which switches off MBA expression in favour of expressing an adjacent gene in the opposite 
genomic orientation (called phase variation). This is thought to respond to immunological 
pressure to allow Ureaplasma to persist for longer duration and promote host adaptation (Mo-
necke et al., 2003; Zimmerman et al. 2009; Viscardi, 2012; Zimmerman, 2014). Loss of the 
major surface antigen (MBA), which could be targeted by the adaptive immune system, is 
thought to help Ureaplasma to evade the host immune response (Paralanov et al., 2012). 
Zimmerman et al., (2009) demonstrated that MBA can undergo size variation through chang-
ing the number of the C-terminal repeats and he proved that some MBA negative Ureaplasma 
strains can be created by exposing the protein to repeated immunological pressure with anti-
bodies against the MBA gene.  This resulted in switching on of the hypothetical gene (UU376) 
instead of the original MBA gene (UU375) through a mechanism of DNA inversion event in 
a gene locus mediated by the XerC recombinase (Zimmerman et al., 2009; Zimmerman et al., 
2011; Zimmerman, 2014). 
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6.2 Aims 
 To further characterise the strains recovered from chronic intrauterine infection from 
Chapter 4, using the characterised reagents of Chapter 5.  
 To compare the serum killing susceptibility of strains recovered from infected sheep 
following various lengths of infection. 
 To purify recovered isolates by repeated colony isolation and compare MBA size to 
serum killing phenotype.   
 To examine MBA gene size and sequence, as well as total genome sequence, for phe-
notypically altered, purified recovered strains to the original annotated genome se-
quence of the infecting HPA5 strain. 
 
6.3 Results 
6.3.1  Analysis of MBA from strains recovered from amniotic fluid. 
 In Chapter 5, I have fully characterised monoclonal antibodies recognising the MBA so that 
I may return to strains recovered from amniotic fluid following experimental intrauterine in-
fection in Chapter 4 for more in depth analysis.  Figure 6.1 reviews the Ureaplasma parvum 
titration in amniotic fluid samples recovered from catheterised sheep and two separate groups 
of sheep with amniotic fluid recovered at delivery and by ultrasound guided needle sampling. 
Western blot analysis of amniotic fluid recovered strains from the catheterised sheep (120 hr) 
and samples recovered from amniotic fluid at surgical delivery after 1 week infection are 
shown in( Figure 6.2).  MBA isoforms detected by monoclonal antibody 6525 show doublets 
for amniotic fluid isolates from sheep 12.068 and 12.073; but these are similar in mass to the 
single isoform observed in original inoculating HPA5 strain.  Two of the strains recovered 
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from the non-catheterised group (amniotic fluid samples obtained at surgical delivery) also 
show a doublet MBA isoform (Figure 6.2). However, the new emerging MBA isoforms are 
approximately 20 kDa increased in size.  Western blot analysis of isolates grown directly from 
ultrasound-guided amniocentesis samples taken at 3 and 5 weeks post-infection, continue to 
show increased numbers of MBA isoforms (Figure 6.3), and by 5 weeks no original 50 kDA 
MBA isoforms are detectable.  To determine if multiple MBA isoforms were expressed by 
single isolates, I plated each of the strains recovered out by amniocentesis on Ureaplasma 
selective agar plates (Figure 6.4) and picked single colonies to be inoculated into broth.  I 
repeated the colony purification twice in duplicate, designating the first round by a or b (i.e. 
13.136a and 13.136b), and a number to the second round (i.e. 13.136a1, 13.136a2, 13.136b1, 
and 13.136b2).  Figure 6.5 shows the isolates arranged by increasing MBA isoform size.  In 
all cases sub-strains containing only a single MBA isoform could be isolated (140b2 and 
132b1 could subsequently be cloned to single MBA species). 
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Figure 6.1 Ureaplasma titration in amniotic fluid samples retrieved from 3 separate groups of pregnant 
sheep experimentally infected with strain HPA5 Group 1: repeat amniotic fluid catheter samples (red; 
N=6), Group 2: amniotic fluid collected at Caesarean delivery (blue; N=6), and Group 3: amniotic fluid 
samples collected by ultrasound guided needle at 3 and 5 weeks post-infection (beige; N=6). Mean and 
standard error of the mean shown for individual animal titres (which represents the average of each 
animal determined in triplicate). 
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Figure 6.2 Western blot analysis of Ureaplasma parvum isolates grown directly from amniotic fluid 
samples collected from the final catheter time point (12.068-12.078) or from samples collected at sur-
gical delivery following a week of intrauterine infection (12.260-12.267) by strain HPA5 (inoculating 
strain included as control= ori). MBA isoforms detected by the monoclonal antibody 6525).Western 
blot represents identical results from three separate experiments. 
 
Figure 6.3 Western blot analysis of Ureaplasma parvum isolates grown directly from amniotic fluid 
samples. For comparison the 1 week post-infection samples from figure 6.2 are included.  Isolates 
grown from ultrasound-guided amniocentesis samples from seven HPA5-infected sheep were collected 
at 3 weeks (13.131-13.137; no viable Ureaplasma was isolated from 13.135) as well as from 10 sheep 
following 5 weeks of HPA5 infection (sheep 13.132. 13.136 and 13.137 are common to both groups, 
but the remaining 7 were sampled for the first time at 5 weeks). MBA isoforms detected by the mono-
clonal antibody 6525.  Western blot represents identical results from three separate experiments, inoc-
ulating original HPA5 strain included for reference (HPA5 ori). 
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Figure 6.4 Colonies of HPA5 recovered by amniocentesis after 5 weeks of intrauterine infection. 
Strains grown in Ureaplasma selective broth were inoculated on to Ureaplasma selective agar and in-
cubated for 48 hr at 37oC. Individual colonies were picked with a 10 µl pipette tip and inoculated into 
broth.  Process repeated twice to isolate purified sub-strains.  Agar plate visualised under a 4x objective 
and scale bar added to the image by OpenLab software utilised to capture image via CCD camera. 
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Figure 6.5 Western blot analysis of amniotic fluid recovered HPA5 strain of Ureaplasma parvum at 
5 weeks post-infection. Isolates were colony purified twice prior to culture scale up and separation by 
SDS-PAGE Isoforms are arranged by increasing MBA isoform mass (increased by 20->70kDA com-
pared to inoculating strain (HPA5 ori). MBA isoforms detected by the monoclonal antibody 6525.  
Western blot represents identical results from three separate experiments. 
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6.3.2  Characterisation of complement susceptibility of recovered isolates  
 Now that it had become clear that the HPA5 strain appear to be altering their MBA isoforms 
with prolonged intrauterine infection, I examined the susceptibility of three of these  strains to 
sera from 95 dGA, 125 dGA and adult sheep (N=3 uninfected controls each).  In chapter 4, I 
show that the complement activity of fetal sera decreases with increasing prematurity and I had 
examined the susceptibility of isolates from amniotic fluid and plasma in strains isolated from 
94 dGA lambs following a 24 day infection.  However, I only examined a 50% dilution of adult 
and 95 dGA sera (Figure4.7).  Therefore, for these isolates I examined a titration of sera between 
50% and 6.25%.  Figure 6.6 shows that the original HPA5 strain and strains recovered from 
amniotic fluid after 1 week post-infection are equivalent in their susceptibility to sera.  However, 
strains recovered after 3 weeks post-infection were less susceptible and after 5 weeks post-in-
fection were almost completely resistant to 125 dGA sera and resistant to seronegative (M18) 
human serum and start becoming more resistant to uninfected pregnant sheep sera (Figure 6.6).   
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Figure 6.6 Serum killing assays for Ureaplasma, comparing original inoculating HPA5 strain to strains 
recovered after 1, 3, and 5 weeks post-infection in sheep Sera from 3 control uninfected 95 day gesta-
tional age (dGA), three 125 dGA and 3 adults (matched to the 125 dGA group), as well as M18 (sero-
negative human serum) were diluted in CFB and incubated with bacterial strains for 30 min at 37oC.  
Data averaged from 3 strains chosen at random for 1, 3, & 5 weeks are shown. Mean and standard error 
for cumulative data shown.   
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I also examined the complement susceptibility of the colony purified isolates from Figure 6.5 to 
see if there were individual differences between strains purified from different sheep 5 week 
post-infection by incubation with 50% 125 dGA sera (Figure 6.7).  These strains were isolated 
from 7 separate sheep and have known MBA isoform mass (Figure 6.5).  They are arranged 
from smallest MBA (13.139a2) to largest MBA (13.132b1).  The susceptibility to killing by sera 
from uninfected 125 dGA lambs was also compared to the highly sensitive parental HPA5 strain 
as well as to ATCC prototype Ureaplasma parvum serovar 3 (700970) and Ureaplasma urea-
lyticum serovar 8 (27618)(Figure 6.7).  Serovar 8 was found to be as sensitive to sheep sera as 
HPA5, while ATCC serovar 3 was found to be slightly less sensitive (Figure 6.7; p<0.05).  Three 
of the isolates (13.139a2, 13.126a1 and 13.122a1) appear to be less resistant than the others, 
however no significance was found between these groups by ANOVA.  In chapter 4, I also 
found one of the ten 125 dGA lambs infected for 10 days had detectable HPA5 in their plasma 
(14.231), I have included this bacteremic strain for comparison and found that this strain was 
resistant to 125 dGA sera (Figure 6.7).  Furthermore, in chapter four I also found that the strain 
isolated from the plasma of 95 dGA lamb 14.115 was more sensitive to 95 dGA sera than the 
other isolates and it was included for comparison in these experiments as well (Figure 6.7).  
Consistent with the initial observations, plasma strain 14.115, was also more sensitive to125 
dGA sera and was not significantly more resistant than the parental strain (although it ap-
proached significance at P=0.0546).  For completeness, in Figure 6.8, I also include the Western 
blot analysis comparing the strains isolated from the amniotic fluid and plasma from 94 dGA 
infected animals from chapter 4 (14.115, 14.116, 14.120 14.121), as well as matched plasma 
and amniotic fluid isolates from another experiment (14.138 and 14.139) and the single plasma-
isolated strain from 125 dGA infected animals (14.231; no amniotic fluid samples were collected 
for comparison in these animals).  It is notable that the unique sensitive strain from the plasma 
of 94 dGA animal 14.115 is the only one (for both plasma and amniotic fluid isolates) that 
retains the original MBA mass compared to HPA5 (Figure 6.8) and that animal 14.231 is the 
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only strain isolated from one of ten 125 dGA animals infected for 10 days, exists as a single 
larger MBA isoform mass (Figure 6.8). 
 
 
 
Figure 6.7 Serum killing assays for Ureaplasma, comparing susceptibility of original inoculating 
HPA5 strain to ATCC prototype serovar 3 and serovar 8 and to strains recovered from plasma of in-
fected sheep (14.115P and 14.231P from figure 4.7) and the colony purified strains obtained from am-
niotic fluid following 5 weeks intrauterine infection (from figure 6.5).  Strains were incubated for 30 
min with 50% sera from 125 dGA uninfected lambs (pooled).  Data shown represent combined data 
from 3 replications of the same experiment (mean and standard error of the mean).  *=p<0.05 significant 
difference, ANOVA comparison between colony purified samples as a subset failed to identify a sig-
nificant difference. 
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Figure 6.8 Western blot analysis of isolates recovered from the amniotic fluid or plasma at surgical 
delivery of 94 dGA lambs infected for 24 days with the exception of 14.231 which was the only plasma 
isolate out of ten 125 dGA lambs infected for 10 days) with HPA5 strain of Ureaplasma parvum. Strains 
were scaled up directly from samples.  Samples 14.115, 14.116, 14.120, and 14.121 were characterised 
in chapter 4; however, samples 14.138 and 14.139 were treated with a potentially confounding variable 
and have been included only for comparison of MBA isoforms between plasma and amniotic fluid from 
the same animal.  Only serum sensitive strains from 14.115 retain the original MBA mass compared to 
the inoculating (HPA5 ori) strain. MBA isoforms detected by the monoclonal antibody 6525.  Western 
blot represents identical results from three separate experiments. 
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6.3.3 Investigation of variation in MBA gene size 
The mass of the MBA protein increases with longer intrauterine experimental infection and this 
appears to be coincident with the decreased susceptibility of the recovered strains to be killed 
by sheep complement.  Therefore, primers were designed based on the prototype serovar 3 strain 
(ATCC 700970) to amplify the MBA gene from the surrounding genomic DNA (Figure 6.9). 
The primers include the previously published primers (Teng et al.,1994)) that amplify the region 
from -125 bp in the promoter (UMS-125) to 226bp in the coding region (UMA226) that is used 
to detect Ureaplasma parvum strains in clinical samples.  Combinations of these primers were 
used to amplify peri-MBA gene DNA from the original HPA5 strain and the colony purified 
strains from Figure 6.5 (Figure 6.10).  Two of the amplified MBA genes were selected for clon-
ing into the TopoTA cloning vector pcr2.1 (Figure 6.11) and the results of this sequencing are 
shown in Figure 6.12.  Analysis of these sequences determined that the predicted amino acid 
sequence for the MBA gene in the original HPA5 strain had 17 repeat units (EQPAGK), com-
pared to the 43 repeats found in the prototype ATCC strain.  This accounts for the much smaller 
MBA mass for original HPA5.  By contrast the MBA gene from 13.136b1 was predicted to 
contain 36 repeat units, which is consistent with the 342 bp increase in the PCR amplicons 
relative to HPA5 ori (Figure 6.11).  However, this would only account for a predicted 11.6 kDa 
to be added to the mass of MBA by Western blot, which seems a bit small for the 20 kDa 
difference observed by Western blot (Figure 6.5).   
 
 
 
 
 168 
 
 
 
 
Figure 6.9 Diagram showing primer direction and placement relative to the sequence of the MBA gene and 
the adjacent genes in the serovar 3 Ureaplasma parvum genome. 
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Figure 6.10 (a) showing primer direction and placement relative to the sequence of the MBA gene and the 
adjacent genes in serovar 3. Ureaplasma parvum genome amplicons separated on a 1% agarose gel, visualised 
by ethidium bromide and UV light.  All PCR reactions were run for 45 cycles with 54oC annealing temperature 
and 2.5 minute polymerase extension time, and the primer pairs used are listed below the bands (separated by a 
dotted line). Yellow arrow heads indicate the specific PCR products, which show increasing size relative to the 
original (HPA5 ori) inoculating strain; blue arrows indicate bands purified for cloning into pMT85 for transposon 
expression. (b) Showing the gel purified bands, 13.136b1From UU374 start (entire promoter from MBA) to 
SV3end and 13.141b2 from UMA-125(partial promoter) to UU374start (intergenic region from SV3 MBA stop 
to next gene).   
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Figure 6.11 Diagram for Topo-TA cloning vector pCR2.1 
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Figure 6.12 Sequence from pCR2.1 vector containing MBA gene and surrounding DNA (including pre-
dicted open-reading frame translation) Xba1 sites used to clone into expression vector pMT85 are also un-
derlined.  Two mutations in the gene, compared to HPA5 original, are highlighted in grey: the first is silent; 
the second alters proline to alanine. 
 
actagtaacggccgccagtgtgctggaattcgcccttgtgtctagagagatggttgttgg 
pCR2.1 vector sequence                 Xba1 in primer sequence    
cttggagctgaagctgcttcaaagttcactttttctgtttgataattcaaataataaaac 
Start of UU376 gene (reverse)^   
ttattaaaaataatatagatatataattaaatttttaatcataatttataataaaaaata 
          <-complete UU376/UU375 intergenic region-> 
tctaataatgttatcgataatgcagaaaaataaaaaaataaaaaaaatagtaaaaattat 
   
ataattaaaagtgcaagtgctaaataaaaagtatttgcaatctttatatgttttcgttaa 
  
aattaaaaattaattactgtagaaattatgtaagatcaccaaatcttagtgttcatattt 
   
tttacatatattaaataaaaacaataaaatgacatattttttatattaggagaatcataa 
start of MBA (UU375) gene> 
atgaaattattaaaaaataaaaaattctgagctatgacattaggtgttaccttagttgga 
 M  K  L  L  K  N  K  K  F  W  A  M  T  L  G  V  T  L  V  G  
gctggaatagttgctatagcagcttcatgttctaattcaactgttaaatctaagttaagt 
 A  G  I  V  A  I  A  A  S  C  S  N  S  T  V  K  S  K  L  S  
aaccaatttgctaaatcaacagacggtaaaagtttttatgcggtttacgaaattgaaaac 
 N  Q  F  A  K  S  T  D  G  K  S  F  Y  A  V  Y  E  I  E  N  
tttaaagatctaagtaatgatgataaaaaatcattaagtaacattgaatttaatgctgca 
 F  K  D  L  S  N  D  D  K  K  S  L  S  N  I  E  F  N  A  A  
cttacatcagctgaaaacaaaacagaaagtacacttgaaaaaggtcatttagttggtgaa 
 L  T  S  A  E  N  K  T  E  S  T  L  E  K  G  H  L  V  G  E  
aaaatttacgttaaattacctcgtgaaccaaaacctaatgaacaattaactatcattagt 
 K  I  Y  V  K  L  P  R  E  P  K  P  N  E  Q  L  T  I  I  S  
aaaagtggattaatcaagacttcaggtttgttaatatctgataatttgaattatcaaaca 
 K  S  G  L  I  K  T  S  G  L  L  I  S  D  N  L  N  Y  Q  T  
gaaaaagtgaactttgaaactacacaagcaggtaaagaacaaccagcaggtaaagaacaa 
 E  K  V  N  F  E  T  T  Q  A  G  K  E  Q  P  A  G  K  E  Q  
ccagcaggtaaagaacaaccagcaggtaaagaacaaccagcaggtaaagaacaaccagca 
 P  A  G  K  E  Q  P  A  G  K  E  Q  P  A  G  K  E  Q  P  A  
ggtaaagaacaaccagcaggtaaagaacaaccagcaggtaaagaacaaccagcaggtaaa 
 G  K  E  Q  P  A  G  K  E  Q  P  A  G  K  E  Q  P  A  G  K  
gaacaaccagcaggtaaagaacaaccagcaggtaaagaacaaccagcaggtaaagaacaa 
 E  Q  P  A  G  K  E  Q  P  A  G  K  E  Q  P  A  G  K  E  Q  
ccagcaggtaaagaacaaccagcaggtaaagaacaaccagcaggtaaagaacaaccagca 
 P  A  G  K  E  Q  P  A  G  K  E  Q  P  A  G  K  E  Q  P  A  
ggtaaagaacaaccagcaggtaaagaacaaccagcaggtaaagaacaaccagcaggtaaa 
 G  K  E  Q  P  A  G  K  E  Q  P  A  G  K  E  Q  P  A  G  K  
gaacaaccagcaggtaaagaacaaccagcaggtaaagaacaaccagcaggtaaagaacaa 
 E  Q  P  A  G  K  E  Q  P  A  G  K  E  Q  P  A  G  K  E  Q  
ccagcaggtaaagaacaaccagcaggtaaagaacaaccagcaggtaaagaacaaccagca 
 P  A  G  K  E  Q  P  A  G  K  E  Q  P  A  G  K  E  Q  P  A  
ggtaaagaacaaccagcaggtaaagaacaaccagcaggtaaagaacaaccagcaggtaaa 
 G  K  E  Q  P  A  G  K  E  Q  P  A  G  K  E  Q  P  A  G  K  
gaacaaccagcaggtaaagaacaaccagcaggtaaagaacaaccagcaggtaaagaacaa 
 E  Q  P  A  G  K  E  Q  P  A  G  K  E  Q  P  A  G  K  E  Q  
ccagcaggtaaagaacaaccagcaggtaaagaacaaccagcaggtaaagaacaaccagca 
 P  A  G  K  E  Q  P  A  G  K  E  Q  P  A  G  K  E  Q  P  A  
ggtaaagaacaaccagcaggtaaagaaactactggaaaataatctagaaagggcgaattc 
 G  K  E  Q  P  A  G  K  E  T  T  G  K  - Xba1 in primer sequence    
tgcagatatccatcacactggcggccgctcgagcatgcatctagagcccaatcgctaaag 
pCR2.1 vector sequence  
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6.3.4 Transposon delivery of a larger MBA gene to HPA5 to increase serum 
resistance 
 The sequenced 13.136b1 amplicon included the promoter region and the entire coding region.  
Therefore, an experiment was designed to express a larger MBA in HPA5 to see if it could 
transfer resistance to 125 d GA serum killing.  The 13.136b1 amplicon was transferred to the 
transposon plasmid pMT85 using the flanking Xba1 site (Figure 6.12) and Dr. Ali Aboklaish 
transformed the original HPA5 strain with the second copy of MBA gene in pMT85.  Three 
separate colonies that contained the gentamicin resistance gene from pMT85 were examined 
by Western blot and compared to HPA5 transformed with pMT85 containing irrelevant genes.  
As can be seen from Figure 6.13, these strains co-expressed two isoforms of MBA: one that 
corresponds to the original mass of HPA5 and the other that corresponds to the mass of 
13.136b1.  Unfortunately, this hybrid strain remained sensitive to killing by 125 dGA sera 
when challenged for 30 min at 37oC (data not shown).  This suggests that serum resistance 
was mediated by some other alteration to the HPA5 genome. 
 
6.3.5 Comparison of whole genome sequence between original HPA5 and recovered 
strains  
HPA5 original strain  and  the recovered strains 13.122a2, 13.126a1, 13.127b1, 13.127b2, 
13.136a1, 13.136b1, 13.137a1 and 13.139a2 were scaled up to 700 ml cultures, pelleted at 
13,000 xg for 3 h and the genomic DNA extracted by Genelute columns.  The entire amount 
of DNA was submitted to Public Health England (via Dr. Victoria Chalker) and the assembled 
contigs were returned to me (Table 6.1).  These contigs ranged in size from 425,777 bp to 
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1,418 bp and each strain yielded about 8 to 12 contigs.  Using the Geneious 8.0.5 analysis 
software these assembled pieces of DNA were compared to the fully annotated genome for 
the original strain HPA5 (completed by Dr. Mike Beeton and Dr. Brad Spiller).  As can be 
seen from Figure 6.14, the contigs from each strain range from 8 to 14 stretches of DNA that 
covers the entire genome.  Direct copies of the 5S, 23S and 16S rRNA operon cause problems 
for the alignment (any repeat >200bp is read as the same sequence). In the Geneious program 
analysis rRNA sequences are red arrows, tRNA are pink arrows, genes are yellow arrows 
(which almost always correspond to green predicted protein arrows).  Comparing sequence 
differences between all recovered sequences that are conserved compared to the original strain 
annotated sequence, very few genetic alterations are observed (other than increasing repeat 
regions for the MBA gene; UU375) as listed in Table 6.2.  Although 3 single nucleotide poly-
morphisms (SNP) were detected in all strains for hypothetical open-reading frame UU046, all 
were synonymous and would not change the amino acid sequence of a resultant protein.  Sim-
ilarly two additional SNPs were found in intergenic regions for all recovered strains between 
genes UU584 and UU583 and between two tRNA sequences that both code for species that 
recognise arginine codons in mRNA.  The only potential significant conserved change relative 
to the original strain was the 17 SNPs distributed between the two copies of the ammonium 
transporter gene.  However, how this could reduce complement sensitivity is unclear.  There 
are other points in the genome that seem to be mutational hot-spots, for example 5 out of 9 
recovered strains showed a mutation in the hypothetical gene UU111(Figure 6.14) that would 
lead to a lost protein product (frame-shift and loss of start codon).  Most of the remaining 
alterations in one or more recovered strain occurred in polyA, polyT or polyTA tracks in in-
tergenic sequences that are unlikely to have had a significant effect on gene expression (Table 
6.2).  On overall analysis, the alteration to the number of C-terminal repeats in the MBA gene 
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was the most significant conserved change in recovered strains relative to the original serum-
sensitive strain, despite the failure of dual MBA strains to have transferred serum resistance. 
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Figure 6.13 Western blot analysis of HPA5 original strain (HPA5 ori), the colony purified 13.136b1 
recovered isolate and HPA5 strains transformed with mini-transposon vector pMT85 without an insert 
(vec control) or containing the 13.136b1 MBA gene and endogenous promoter (entire intergenic region 
between genes UU375 and UU376; dual MBA).  Three separate colonies of the transformed HPA5 
were grown up separately and processed, showing that transposon delivery does not alter MBA isoform 
and the delivered second copy of MBA is universally expressed in all transposon mutants resistant to 
selection in 128 g/L of gentamicin.  MBA isoforms detected by the monoclonal antibody 6525.  Western 
blot represents identical results from three separate experiments. 
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Table 6.1 Details of genomic DNA contigs. 
 
 
Contigs are listed by decreasing size, listed next to the strain of origin.  Each strain is com-
posed of 8 to 14 contigs and the largest contig (for 127b2) represents a 61.8% coverage of the 
complete HPA5 genome. 
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Table 6.2 Summary of genetic sequence alterations in recovered strains 
 
 
Ins = Inserted nucleotide, Del = Deleted nucleotide, SNP = single nucleotide polymorphi 
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Figure 6.14 Geneious 8.0.5 alignment of recovered strain genomic DNA sequence contigs to the com-
pleted and annotated HPA5 strain sequence.  Top panel shows alignment of all contigs from table 6.1, 
while the lower panel shows a zoomed view showing the complete agreement in sequence identity to 
the parent HPA5 strain. 
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Figure 6.15 Geneious 8.0.5 alignment of recovered strain genomic DNA sequence contigs to the com-
pleted and annotated HPA5 strain sequence. This screen shot shows an example of the pan-genome 
analysis comparing between recovered strains and original infecting HPA5 strain.  In this example the 
gene UU111 (circled) showed variations for the recovered strains: 13.122a1, 13.139a2 and 136b1 which 
had a deletion of a single A nucleotide (blue arrows, zoomed in within the inset), while strain 13.126a1 
has a SNP converting the first codon from ATG to ATA, removing the start codon, and strain 13.136a1 
has a SNP creating a stop codon sequence that would truncate the resulting protein at 114 amino acids 
of the predicted full length 200 amino acids. 
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6.4 Discussion 
There has not been an equivalent study to this one previously carried out.  Phenotypic altera-
tions in Ureaplasma parvum have been induced in vitro by serial challenge to increasing con-
centrations of macrolide antibiotics (Pereyre et al., 2007).  This resulted in mutations in the 
genes encoding 23S rRNA and ribosomal proteins L4 and L22, which resulted in high level 
macrolide resistance. Furthermore, studies running in parallel to this thesis (Ali Aboklaish 
thesis) have found that serial in vitro challenge of Ureaplasma parvum strains with sublytic 
concentrations of seropositive human serum resulted in induced serum resistance.  However, 
the HPA5 strain has been previously reported to be very susceptible to serum killing (Beeton 
et al., 2012), and HPA5 was the only strain examined found to be incapable of undergoing in 
vitro induction of serum resistance (Aboklaish thesis).  Furthermore, induced resistance to 
human sera was found to coincide with induced expression of a 41 kDa protein (Aboklaish et 
al., 2014).  While these strains had induced resistance to human sera, no alteration to sensi-
tivity to sheep sera was observed and no expression of the 41 kDa protein was observed in 
HPA5 strains recovered from chronically infected pregnant sheep after 5 weeks.   
Alterations in the major surface protein associated with complement resistance have been re-
ported for the mouse pathogen Mycoplasma pulmonis (Simmons and Dybvig, 2003). For these 
studies transposon mutants were characterised and it was found that strains with large variable 
surface antigens (Vsa) were resistant to mouse complement, while short Vsa strains were sus-
ceptible to killing.  In a subsequent publication by the same group (Simmons et al., 2004; 
Warren and Dybvig, 2003), they found that the increased resistance was directly related to the 
increase in glycocalyx surrounding the cell as the repeat unit for Vsa included a signal for N-
linked glycosylation.  Similar to their studies, susceptibility to sheep serum killing was high 
for original HPA5 and 14.115P strains (Figure 6.7) which had the smallest MBA isoform , 
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compared to 14.231P and 13.139a2 (Figure6.8) which had an MBA approximately 20 kDa 
larger.  However, the difference in the size of these MBA isoforms was the number of 
PAGKEQ repeats, which do not contain a known glycosylation motif.  Lack of a known gly-
cosylation motif does not exclude a novel Ureaplasma glycosylation mechanism; however, 
Schiff acid reagent staining (reacts with sugars) of whole cell proteins by Western blot did not 
identify the MBA protein as glycosylated (Aboklaish thesis). 
Capacity for MBA size variation following experimental intrauterine Ureaplasma infection 
has been reported for prolonged chronic infection previously (Knox et al., 2010), and the pa-
thology in these animals was directly related to the number of MBA isoforms.  They found 
fewer than 5 isoforms were detected in severe chorioamnionitis, whereas more than 7 isoforms 
was associated with lower pathology.  The later showed that the number of MBA variants 
increased with length of infection (Robinson et al., 2013), similar to what I have found. Fur-
ther, investigations found that the presence of maternal anti-Ureaplasma antibodies correlated 
to increased cytokine levels and chorioamnionitis (Dando et al., 2012), and the authors found 
that incubation of recovered isolates with polyclonal anti-MBA resulted in phase variation 
shut-off of MBA expression.  However, my studies have found that maternal antibodies are 
incapable of crossing the placenta (Chapter 3) and in my studies no evidence of MBA negative 
recovered strains or of significant maternal or fetal anti-Ureaplasma response (Chapter 4) was 
found.  Irrespective of the previous findings, my data is the first to show a change in phenotype 
for the recovered isolates that evolves over a span of weeks and more importantly that full 
genetic sequence analysis of the phenotypically altered evolved strains shows that increased 
number of MBA repeats is one of the few alterations to have occurred in the genome.  It was 
disappointing that artificial delivery by transposon mutagenesis of a longer MBA gene to the 
serum-susceptible original HPA5 strain did not mediate resistance; however, an alternative 
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explanation could be that the shorter form is the dominant determinant meditating suscepti-
bility.  If time had permitted I would have liked to use transposon mutagenesis to deliver the 
original HPA5 MBA gene to one of the resistant recovered strains to see if that resulted in 
rescued serum sensitivity to test this hypothesis. 
In conclusion this chapter has demonstrated an adaptive strategy whereby Ureaplasma par-
vum changes its genetic code resulting in increased resistance.  The mechanism underlying 
this change is unknown and the process took time to manifest (it was not present after a week 
and the phenotype continued to adapt after 3 weeks).  While there were a few alterations that 
were conserved amongst all of the strains recovered after 5 weeks chronic infection, only 
alterations to the length of MBA gene and sequence alteration to the duplicate ammonium 
transporter genes occurred in coding regions of the genome. 
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7 General Discussion 
7.1 Overview 
This thesis has addressed and dealt with different questions about Ureaplasma a bacteria from 
class Mollicutes and I focused on the reason why preterm babies are more liable to acquire 
this infection in utero or after birth and how this bacteria can adapt to the host in spite of its 
extreme sensitivity to human and sheep sera. The first results chapter investigated the func-
tional complement activity of preterm neonatal sheep in comparison to the adult sheep and 
how its efficiency evolves with increasing gestational age and that maternal sheep antibodies 
were incapable of crossing the placenta. The second results chapter (4) provided the first de-
tailed kinetic analysis of establishment of Ureaplasma infection in the amniotic cavity fol-
lowing experimental infection. It also dealt with level of bacteraemia in Ureaplasma-infected 
lambs: how it increases proportionally to increased insufficiency of the complement system 
with greater prematurity. The third result chapter (5) characterised a panel of commercial and 
non-commercial monoclonal antibodies and provided a detailed analysis that differentiates 
between the reactivity of a panel of monoclonal antibodies raised against a highly expressed 
major antigenic component of Ureaplasma termed the multiple banded antigen (MBA) which 
is regarded an excellent target for separation of the Ureaplasmas into distinct sub-groups. 
These results will enable other researchers to speciate clinical isolates, or allocate specific 
serovars in some cases, based on differential detection by Western blot or immunohistochem-
istry. Also these reagents will enable researchers to begin to examine correlations between 
MBA size or numbers of MBA isoforms present in clinical isolates and pathology. Finally, 
the last result chapter (6) demonstrated an adaptive strategy whereby Ureaplasma parvum 
becomes more resistant to serum killing with infections longer than 1 week in utero. It also 
addressed surface protein modulation by which Ureaplasma may influence recognition by the 
host immune system, particularly variation in the multiple banded antigens (MBA).  While 
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increasing MBA size appeared to be dominant genomic alteration in the recovered serum-
resistant strains, artificial addition of a larger MBA to the original strain failed to transfer se-
rum resistance.  However, in several experiments, where recovered strains were compared to 
the original inoculating strain, there was a consistent drive towards MBA isoforms with in-
creased numbers of repeats.  The only conclusion that can be drawn is that the increased MBA 
isoform size is selected for and there is an unknown mechanism in Ureaplasma parvum that 
specifically modifies the MBA gene, while retaining high fidelity for the rest of the 619,000 
bp genome during replication.   
 
7.2  Complement activity in preterm infants 
The innate immune components represent the first line defence against invading pathogens 
but because of the suboptimal development of the cellular and humoral components of this 
system during fetal life, the foetus start life more susceptible to infection. In 2009, Soto et al. 
had reported the increase in complement activation markers in the amniotic fluid of pregnant 
women with spontaneous preterm labour as a result of infection through measuring C3a, C4a, 
and C5a and correlating higher levels to initiating labour prematurely (Soto et al., 2009). The 
use of sheep as a non-primate model of human disease is increasing, especially for studies of 
disease in pregnancy and pregnancy complications. Sheep models have been developed to 
investigate intrauterine inflammation induced by injection or infusion of lipopolysaccharides 
or bacterial infection (Kemp et al., 2011; Matteo et al. 2010; Zhang et al. 2012; Dean et al. 
2011). None of these studies has investigated the contribution of the complement system to 
the disease pathogenesis largely due to the current lack of knowledge on the sheep comple-
ment system activity and its role in lamb pathophysiology. The complement system is a key 
part of innate immunity; it does not require previous exposure to be effective, it orchestrates 
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both immune and inflammatory reactions and supports the immune system in clearing patho-
gens, and remodelling damaged tissues. Complement activation recruits innate and adaptive 
immune cells to the site of inflammation where it aids in modulating and refining the adaptive 
immune response (reviewed in McGreal et al. 2012). I optimised an assay that allows the 
comparison of sheep sera complement activity from different sources (adult non-pregnant, 
maternal and preterm fetal sera).  No difference was found in haemolytic capacity between 
pregnant and non-pregnant adult sheep sera, but found that complement activity in preterm 
fetal sheep was decreased relative to matched maternal sera, but still had considerable activity 
even in sera from preterm lambs at 85 days gestation (term=150days), which makes them 
considerably more immune competent than the equivalent gestational age humans (reviewed 
in McGreal et al 2012). From these studies, I demonstrated that fetal sheep sera unlike their 
mothers are unable to lyse rabbit and un-sensitised guinea pig erythrocytes which was the 
biggest difference observed. This was attributed to the complete absence of cross-reacting 
antibodies in fetal serum that bound to rabbit and guinea pig erythrocytes, which were abun-
dant in adult sheep sera when examined by flow cytometry.  However, adult sheep are unlikely 
to have been exposed to rabbit and guinea pig erythrocytes either; therefore, the obvious con-
clusion is that non-sheep glycosylation patterns on these erythrocytes resemble those on mi-
crobes which the sheep are readily exposed to as these sheep are sourced from normal farming 
practice. Anecdotal evidence for this is found in investigation of glycosylation differences of 
IgG between species.  Ragu et al., (2000) found that sheep IgG only contain oligosaccharides 
with N-glycolylneuraminic acid (NGNA) while IgGs from guinea pig and rabbit have post-
translational modification with oligosaccharides containing both N-acetylneuraminic acid 
(NANA) and NGNA (Ragu et al., 2000). Bacteria including E. coli, have been shown to syn-
thesize this form of glycosylation for use in their cell walls (Severi et al., 2007) supporting 
this hypothesis. Failure to transfer IgG from mother to foetus is not unique to sheep. In fact, 
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other than primates, it appears that only rabbits and guinea pigs have the capacity to transfer 
maternal IgG to foetuses across the placenta (Pentsuk and van der, 2009). This means that any 
immune response observed in fetal sheep and other ruminants must reflect the fetal immune 
response alone. In contrary to our findings Silverstein et al., (1964) titrated the complement 
activity in fetal lambs bled at different gestational ages and reported very low complement 
activity in embryonic lambs before 123 days of gestation and even at term (Silverstein et al., 
1964). While in 1968, Colten and colleagues reported sheep complement activity was detect-
able as early as 39 days of gestation and increased rapidly thereafter to become stable at 60 
days gestational age.  They further reported an absence of detectable complement activity in 
the amniotic fluid itself and found that 2 days after birth complement activity was equivalent 
to the adult levels (Colten et al., 1968). In 1978, Renshaw and Littenecker measured the com-
plement activity using a similar assay to mine (CH50) in new born lambs and found the ewe: 
lamb ratio of activity ranged between1.48 to 5.3 (Renshaw and Litteneker, 1978). Studies in 
humans around this time found similar findings for the CH50 values in human neonates.  Fire-
man (1969) found that the ratio of maternal to new born haemolytic activity was 1.87( Fireman 
et al.,1969)., while Adinolfi (1970) reported a ratio of 2.01(Adinolfi et al.,1970).A full review 
for the correlation between gestational age and complement has been published by McGreal 
et al. (2012). 
 
7.2.1  The complement inhibitor CDX-1135   
Although complement plays an important role in immune surveillance, it acts as a double edge 
sword, as it can cause tissue damage and pathology following inflammation and reperfusion 
injury.  Anti-complement therapies have been developed to protect tissues from side effects 
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of complement activation by the use of recombinant complement regulators (Morgan and Har-
ris, 2003).  In my experiment, I found that the most potent complement inhibitor for human 
sera, CDX-1135, a recombinant form of sCR1 (soluble human complement receptor 1) was 
capable of inhibiting rat sera and human sera, but had negligible inhibition of sheep sera. 
CDX-1135 is composed of the 30 N-terminal domains of the potent complement regulator 
CD35 found mainly on human erythrocytes, but has been proven to be as effective in solution 
when added as a soluble form. Previous studies showing effective reduction of complement-
mediated pathology by CDX-1135 in other rat models include significantly reduction by 
CDX-1135 of placental mean arterial pressure, C3a production, and vascular endothelial 
growth factor (VEGF) levels (Lillegard et al., 2013) and reduction of reperfusion-induced 
complement-mediated myocardial infarction by 44% (Weisman et al., 1990). Therefore, my 
studies show that an alternative regulator of sheep complement must be found, before the role 
of complement activation in hypoxia, infection and inflammation damage to the developing 
neonate using this model, can be addressed experimentally.  
 
7.3 Ureaplasma and preterm labour 
The genus Ureaplasma which belong to the class Mollicutes, have long thought to be com-
mensals of the urogenital tract in humans.  However, they are found to be pathogenic, partic-
ularly in subpopulations who are immunologically compromised. In pregnant women it can 
ascend from the colonised vagina into the upper genital tract even before pregnancy com-
mences (Cassell et al., 1983) or be acquired during passage of the baby through the colonised 
birth canal (both represent the extremes of vertical transmission) which is reported to occur at 
a rate of 45- 66% in full-term infants and about 58% in preterm infants (Sanches and Regan, 
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1987). Most of these intrauterine infections present as chorioamnionitis, which comprise in-
fection and inflammation of the fetal membranes (amnion and chorion), placenta and/or de-
cidua.  This represents a substantial risk to the fetal well-being and influences pregnancy out-
come and subsequent short and long term neonatal sequel (Romero and Mazor, 1988; Sung, 
2010; Viscardi, 2010). Many studies in human pregnancies showed that Ureaplasma can be 
isolated from the amniotic fluid and fetal tissues as early as 16-20 week of pregnancy (Cassell 
et al., 1986) or even earlier at the time of conception (Kasprzykowska et al., 2014). 
The rate of Ureaplasma colonisation and subsequent chorioamnionitis is reported by many 
studies to be inversely proportional to gestational age. Goldenberg and his team in the Ala-
bama preterm birth study reported that 23% of neonates born between 23-32 weeks of gesta-
tion had positive umbilical blood cultures for Ureaplasma and Mycoplasma (Goldenberg et 
al., 2008). My analysis of these findings would contribute that the earlier the gestational age, 
the more likely that these organisms would be isolated from the amniotic fluid, placenta, and 
membranes due to increased developmental insufficiency of the complement system.  Beeton 
et al. also reported in 2011 that colonisation of the new born lungs by Ureaplasma is higher 
in preterm infants born between 23-26 weeks than those born near term, which contributed 
subsequently to greater risk for chronic lung diseases (CLD) development (Beeton, 2011).  
The most recent meta-analysis of all Ureaplasma studies bares this correlation out showing 
Ureaplasma infection gives an odds ratio of 3.04 for development of CLD in preterm neonates 
(Lowe et al., 2014). 
However, studies determining the association of timing, dose, serovar type and co-infection 
with other microorganisms have not been possible to examine systematically before now.   
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7.4 Kinetics of Ureaplasma infection in sheep 
HPA5 grown from samples collected from the AF of catheterised pregnant sheep showed that 
Ureaplasma titres continued to increase to a peak at 48 hr and then remain relatively stable. 
This pattern is consistent with the studies performed on pregnant macaque monkeys reported 
by Novy et al. in 2009. If I compare the titres at 5 days for the catheterised animals to the 
titres from other groups of sheep infected for varying lengths of time (from 1-5 weeks), it 
would appear that the levels of Ureaplasma during chronic infection remain reproducibly sta-
ble. Knox et al. (2012) also reported that Ureaplasma can stay viable for more than 70 days 
in the amnion and lungs of sheep foetuses ( Dand et al., 2012; Knox et al., 2010). Moss et al. 
(2005) also reported the ability to recover Ureaplasma from the amniotic and lung fluid of 
lambs up to 10 weeks after inoculation (Moss et al., 2005). This ability of Ureaplasma to 
overwhelm the continually developing innate immune system and any potential adaptive im-
mune response resulting in colonisation of the host tissue for extended periods could be at-
tributed to a strategy in Ureaplasma to adapt dynamically to avoid recognition by the host 
immune system as will be discussed later on in 7.8.  
 
7.5 The increased incidence of bacteraemia with increasing prematurity 
The use of sheep as a non-primate model of human disease is increasing, especially for studies 
of disease in pregnancy and pregnancy complications. For example, neonatal asphyxia in-
duced by transient occlusion of the umbilical cord before birth has been shown to lead to 
complement-mediated reperfusion injury and to mimic the intrauterine hypoxia that compli-
cates a proportion of human births (Castillo-Melendez et al., 2013).  Further, hypoxic injury 
following preterm birth and associated newborn respiratory disease is also studied in sheep 
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models (Wolfson et al., 2012). More recently, sheep models have been developed to investi-
gate intrauterine inflammation induced by injection or infusion of lipopolysaccharides or mi-
crobial infection (Dean et al., 2011; Hillman et al., 2014; Kemp et al., 2011; Maneenil et al., 
2015; Zhang et al., 2012). None of these studies has investigated the contribution of the com-
plement system to the disease pathogenesis or to the role of complement in controlling sys-
temic spread, largely due to the current lack of knowledge on the sheep complement system. 
The increased incidence of bacteraemia in younger infected lambs relative to more mature 
lambs is directly related to the underdeveloped complement function in the fetal sera with 
increasing prematurity.  Adinolfi and Beck (1975) found that after 16 weeks of gestation all 
complement components were detectable in human fetal serum and then increased subse-
quently in concentration, nevertheless, newborn infants remain more susceptible to infection 
especially those born prematurely (Adinolfi and Beck , 1975). This hypo-activity of the com-
plement system and its low haemolytic activity may enhance capacity for microorganism in-
vasion and greater potential susceptibility to infection (Grumach et al., 2014). Fonseca et al. 
reported in 2011 that spontaneous preterm human babies had a 9-fold increased chance of 
having Ureaplasma bacteraemia and he stated that about 12.6% of very low birth weight new 
born babies (VLBW) with gestational age ≤32 weeks have positive blood culture for 
Ureaplasma.  Again the enrichment of Ureaplasma bacteraemia likely attributed to the defi-
cient complement activity in this group of babies (Fonseca et al., 2011).  
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7.6  Bactericidal activity of preterm infant’s sera 
Neonates particularly those born prematurely are more prone to infection and even term babies 
are known to have an under-developed immune system relative to adults particularly the com-
plement system whose activity decreases with increasing prematurity (McGreal et al., 2012). 
All clinical Ureaplasma of serovar type 3 were reported by Beeton et al. (2012) to be suscep-
tible to seronegative human serum in the absence of anti-Ureaplasma antibodies and this kill-
ing was mainly mediated by the classical pathway of the complement system.  They found 
that using anti C1q antibodies blocked the complement–dependent Ureaplasma-cidal activity 
of the human serum (Beeton et al., 2012). Therefore, I planned to use the sheep model to 
investigate the susceptibility of one of the characterised strains from that manuscript (HPA5) 
to examine susceptibility to fetal and adult sheep sera (both from infected and non-infected 
animals) and to examine the effect of developmental complement insufficiency on systemic 
spread of Ureaplasma in vivo from the site of experimental injection (amniotic fluid) to the 
fetal circulation.  The in vivo bacteraemic status relating to gestational age was consistent with 
the bactericidal capacity of serum in vitro, which increased with gestational age. As with hu-
man serum studies, sheep serum bactericidal activity against this strain appears to be mediated 
mainly through the classical pathway (as no killing is observed when the alternative pathway 
is isolated with EGTA), unfortunately no reagents are available to test the lectin pathway, or 
to block C1q in the sheep sera, therefore, further dissection of the calcium-dependent path-
ways was not possible (as was performed for human sera in Beeton et al., 2012).  While the 
classical pathway is expected to mediate Ureaplasma killing, failure of complement inhibitor 
sCR1 to block killing was unexpected, and this failure appears to be species specific as CDX-
1135 regulates human, mouse, guinea pig, and rat sera. 
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Regarding the Ureaplasma-cidal efficiency of preterm sheep foetuses, the most immature sera 
were significantly deficient in bactericidal activity in comparison to adult sheep sera and apart 
from the prolonged killing curve, the kinetics for both the adult and preterm sheep serum 
killing were identical.  Maximum killing was obtained in the first 10 minutes with all sera and 
no increase even after prolonged incubation for 4 hours. This also agrees with unpublished 
data examining term human serum and Ureaplasma killing (Abdulla S. thesis, 2012), where 
she found low Ureaplasma-cidal capacity of human cord sera in comparison to adult sera and 
attributed that to the lower complement components in the cord blood despite transfer of ma-
ternal anti-Ureaplasma IgG observed by Western blot using the cord sera.  
In terms of fetal sheep  immune response, less than 50% of the chronically infected (6 week 
infection) animals developed anti-Ureaplasma antibodies that reacted with whole HPA5 an-
tigens separated by SDS-PAGE.  Comparing the weak response of those that did develop an 
immune response, using HPA5 and a serovar 6 isolate (HPA61) identified the leading recog-
nised antigen as the surface-exposed Ureaplasma antigen called the multiple banded antigen 
(MBA).  This was confirmed by reactivity of the sera with recombinant MBA expressed by 
E.coli.  However, those animals infected for 24 days from 70 days gestation, showed no sero-
reactivity. When matching the fetal sera anti-Ureaplasma reactivity to reactivity with antibod-
ies in the amniotic fluid, they both showed equivalent reactivity reflecting leakage of the an-
tibodies from the fetal sera into the amniotic fluid (data not shown).  
The deficiencies in bactericidal activity of the immature sera were consistent with significant 
bacteraemia being observed in preterm lamb sera, both of which could be explained by the 
underdeveloped complement activity. This correlation between Ureaplasma bactericidal ac-
tivity and complement function was not influenced by experimental infection, as a range of 
complement function and bactericidal activity was observed in sera examined ex vivo from 
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uninfected lambs at 95 days gestational age.  Hence a normal variation in development of the 
complement system is observed in this hetrogenous population of Merino sheep.  Less varia-
tion would likely be observed in defined inbred strains of labouratory animals. 
 
7.7 Characterisation of monoclonal antibodies used for typing different 
strains of Ureaplasma species 
Real-time PCR technology can segregate the 14 serovars of Ureaplasma from each other as 
can analysis of 16s rRNA sequence (Xiao et al., 2010; Maniloff, 2002; Robertson et al., 1994; 
Harasawa & Cassell, 1996 ) and standard PCR can separate Ureaplasma species by amplicon 
product size by using primers that target a 40 bp insert in the 5' end of MBA gene, and strains 
can be grouped into genotypes by sequencing an internal fragment of the ure gene (Knox et 
al., 1998).  These methods represent a range of technical ability for labouratories, from stand-
ard PCR, to primer/probe sets and genome sequencing.  They all examine nucleic acid varia-
tion, and have the advantage of not requiring culture of fastidious organisms.  There is no 
reason; however, why monoclonal antibodies cannot be used to detect surface proteins and 
even to separate these into species or in some cases serovars. Differences in epitopes are cer-
tainly predicted to be able to separate serovars and many labouratories have generated serovar-
specific monoclonal antibodies (Watson, et al. 1990; Cheng, et al. 1994; Zheng, et al., 1995; 
Zheng, et al. 1996). 
Screening the MBA protein from a panel of prototype strains of Ureaplasma, the only com-
pletely sequenced and annotated U. urealyticum genome (serovar 10) identified a single MBA 
protein with the C-terminal repeat TQPGSGST was found to be the best MBA candidates. 
Some serovars were found to have close homology to serovar 10 N-terminus as serovars 2, 5 
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and 8 with the expected TKPGSGET repeat as shown in (Table 5.2) with only 3 polymor-
phisms.  The next closest group of homologues comprised serovars 4, 12 and 13 with the 
expected TSPEKPGNGT repeat.  MBA homologues with no identifiable repeat in the C-ter-
minus were found for two serovar 7 MBA genes, as well as putative genes for serovar 2, 11 
and 13.  The potential repeat of GAQSGNGSGSASGS was identified for serovar 11 in an 
MBA homologue, but the potential MBA protein with this repeat for serovar 7 does not retain 
high homology for the N-terminal sequence.  Furthermore, two different MBA putative pro-
teins were identified for serovar 10 (ACI60338.1 and AAD02692.2) were found in the data-
base with 100% identity, both with the expected TQPGSGST repeat.  However, variants (other 
than the validated annotated serovar 10 genome) of the U. urealyticum may be due to errors 
in the shotgun genome sequencing data. 
Using these prototype strains, MBA proteins from U. parvum can be visualised  by western 
blot by probing the membranes with a panel monoclonal antibodies previously published by 
Watson et al., (1990) (Table 5.3). Comparing our findings with the previously published (Wat-
son et al., 1990), mAbs behaved mostly as expected: 5B1.1 detected only serovars 3 and 14, 
10C6.6 detected only serovar 3 and 8A1.2 did not react with any of the U. parvum MBAs, but 
did uniquely identify U. urealyticum serovar 10. Three of the commercial mAbs detected all 
the U. parvum MBA species equivalently (6522, 6523 and 2B11), performing better than the 
previously published mAb 8B5.2. 
Echahidi and colleagues found that there is a cross reactivity between SV3 and SV14 and also 
between SV1 and SV6 (Echahidi, et al. 2000). Monoclonal antibody 5B1.1 and 6525 recog-
nized both serovars 3 and 14, while 2G9 only recognised SV1 and SV6, and mAb 3B1.5 re-
acted strongly with serotype 3 with minimal cross-reaction with other serovars. Cross-reac-
tivity between serovars, or in my case cross-reactivity across all U. parvum and U. urealyticum 
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by 6522, cannot be attributed to the reported expectation of high frequency horizontal genes 
transfer which occur in clinical isolates (Paralanov, et al. 2012). Furthermore, Thirkell et al., 
(1989) generated mAb UU8/39, by immunising mice with serovar 8, which recognized the 
16- and 17-kDa surface-expressed polypeptides in all serovars of Ureaplasma, but the 17-kDa 
polypeptide was only present in serotypes of the smaller serocluster B (serovar 1, 3, 6, and 14 
Ureaplasma).  The lack of variation in isoform mass for this protein signifies that these pro-
teins are not MBA and therefore are likely not the basis of “serovar” specificity.  However, 
the mAb UU8/29 reported in the same manuscript could identify a 96 kDa band which is the 
first serovar-specific mAb for SV8 (Thirkell et al., 1989).  Ureaplasma isolates showed a 
different immunoblot patterns and in some cases even different from each other as well as 
from some of the reference strains, signifying a high rate of antigenic variation among 
Ureaplasma strains ( Teng et al., 1994 ; Zheng et al., 1992).  
In 2008, Vancutsem and his colleagues succeeded in generating a recombinant MBA antigen 
of Ureaplasma SV3 and SV6 (rMBAs) by using a PCR method then cloning it into an expres-
sion vector plasmid and he proved the usefulness of this (rMBAs) in testing the sera of women 
with Ureaplasma infection for seroreactivity (Vancutsem et al. 2008). I also succeeded gen-
erating a recombinant SV3 MBA form created solely by gene synthesis of a codon-optimised 
predicted protein sequence with a histidine tag, complete with promoter (also from 
Ureaplasma – house-keeping gene EF-tu) that was expressed in E. coli and subsequently used 
for Western blot and immunohistochemistry testing of antibodies.  
The future use of mAb in Ureaplasma infection diagnostics would depend on whether detec-
tion of all Ureaplasma species was required, or if differential determination of U. parvum 
versus U. urealyticum was required (or if specific serovars are subsequently found to be more 
pathogenic than others).  Use of mAb as the basis of lateral flow methods (like pregnancy 
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tests) or bead agglutination (like many serological tests) would need to further investigate if 
these mAb recognise native proteins on Ureaplasma species.  Furthermore, the use of mAb 
may be developed for therapeutics, as preliminary data in sheep show that inducing a strong 
fetal immune response against the MBA results in decreased amniotic fluid clearance.  Other 
mAb that have been humanised have been used as therapeutics in the past as well.  
 
7.8 Evolution of Ureaplasma SV3 during in utero infection 
Although Ureaplasma species long thought  to be harmless commensal microbe of the muco-
sal epithelium of the human urogenital tract, they are also endowed with the ability to be 
transmitted both horizontally during sexual intercourse and vertically during gestation (up to 
90% vertical transmission rate)(Abele-Horn, et al. 1997; Behnam et al., 2014) where it can 
exist asymptomatically inside the amniotic fluid  for extended periods and cause subclinical 
infection in spite of its extreme susceptibility to fetal serum and may end in devastating re-
productive outcome (Waites et al., 2006; Cassell et al., 1986; Viscardi et al., 2010; Alfa et al., 
1995). Once inside the host, it will be confronted by the immune response of the host: both 
the immediate innate response and later by the adaptive immunity. In spite of that, 
Ureaplasma can remain viable, colonise and replicate inside the host tissues. Experimental in 
utero infection in sheep with U. parvum has been used to investigate the pathogenicity of these 
bacteria which is associated with induction of preterm birth and the ability of Ureaplasma to 
escape host immune response during its colonisation in the uterus has been challenged by the 
scientists for many years. Ureaplasma has many virulence factors to overcome the host im-
mune response like IgA protease, phospholipase A and C, urease as well as the hydrogen 
peroxide-generating activity, which help the organism to overcome host defence and enable 
it to hydrolyse and invade host tissue (Viscardi et al. 2012;   Kallapur et al. 2013). Yet, the 
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most important immunodominant antigen in Ureaplasma is a surface- exposed lipoprotein 
referred to as the MBA.  This lipoprotein has two domains: the variable part consisting of a 
number of uniform repeating units and a conserved part consisting of a signal peptide and a 
membrane –anchor signal.  These domains represent the serovar-specific and cross reactive 
epitopes, respectively (Teng et al., 1994; Viscardi, 2012; Monecke et al., 2003). In all 14 
Ureaplasma serovars, the gene which encodes MBA (MBA gene) consist of a conserved 5'  
nucleotide sequence and a variable 3'  region, and proceeds to produce a molecule which con-
sists of both a conserved N-terminal intracellular domain (later cleaved and replaced with a 
lipid anchor) and variable C-terminal extracellular domain respectively. This variable extra-
cellular domain is defined by a varying copy number of a tandem amino acid sequence 
(QPAGKE in Ureaplasma SV3), and is the primary immunogenic antigen of Ureaplasma 
cells (Zheng et al., 1995). The MBA gene can undergo continual antigenic variation either by 
changing the number repeats by expansion of the multiple C-terminal short amino acid 
(QPAGKE) repeats (size variation) or by synchronised switching on some genes and switch-
ing off other genes (phase variation) when struggling against an immunological pressure to 
help Ureaplasma to evade the host immune response (Paralanov et al., 2012) and to allow 
Ureaplasma to persist for longer duration and promote host adaptation (Monecke et al., 2003; 
Zimmerman et al., 2009; Viscardi, 2012; Zimmerman et al.  2014).  
 
7.8.1  Susceptibility of Ureaplasma isolates to sheep sera 
The susceptibility of Ureaplasma serovar 3 to fetal lamb sera compared to the matched ma-
ternal and to adult seronegative sera from non-pregnant sheep was investigated and  I found 
that Ureaplasma parvum SV3 (HPA5) was very sensitive to non-immune sheep sera, while 
an unrelated clinical isolate, HPA61 strain of SV6, was identified as completely resistant to 
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non-immune sheep sera. Comparing sensitivity of original HPA5 to HPA5 recovered from 
experimentally infected sheep of differing lengths of infection, demonstrated that the original 
HPA5 and isolates recovered one week post-infection were equally sensitive to non-immune 
adult sera even at concentration of 6.25%. I demonstrated that the adaption is not simply a 
rapid selection and takes time to occur.  Isolates recovered following a 3 week infection, how-
ever, started to become serum resistant to fetal sheep sera. However, by 5 weeks post-infection 
HPA5 had completely adapted and was resistant to fetal sheep sera and was starting to become 
resistant to adult sheep sera.   
Additionally, some isolates recovered 24-42 days post infection in sheep gained serum re-
sistance to seronegative human sera, which could not be induced by repeated sub-lytic chal-
lenge (Aboklaish thesis, 2014).   This confirms that the longer the time the Ureaplasma re-
mained in utero, the more it changed phenotypically. Genomic sequencing of the DNA of the 
above isolates was compared to a reference strain of SV3 (American Type Culture Collection 
(ATCC), strain 700970) and will be discussed below in 7.8.2.    
The slow adaptation of Ureaplasma in utero supports the hypothesis of Citti et al. (2010) that 
it is the delayed, adaptive immune response which acts as the selection pressure driving MBA 
diversification. Interestingly, it is worth noting that increasing MBA size and diversity, does 
not accompany a significant immune response from the sheep, and size of the MBA mass 
appears to be consistently driven to an increase, which would be expected to result in increased 
immunogenicity, with only the largest isoforms being apparent by 5-6 weeks post-infection 
in utero. As of yet, no in vivo recovered isolate has displayed phase variation (shut-off) of 
MBA expression, although in vitro this is a repeated phenomenon that accompanies sub-cul-
ture in the presence of polyclonal anti-MBA (Zimmerman et al. 2009; Samantha et al., 2012). 
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7.8.2 Genomic adaptation of HPA5 
The genome of HPA5 was annotated against the 700970 reference strain with a genome size 
of 751,719 bp [American Type Culture Collection (ATCC)] downloaded from GenBank 
(GenBank accession number NC_002162). Automated annotation of the completed genomic 
sequence of HPA5 (Spiller and Beeton, unpublished data) revealed that HPA5 was consider-
ably smaller (688,770 bp), due to large areas of gene deletion resulting in a loss of 50 genes 
relative to the prototype strain. Using the Geneious 8.0.5 analysis software the assembled 
pieces of sequenced genomic DNA from recovered isolates were compared to the fully anno-
tated genome for the original strain HPA5, very few conserved genomic differences were ob-
served.The most notable alterations were 17 SNPs between 2 copies of the ammonium trans-
porter genes amt1 and amt2, which should have no role in complement resistance.  There were 
also very few other individual or small group SNPs across the entire genome, despite having 
undergone approximately 800+ generations (generation time for Ureaplasma is approxi-
mately 1 hour), indicating a robust proof-reading mechanism and lack of spontaneous intra-
genomic recombination.  Regions of repeats of greater than 150 bp are not visible to genomic 
sequencing by Illumina technology due to the underlying chemistry and the leading unique 
characteristic of the MBA is the variation in 18 bp repeats at the C-terminus.  Variation in the 
MBA protein was already apparent from the Western blot analysis; therefore, examination of 
the MBA gene had to be performed separately using primers, standard PCR and sequencing 
of the amplicons.  The original HPA5 sequence was found to have 17 repeats of the QPAGKE 
motif; while the recovered strains were found to have significantly more.  Some of which were 
too large to amplify clearly as the PCR products exceeded 2 kb for the largest isoforms of 
MBA gene.  There was an apparent correlation in increased MBA protein mass in serum re-
sistant strains recovered after 5 weeks infection as well as 14.231 isolated from the plasma of 
a 125 dGA lamb, which was absent in the serum sensitive strain from lamb 14.115 which had 
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retained the original MBA size.  However, delivery of the MBA from serum resistant 13.136b1 
to the original HPA5 strain, resulting in dual MBA isoform expression, did not result in a 
transfer of serum resistance.  The alternative possibility that should be investigated in the 
future is that the shorter MBA isoform is dominant and mediates sensitivity to complement.  
The next experiment should deliver the original MBA from HPA5 to the resistant strain 
13.136b1 to see if serum sensitivity is rescued as a phenotype.  Failing that, there are the amt1 
and amt2 alterations as well as the UU046 gene SNPs, although these latter gene variations 
are synonymous and would not result in amino acid alteration in the mature protein. This did 
not turn out to be an easily provable hypothesis, despite all of the supporting evidence appear-
ing to be very clear. The mechanism of how the repeat unit consistently increases in the ab-
sence of other genomic alterations is also unknown.  In humans, increasing repeat sizes asso-
ciated with pathology, including Huntington’s disease, are well known.  In a review by Pear-
son (2005), examining the underlying mechanisms of repeat stability, they state: “Hairpins 
and slipped structures occur at DNA sequences with direct repeat (DR) symmetry. The cellular 
processes of replication and transcription cause unwinding of the duplex that renders the DNA 
single-stranded, thus giving the repeat sequences the opportunity to fold back and form alter-
native base pairs within the same DNA strand (Pearson et al., 2005). The repeat sequences 
that have been associated with neurological diseases, in particular, are prone to slipped-mis-
pairing and hairpin formation during replication and transcription. The formation of these 
structures can presumably lead to expansions and deletions of the repeating tract because of 
the stability of the misaligned intermediates. These authors also go on to show that these 
mechanisms are present in bacteria, but they concentrate on CAG or CTG repeats.  The repeat 
region of MBA does have a CAGCAG motif as part of the 18 bp repeat, but most of the models 
refer to long tracks of CAG repeats required to form hairpins. Whether CAGCAGN12CAG-
CAG would suffice is impossible to speculate.  Interestingly, there is also a CAGCAGCAG 
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motif in both amt1 and amt2, but alterations to these genes are not due to repeat length alter-
ation – simply SNP (Panigrahi et al., 2005). 
 Studies concerning human genetic differences: mutations and polymorphisms leading to al-
terations in complement activity affecting individual susceptibility to Ureaplasma were car-
ried on in patients with acquired immunodeficiency syndrom (AIDS) who proved to have 
increased susceptibility to facultative anaerobes like Mycoplasma, AIDS-associated Myco-
plasma.   Equally, further studies investigated the role of polymorphic genes in pregnancy 
outcome and they reported some inter-individual differences among white, black, and His-
panic pregnant women in allelic carriage of immune system-related genes like interleukin-1 
receptor antagonist ( IL-1ra )gene( which binds to IL-1 receptors and inhibits the binding of 
IL-1α and IL-1β) and IL-4 –590C homozygosity were 4-fold less common in blacks than in 
whites or Hispanics (Daniel et al.,2004; Witkin et al.,2002). Another molecular study was 
done by Van der Schee et al.,in 2001 confirmed  increased susceptibility to infection by U. 
urealyticum in human with genetic polymorphism in the interleukin-1 receptor antagonist(IL-
1RA)gene (Van der Schee et al.,2001). 
 Additionally, whole-exome sequencing was used to test the association of polymorphisms in 
immune regulatory genes on the response of the host to infection and subsequent PTL which 
mandate potential genetic screening in nuclear families to start appropriate interference meth-
ods to prevent prematurity. McElroy and his team examined the six genes in the complement 
and coagulation pathways; complement factor H (CFH), complement regulator 1(CR1), co-
agulation factor XIII (FXIII), coagulation factor V( F5), CR2, and the human complement 
component C4b-binding protein. (C4BPA) and found that 50% of all the exoms hide at least 
one novel missense variants (McElroy etal. 2013).
 203 
 
 
8 Summary  
In this study I focused on the reason why preterm babies are more liable to acquire 
Ureaplasma (a bacteria from class Mollicutes) infection in utero or after birth and how can 
this bacteria adapt to the host in spite of its extreme sensitivity to human and sheep sera.  
Using an experimental infection model of pregnant sheep, I found the following: 
 The functional complement activity of preterm neonatal sheep sera is low in compar-
ison to matched adult sheep however; its potency increases with increasing gestational 
age and that maternal sheep antibody were incapable of crossing the placenta.  This 
latter observation means that any immune response observed in fetal sheep and other 
ruminants must reflect the fetal immune response alone. 
 The most potent complement inhibitor for human sera, CDX-1135, a recombinant 
form of sCR1 (soluble human complement receptor 1) was capable of inhibiting rat 
sera and human sera, but had negligible inhibition of sheep sera. 
 The increased incidence of bacteraemia in younger infected lambs relative to more 
mature lambs is directly related to the degree of complement system development: a 
low haemolytic activity in the fetal sera at earlier gestational ages correlated to dimin-
ished bactericidal activity. 
 The presence of Ureaplasma bacteraemia in vivo corresponded to gestational age and 
was consistent with the individual bactericidal capacity of serum from those animals 
in vitro. 
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 As with human serum studies, sheep serum bactericidal activity against Ureaplasma 
was calcium dependent, as EGTA removed all haemolytic and bactericidal activity.  
However, the contribution of classical and lectin pathways could not be further sepa-
rated due to a lack of reagents specific for sheep complement components. 
 Monoclonal antibodies (mAbs) specific for Ureaplasma surface protein MBA protein 
can differentiate between U. parvum and U. urealyticum, and in some cases identify 
specific serovars.  While these reagents work extensively by Western blot analysis and 
can be used in immunohistochemistry, the epitopes for the antibodies have not been 
identified and capacity for their use against native antigens has not been conclusive.  
 A recombinant serovar 3 MBA form was created solely by gene synthesis which con-
firmed the specificity of the panel of monoclonal antibodies. 
 The levels of Ureaplasma during chronic infection remain reproducibly stable. 
 Ureaplasma adapts to sheep during intrauterine infection, but required a few weeks to 
achieve distinctive phenotypic alterations. By 5 weeks post-infection, HPA5 strain had 
completely adapted and was resistant to fetal sheep sera and was starting to become 
resistant to adult sheep sera.  This adaptation occurred in the absence of specific anti-
Ureaplasma antibodyin serum and coincided with increased MBA isoform mass.  
 By 5 weeks post-infection all low mass MBA isoform strains had disappeared, and 
increased MBA isoform mass accompanied the acquisition of resistance to sheep and 
human sera killing.  
 Besides increasing numbers of AGKEQP repeats in the MBA gene as the underlying 
mechanism of increased MBA isoform mass, very few conserved genomic differences 
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were observed comparing the whole genome sequences from the recovered 
Ureaplasma strains 5 weeks post-infection. The only other notable conserved genetic 
alteration in 9 recovered strains was 17 SNPs between 2 copies of the ammonium 
transporter genes amt1 and amt2, which is not expected to play a role in complement 
resistance.   
 Transposon delivery of a second longer isoform of MBA gene to the original HPA5 
strain, with successful expression, did not transfer serum resistance.  This suggests that 
the presence of the shorter isoform, even in the presence of larger MBA isoforms, may 
have a dominant determination for complement sensitivity.  
 
Future recommendations, 
Identifying pregnant women at risk of PTB: the most trustworthy method is detecting in-
creased pro-inflammatory cytokine levels in the amniotic fluid of women highly colonised 
with Ureaplasma (detected as microbial load in their vagina and cervix) represent those who 
are probably at highest risk to deliver prematurely. However, this method is invasive and may 
cause complications later on therefore is unlikely to be accepted as a screening method even 
with the advent of therapeutic strategies. Other methods in the future may involve use of char-
acterised anti-MBA mAbs, especially if an association for a particular species or serovar can 
be determined. Alternatively, these mAbs may form the basis of diagnostics to determine such 
an association. Equally, further studies regarding the number and size of MBA isoforms, irre-
spective of the species or serovar should be examined, as this has been highlighted in previous 
sheep studies (Knox et al., 2010) and the mAb based Western blot analysis is the only method 
of investigating this appropriately. Another future suggestion is to use the synthetic re-
combenant MBA gene instead of the whole Ureaplasma protein to confirm that polyclonal 
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antibodies in serum are picking up MBA .Probably the most important future experiment 
would be to determine if delivering the short MBA form to a serum-resistant recovered strain 
of HPA5, returns the strain to serum susceptibility, then the role of MBA as a sole contributor 
to pathogenicity could finally be ascertained to determine most suitable therapeutic targets in 
animal models.  
.
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Appendix I: Supplementary methods for chapter 3 
Improved measurement of CH50 assay.   This method for measuring the lysis of target eryth-
rocytes by complement depends on increasing transmission of light through the solution of 
erythrocytes rather than measuring the release of haemoglobin.  Other methods that rely on 
measurement of released haemoglobin have to take into consideration the amounts of haemo-
globin that are already in partially haemolysed samples and require centrifugation of unlysed 
cells with transfer of supernatant to be measured.  Certainly repeated measurements on the 
same samples following different incubation times (as we utilise in this thesis) would not be 
possible with these methods.  We utilise a 96-well plate reader set at 595 nm to measure the 
obstruction of light by the intact erythrocytes.  This is a common filter set utilised for many 
chromogenic protein measurement assays and is at the very edge of the absorbance spectra for 
released haemoglobin (image copied from quizlet.com/7051703/bc-ch-7-hemoglobin-and-
myoglobin-flash-cards/) 
 
We set up our assays in a 96-well plate, as follows: 
A1/A2: 50 µl 0.1% sodium dodecylsulphate in water (for total lysis background subtraction) 
B1-H12: 50 µl complement fixation buffer (Oxoid ltd. Basingstoke, UK) 
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Then add 50 µl test sera in triplicate columns (B1-B3, B4-B6, B7-B9, and B10-B12), then 
transfer 50 µl from each well in B to the well directly below in C (2-fold dilution), repeat to 
row G, and then discard 50 µl.  The H row is left as a no complement/no lysis control for 
calculation of percent lysis. 
Add 50 µl of approximately 1% target erythrocytes (sensitised or unsensitised) to A1-A2 and 
B1-H1 and incubate at 37oC.  At various time points (5, 10, 20, 30, 60, 90, and 120 min) read 
the absorbance of the plate at 595 nm utilising the blank correction option of the MRX Reve-
lation software to subtract the average absorbance from total lysis control wells A1 and A2 
from the rest of the plate. 
At each time point calculate the percent remaining target using the following formula: 
% remaining target = (Bn / Hn) x100, where n is the column number.  Percent lysis is then 
calculated = 100 - % remaining target. 
Demonstration data set (abs at 595 nm) 
  
Calculate % target remaining after incubation at 37oC 
1 2 3
Serum concentration A blank blank
50% B 0.000 0.000 0.000
25% C 0.000 0.045 0.001
12.50% D 0.127 0.136 0.079
6.25% E 0.622 0.585 0.612
3.12% F 0.749 0.760 0.795
0.16% G 0.777 0.786 0.789
0% H 0.795 0.799 0.797
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Calculate % lysis from above: 
 
Mean and standard deviation (or standard error of the mean) can then be calculated for each 
serum concentration from these triplicates. 
 
 
 
 
 
 
1 2 3
A blank blank
B  100 x (0/0.795)  100 x (0/0.799)  100 x (0/0.797)
C  100 x (0/0.795)  100 x (0.045/0.799)  100 x (0.001/0.797)
D  100 x (0.127/0.795)  100 x (0.136/0.799)  100 x (0.079/0.797)
E  100 x (0.622/0.795)  100 x (0.585/0.799)  100 x (0.612/0.797)
F  100 x (0.749/0.795)  100 x (0.760/0.799)  100 x (0.795/0.797)
G  100 x (0.777/0.795)  100 x (0.786/0.799)  100 x (0.789/0.797)
H  100 x (0.795/0.795)  100 x (0.799/0.799)  100 x (0.797/0.797)
1 2 3
A blank blank
B  100 - 0 = 100%  100 - 0 = 100%  100 - 0 = 100%
C  100 - 0 = 100%  100 - 5.6 = 94.4%  100 - 0.1 = 99.9%
D  100 - 16.0 = 84.0%  100 - 17.0 = 83.0%  100 - 9.9 = 90.1%
E  100 - 78.2 = 21.8%  100 - 73.2 = 26.8%  100 - 76.8 = 23.2%
F  100 - 94.2 = 5.8%  100 - 95.1 = 4.9%  100 - 99.7 = 0.3%
G  100 - 97.7 = 2.3%  100 - 98.4 = 1.6%  100 - 99.0 = 1.0%
H  100 - 100 = 0%  100 - 0 = 0%  100 - 0 = 0%
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Lysis of rabbit antibody pre-sensitised human erythrocytes by adult sheep sera at increasing 
concentrations after 60 min incubation at 37 C. Cells were prepared in parallel except that 
"fresh" erythrocytes were obtained 24 hours before the experiment and the "aged" cells had 
been kept at 4 C for 4 weeks prior to use in the assay. 
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Appendix II: Abstracts and Publications from this work 
 
Puplished paper “Comparison of Complement Activity in Adult and Preterm Sheep 
Serum”. 
Shatha, A., Matthew, W., Matthew, K., Payne, S., Suhas G., Kallapur., S., Stock,H.J., 
Marsh,C., Alan H. J., Newnham, J. P. and  Spiller,B.O. published manuscript in the  Amer-
ican Journal of Reproductive Immunology 73 (2015) 232–241. 
Problem 
Functional complement activity is routinely measured utilizing rabbit antibody-sensitized 
sheep erythrocytes. Due to complement inhibitor expression on erythrocytes, the development 
of an alternative method to measure complement function in sheep serum was required. 
Method of study 
Several species of target erythrocyte and sensitizing antibody were investigated for improved 
measurement of complement function testing. 
 Results and conclusion  
Guinea pig erythrocytes were identified as the optimal target, although sensitizing them with 
rabbit antiguinea pig erythrocyte antibody did not enhance the lysis by maternal sheep serum. 
In contrast, preterm neonatal sheep serum was unable to efficiently lyse guinea pig erythro-
cytes unless pre-sensitized with antibody. Further investigation revealed that maternal serum 
contained high levels of antibodies that cross-reacted with guinea pig and rabbit erythrocytes, 
while no cross-reacting antierythrocyte antibodies were found in preterm neonatal serum. 
Therefore, unlike primates, rabbits, and guinea pigs, no transplacental transfer of maternal 
IgG to foetal sheep occurs. Use of exogenous complement regulators is often used to dissect 
the contribution of complement to disease pathogenesis; however, we found that while full-
length soluble human complement receptor 1 (sCR1, CDX-1135) was able to inhibit lysis of 
guinea pig erythrocytes by human and rat serum, no inhibition of sheep serum could be ob-
served. Investigation of complement contribution to disease pathogenesis in the future will 
require the identification of an inhibitor that is effective against sheep complement.
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II- Poster to Postgraduate Research Day 2012, 27th Annual Life Sciences 16th November. 
“Bacterial evolution of Ureaplasma parvum during in utero infection in pregnant sheep” by 
Shatha, A., Matthew, W., Matthew, K., Payne, S., Suhas, G., Kallapur, S., Stock,H.J., 
Marsh,C., Alan, H. J., Newnham,J.P. and  Spiller,B.O. 
 
III -Power point presentation ”Bacterial evolution of Ureaplasma parvum during in utero 
infection in pregnant sheep”presented in Welsh Microbiological Association(WMA) SUM-
MER MEETING 20th – 21st June 2014 in the Village Hotel, Swansea.  .                                                                  
 
1V- Poster presentation to MITReG Annual Event in the 19th January 2015 for which I was 
awarded the first prize. “Bacterial evolution of Ureaplasma parvum during in utero infection 
in pregnant sheep” by Shatha, A., Matthew, W., Matthew, K., Payne, S., Suhas, G., Kallapur, 
S., Stock, H.J., Marsh, C., Alan, H. J.,Newnham, J.P. and Spiller, B.O. 
 
 
 
 
 
 
